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Abstract 
 
Approximately half of all patients diagnosed with cancer will receive radiotherapy as a 
part of the management of their tumours. Radiotherapy allows organ sparing treatment 
but it is associated with a number of acute and late unwanted effects. Radiotherapy has a 
crucial role to play in the treatment of urothelial malignancies. However, the late non-
tumoricidal consequences cause significant morbidity, particularly in relation to fibrosis 
of the pelvic structures. The unwanted effects of radiotherapy were originally though to 
be due to the result of direct cell injury, cell death and subsequent fibroatrophic 
changes. It is now clear that radiation initiates a series of events in cells and tissues that 
is primarily based upon the release of cytokines, including growth factors, which lead to 
the development of late radiation injury. This study investigates the changes that occur 
in the lower urinary tract after radiotherapy and looks for a possible role for platelet 
derived growth factor (PDGF) in this process.  
Fifty-six cystectomy specimens were retrieved from the archives of the Pathology 
Department of patients who had been treated with a similar schedule of radiotherapy for 
bladder cancer. Morphological changes were identified by routine light microscopy, 
focussing mainly on the bladder and prostate gland. The degree of fibrosis was 
measured using an image analysis system and this was related to time since irradiation. 
Immunohistochemistry for fibronectin, PDGFs and PDGF receptors was performed and 
the expression assessed by a semiquantitative scoring method. The results were 
compared to non-irradiated control bladders, either with or without tumours. 
A range of histological changes were identified including inflammatory, epithelial, 
stromal, vascular and neural alterations. These were either more commonly seen in the 
irradiated group or the normal age/physiological changes usually encountered in these 
organs were exaggerated in this group after irradiation. Predictably, fibrosis and 
fibronectin production was more obvious in the irradiated group, and this increased with 
time since irradiation for period of study. PDGFs and their receptors were expressed 
after irradiation and the levels were higher than in the non-irradiated group.  
The histological basis for the unwanted side effects of irradiation is described in this 
study. The fibrosis is progressive, with accumulation of connective tissue long after the 
radiation dose has been delivered. It is likely, from these results, that PDGF and its 
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receptors play a role in this process. These results pave the way for manipulation of 
growth factors and/or their receptors, including PDGF, in the future management of 
patients who are symptomatic with radiation injury. 
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Chapter 1. The effects of radiation on human tissues 
 
Radiation can be defined as the passage of energy through matter or the transfer of 
energy from one object to another as it passes through matter. There are many different 
types of radiation which are classically separated into electromagnetic and particulate. 
The former is concerned with energy propagated as waves, the second by the movement 
of subatomic particles produced either by naturally decaying elements or artificially. 
Electromagnetic radiation comprises a spectrum of wavelengths that includes γ-rays, x-
rays, radiowaves, ultraviolet (UV) and microwaves which are split into ionising (that 
which produces ions and ejects electrons as they pass through matter) and non-ionising. 
Their wavelength dictates the penetrating power. Gamma and x-rays are for all intents 
and purposes the same but the former are naturally produced and therefore the physical 
characteristics depend on the substance producing them, while x-rays are man-made and 
depend on the properties of the source. Although UV radiation is non-ionising it is still 
potentially harmful to humans and is associated with skin cancer. Particulate radiation is 
subclassified by the type of particle into alpha, beta, protons, neutrons, deuterons and 
mesons. 
Radioactive materials are present universally either as naturally occurring or artificially 
produced molecules. They are present both inside and outside the body with the 
majority of external natural background radiation being from radon gas. Other 
background sources include radioactive elements naturally occurring in the earth and 
the body, and cosmic rays in the atmosphere. In addition to these, there are several 
artificial sources such as medical instruments concerned with diagnosis and treatment, 
fallout from atomic weapons and nuclear power installations. There are many less 
important sources such as “consumer products” (luminescent instruments etc) and 
“technologically enhanced” (radionuclides in fertilisers and building materials) of which 
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the majority of people are unaware. In consequence, nobody can escape radiation 
exposure and a large number of patients that seek the advice of a doctor also undergo 
radiological investigation as part of their medical assessment1. In addition, half of all 
patients with cancer with have radiotherapy at some time during the treatment of their 
illness and in 1990 almost 500,000 patients with cancer in the USA were treated with 
this modality2. Unfortunately all forms of radiation can potentially be harmful to 
humans under appropriate conditions and in some cases this can be lethal.  
One of the earliest informal measures of the dose of radiation was the degree of skin 
erythema produced after exposure. The oldest unit of radiation introduced was the 
roentgen for rays x and g and is the unit of the charge produced when the rays ionise a 
given volume of air. Some time later the rad was introduced in order to try to compare 
with particulate radiation whereby 1 rad equals the dose of radiation that will result in 
the absorption of 100 ergs of energy per gram of absorbing substance. Energy of most 
tissues on exposure to 1 roentgen is 93 ergs or nearly 1 rad therefore some use the units 
interchangeably. The SI unit is the Gray which is equal to 100 rads. However these are 
not a measure of energy absorption only of exposure and a time unit required (usually 
per minute). However, 1 rad of particulate energy causes more damage than 1 rad of x 
or y rays and more recently the rem has been introduced. Loosely this represents the 
biological effect equivalent to 1 rad of x or y rays. The SI equivalent is the sievert which 
therefore equals 100 rem. The biological response of the same dose of different 
radiation types is different and so the terms linear energy and relative biological effect 
have also evolved. 
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1.1 Radiation and medicine 
 
In 1895 Roentgen discovered a ‘new ray’ which was capable of producing an image on 
photographic film when directed from his ionising tube and shortly afterwards the 
Curies discovered radium and the ability of rays to produce images of human structures 
not visible by conventional means. It was only a matter of time before this became an 
important part of diagnostic and therapeutic medical practice. Now around half of the 
25% of the population who will develop cancer will receive radiotherapy 2,3. It was soon 
appreciated however that radiation led to morphological changes in the tissue exposed. 
Since then the morphological and cancer induction properties of irradiation have been 
studied. From early observations and subsequent epidemiological studies it became 
clear that radiation could also cause non-morphological effects. These have been split 
into 4 main groups: genetic, fetal, aging effect and risk of cancer4. 
The genetic effects are mostly discussed later with radiocarcinogenesis (section 1.8.1), 
but it should be noted that although it was previously thought that the effects of 
radiation exposure were restricted to the parent in humans and do not pass on to the 
offspring, this may not necessarily be thte case accoding to recent mutagenesis studies5. 
The fetal effects of radiation depend on the age of exposure with lethal consequences of 
very early exposure after conception. During the period of organogensis exposure is 
more likely to result in a wide range of congenital malformations. Chromosomal 
aberrations may occur and radiation may be associated with Downs syndrome6. From 6-
15/40 getsational stages exposure is associated with mental retardation, decreased IQ, 
decreased head size and seizures. Maternal treatment with radioiodine during pregnancy 
may result in cretinism due to passage across the placenta. The post-natal effects are 
discussed later with the specific organs. 
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It was predicted from animal experiments that non-specific ageing processes increased 
after irradiation and in the past it has even been held that 1 rad of exposure led to 10 
days of life lost. However, when the data is interpreted correctly it seems there is no 
general life-shortening effect, and Doll suggests that with the current evidence this idea 
should be abandoned unless new evidence comes to light4. This view is not universally 
accepted however and some believe that radiation induces senescence mechanisms via 
telomere damage or loss8 or dysfunction without direct telomere DNA damage9. 
Pioneer radiologists developed squamous and basal cell carcinomas of their hands and 
the carcinogenic risk of radiation exposure was noted early. By the 1950s this increased 
risk was confirmed by epidemiologists. However it became obvious that the increased 
risk also depended on many other factors such as sex, age and presence of underlying 
hereditary susceptibility, and that there were differences between tissues (the risk of 
developing leukaemia is greater than cervical carcinoma for example and the increased 
risk for bladder carcinoma develops later and persists longer). Although the risk of 
developing cancer was discovered early the mechanisms are still not elucidated. There 
continues to be debate about the risk of low dose exposure such as radon gas in the 
home. Several models (such as linear and linear-quadratic) have been employed to 
predict the risk of low dose exposure but their interpretation remains controversial1. It is 
generally felt, however, that there is probably no risk with low dose exposure or at least 
the effects are so small as to be undetectable1. 
 
1.2 Radiobiology 
 1.2.1 Effects on the cell 
 
Although radiation energy is capable of damaging many components of the cell, the 
main target of the cytotoxic effects is the nuclear DNA. The radiant energy delivered to 
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a tissue causes its effects by two main mechanisms, direct and indirect. The former is a 
consequence of direct interaction between the damaging waves and the nuclear 
chromatin. The second reflects the production of free radicals in the cytoplasm from 
ionisation of the cellular water (which constitutes around 80% of the cell). The 
ionisation results from electrons being ejected from cellular molecules as the radiant 
energy wave passes through. Free radicals are toxic oxygen metabolites that are able to 
cause local damage by oxidising and reducing structures in the local environment. The 
most important radicals implicated are hydroxyl groups. These lead to peroxides or 
cross-linkages with critical molecules such as DNA or RNA or attach to membranes to 
impair normal function. Therefore these two mechanisms both contribute to DNA 
damage causing inter and intra strand cross-linkages, strand breaks, mutations and result 
in impaired ability of DNA to act as template for new strand, and chromosomal 
aberrations such as translocations, deletions, fragments and  rings. Radiation may break 
hydrogen bonds, damage nucleotides and disrupt the sugar-phosphate backbone of 
molecule. The damaged DNA is mostly repaired by efficient mechanisms and if the 
damage is limited then complete repair is possible9. This is thought to be the case with 
single-strand breaks and 90% of chromosomal breaks. However, with more significant 
injury, such as double strand breaks, there will be some which are partially repaired or 
irreparable and the critical reproductive integrity of the cell will be lost, leading to cell 
death. This reproductive cell death may occur either at the first or early subsequent 
mitotic phases. Incomplete repair of this damage may also lead to apoptosis, necrotic 
cell death (pyknosis or karyorrhexis), inhibition of mitotic division with giant cell 
formation and derangement of the mitotic process leading to abnormal mitotic figures. 
The effects on RNA synthesis are thought to be less radiosensitive than DNA and RNA 
may be more stable after irradiation. Proteins can also be directly damaged but larger 
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doses are necessary. Radiation can cause mitochondrial injury also, either direct injury 
to the mitochondrial structure or disruption of mitochondrial processes5. 
 
1.2.2 Cell cycle changes 
 
It has been known for a long time that after irradiation there is a cell division delay 
within exposed cells which may result from G1 block, G2 arrest or S phase delay. This 
is presumably important as a stop-gap for damage repair. Cell cycle regulation is 
controlled by several important regulatory proteins which include p53, GADD45, RAD-
9, possibly bcl-2 and cyclin B. Most are increased after irradiation10 but cyclin B is 
transiently decreased11. Cyclin B is required for the cell to proceed from G2 to M and 
when cyclin B levels are restored the delay is terminated11. DNA double stranded breaks 
are easily detectable after radiation exposure but they are virtually completely repaired 
within 6 hours after administration of highly lethal doses. It has been suggested that the 
significant breaks are not repaired correctly leading to cell death in the next 1 or 2 
mitoses13. 
 
1.2.3 Other changes associated with cellular irradiation 
 
After irradiation there is rapid induction of signal transduction pathways mediated by 
protein kinase c and tyrosine kinase with increased second messengers/inositol 
trisphosphate. In turn this leads to increased gene expression including the early 
response genes c-fos, c-jun and NF-kB. The activation of later responding genes 
including TNF, bFGF, TGFβ is associated with subsequent protein production. This 
cascade of gene activation, gene transcription and protein synthesis is likely to promote 
key cellular functions that allow survival of the cell12. Several other proteins, such as 
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tPA, are increased after irradiation and their presence and relevance to the radiation 
response is only just beginning to be unravelled14-16. These will be discussed in more 
detail later on in this chapter (section 1.4). 
Growth factors are not only stimulated by radiation but their presence also seems to 
affect the response of cells to irradiation and they may play a role in radioprotection17. 
For example IL-1, GMCSF and GCSF all modulate the effects of radiation on 
haematopoiesis. Similarly, bFGF increases the radioresistance of endothelial cells by 
stimulating damage repair17.  Therefore growth factors are attractive as agents of 
radioprotection clinically (discussed later). On the other hand, other genes and proteins 
appear to confer radiosensitivity. This unlocks the possibility of gene therapy since it 
may then be possible to introduce target genes coupled with a radiation responsive 
element into cells prior to irradiation, or small molecule therapy for upregulation of 
specific protective genes. 
 
1.2.4 Morphological changes in cells 
 
Cellular morphological effects may occur in the nucleus, cytoplasm or membrane. The 
nucleus may appear swollen with clumped chromatin. It may have bizarre morphology 
due to aneuploidy/polyploidy and any mitoses present may also be abnormal. The 
cytoplasm is also swollen due to intracellular oedema. Ultrastructurally organelle 
damage is manifest as mitochondrial distortion with degeneration of the rough 
endoplasmic reticulum. Membrane defects and breaks may also be visible13.  
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1.2.5 General effects of irradiation on tissues after uncontrolled exposure 
 
The effects of radiation on tissues depend on the dose delivered and the time since 
exposure1. The results can either manifest soon after exposure or at some later time, 
especially if the dose of exposure is relatively low. It is unfortunate that the effects of 
uncontrolled large dose exposure to the entire human body are known, but following 
studies on nuclear fallout cases the information is all too readily available1. The 
immediate and most rapidly lethal effects of high dose exposure are due to blast injury 
and heat. For those that survive the initial insult, acute radiation sickness may develop13. 
This is a syndrome with variable effects depending on the dose and therefore organs 
involved. Several thousand people died after the atom bomb explosions in Hiroshima 
and Nagasaki from acute radiation sickness. With lower doses of exposure, the effects 
can either be seen relatively early or some time after exposure. The most sensitive tissue 
is the bone marrow which will show effects after quite low doses of exposure. These 
develop over a period of weeks and result from panhypocellularity and peripheral 
cytopenia. Death is unusual after exposure to lower doses but may occur after some 
time from haemorrhage or infection. The gastrointestinal tract is relatively more 
resistant, but will show evidence of damage at higher doses. These will manifest earlier 
than the effects on the bone marrow and will lead to earlier mortality if severe enough. 
The central nervous system is much more resistant but if exposure is large enough 
manifestations may be apparent within minutes. Symptoms reflect an increase in 
intracranial pressure associated with cerebral oedema and mortality is frequent and 
rapid1. 
Thankfully such high dose exposures are rarely, if ever, seen in medical practice. 
However, in contrast to chemotherapy, there is little prospective dose-escalation data to 
determine the maximum tolerated dose of radiation at any given site. It would obviously 
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be difficult to carry out such studies because sub-lethal radiation dose is usually limited 
by late normal tissue effects and not by acute effects. Consequently, the commonly 
accepted tolerable doses have largely been derived empirically during the history of 
radiation therapy, and are based on limited retrospective data and unpublished clinical 
observations and teachings. Although the radiation tolerance of most organs is not 
known, there are published guidelines which serve as reasonable estimates18,19. A 
variety of factors can affect the usable dose and these will be discussed in more detail 
later. In many instances one crucial feature is the type of tissue exposed. In some 
tissues, a reasonable amount of radiation damage may be acceptable, especially if there 
is a realistic hope of tumour control. For example, a small amount of fibrosis in the lung 
is well tolerated and is commonly present after radiotherapy for lung cancer. On the 
other hand, in the central nervous system, the consequences of radiation injury can be 
severe and the dose must be modified to minimise the likelihood of serious brain injury. 
The symptoms may be mild or severe, self-limiting or progressive, gradual or sudden. 
Often the most significant effects of irradiation are seen in rapidly proliferating cells 
which quickly leads to symptoms when functional cell are lost and they are not replaced 
by stem cells18. On the other hand, tissues with considerable stem cell pools and niches 
lead to better recovery – this is especially seen in the skin and gut.  Radiation may also 
induce senescence and/or differentiation of cells rather than perishing and this may be 
particularly important in fibroblasts which then produce excess collagen and fibrosis. 
This will be discussed further later in section 1.5. 
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1.3 Tissue effects after controlled exposure 
1.3.1 Overview 
 
There appear to be quite predictable effects of radiation injury on human tissue. In many 
organs the manifestations follow a set pattern with early and late changes either before 
or after 12 months. These phases of post-radiation injury are frequently split further into 
three stages with acute changes occurring within 60 days, subacute changes progressing 
over the next year or so - due to persistence or evolution of the acute changes 
(sometimes called consequential changes), and late or delayed events developing after 
many months or years. Conventionally, three phases of radiation damage are described; 
prefibrotic inflammatory changes, followed by constitutive fibrotic cellular phase 
leading to a matrix densification but the processes behind these phases do not strictly 
begin and end during each stage, rather there is an overlap where one aspect of the 
process dominates over the others18. 
Whereas the typical side effects of drug therapies are systemic, they are local or loco-
regional after radiation therapy. Therefore, the side effects make themselves manifest in 
tissues and organs that have been irradiated. In most instances the pathological changes 
associated with radiation injury begin immediately after exposure, but the clinical and 
histological features may not become apparent for weeks, months, or even years after 
treatment. For example, radiation changes in the lung can be detected 6 weeks after 
irradiation but these are mild even after a high dose. However, by 6 months there is 
widespread fibrosis. As has been mentioned, radiation injury is commonly classified as 
acute, consequential, or late, depending on the time taken for symptoms to appear. 
Acute (early) effects are those that are observed during the course of treatment or within 
a few weeks after treatment. Consequential effects (sometimes called consequential late 
effects) appear later, and are caused by persistent acute damage. Late effects emerge 
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months to years after radiation exposure. The terms acute and late have been introduced 
in radiation therapy, but because the underlying molecular and cellular processes are 
complex and lead to a range of events, the definitions are rather loose and may be more 
operational than mechanistic. Early symptoms may not be apparent in some organs that 
develop late injury, such as the kidney, and trauma or surgery months or years after 
irradiation can precipitate acute breakdown of tissue that had been functioning 
normally20. 
The early or acute changes are seen most commonly in rapidly dividing cells such as gut 
epithelium and the early vascular changes reflect non-specific dilatation and increased 
permeability leading to oedema. The chronic or delayed effects are dominated by 
degeneration and repair which again probably result from vascular damage. It seems 
that other cells such as fibroblasts and smooth muscle cells may play important roles in 
the production of delayed effects20. 
In many ways, the acute and late manifestations may be consequences of the same 
underlying mechanisms. However, late effects tend to occur more in tissues with low 
cellular turnover than proliferation and therefore different parts of a tissue may be 
affected differently (such as the mucosa and muscularis propria of the bowel wall for 
instance). Therefore although there are overlaps between the mechanism of early and 
late injury, there are also important differences. Fibroatrophic processes dominate the 
late changes21. These tend to be local to the site of exposure, generally unavoidable and 
usually considered to be irreversible. The effects, together with their consequent 
functional effects can mimic or promote aging and/or growth retardation. They may also 
eventually be involved in the carcinogenetic process1. 
The late effects occur through complex interacting processes that are not completely 
understood especially with respect to cell death during proliferation. Cells exist in a 
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complex community where cells depend on each other for, and contribute individually 
to, the welfare of the whole tissue. Clearly some of these late manifestations and 
associations with vascular damage, endothelial cell injury and thrombosis can lead to 
downstream hypoxic cell death; additionally parenchymal cells may die and lead to 
atrophy and loss of vascular supply. 
The consequential late features are produced by failure of acute lesions to heal or 
resolve and therefore the process persists into the later period. Consequential damage is 
most frequently seen in the urinary system, gastrointestinal tract and skin, and is more 
common after more intense therapies18. 
The early or acute changes of radiation reflect a rapid molecular response to the insult 
including cytokine production leading to adaptive response in surrounding tissues and 
inflammation18. The process is very much the same as any acute inflammatory process 
with subsequent wound healing18. Early effects become manifest within a few weeks of 
the completion of a course of fractionated radiotherapy. These effects include skin 
erythema, dry or moist desquamation of the skin, mucositis, nausea and diarrhea, 
depending on the site of irradiation22. Late effects typically present after latent periods 
of months to years, and are generally related to radiation-induced fibrosis, atrophy, 
vascular damage, neural damage and a range of endocrine and growth-related effects. 
The pathophysiological and functional expression of this damage will be outlined in 
more detail later, but it depends very much on the tissue or organ affected. Of course, 
radiation-induced second malignancies are obviously important, especially in patients 
with a long life expectancy. In general the early effects are transient and they settle after 
a few weeks, but late effects tend to be irreversible and often even progressive in 
severity. 
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A short time after irradiation of any tissue there follows a combination of inflammatory 
and cellular (necrotic/apoptotic) events. In the small bowel for example, epithelial cells 
show evidence of cell death and, due to cell cycle arrest, there is a lack of repopulation 
from the crypts leading to erosion23. An inflammatory cell infiltrate is seen and, 
although mild, is characterised by prominent numbers of eosinophils and mast cells. It is 
interesting that the latter are very radiosensitive and contain inflammatory mediators 
and fibrogenic proteins thereby suggesting a role for them in more chronic changes24. 
Platelets are also packed with inflammatory mediators and their role in radiation injury 
may be significant, but there are few studies on this topic. With high enough doses any 
tissue may show necrosis. General epithelial changes include nuclear pleomorphism, 
giant cell formation and hypo/hyperplasia early on with atrophy, dysplasia, metaplasia 
and neoplasia developing later. 
Early vascular changes include dilatation, increased permeability and endothelial cell 
swelling. More chronic lesions show endothelial cell atypia, intimal thickening, medial 
hypertrophy, luminal thrombosis and endarteritis obliterans with subsequent ischaemic 
consequences25. A characteristic delayed consequence of irradiation is fibrosis with 
multinucleate fibroblasts and increased collagen deposition. This is probably a result of 
a combination of early repair followed by late ischaemia. The fibrosis appears to be a 
progressive feature. Other stromal changes include collagen degeneration and fat 
necrosis. Necrosis and ulceration may occur as a late complication following 
progressive vascular compromise and increasing ischaemia. 
In general the tissue effects depend on the dose and type of exposure but many factors 
influence the response such as the age of the patient, the relative radiosensitivity of the 
cells, the capacity for repair and the architectural make up of the tissue. Effects in 
general may be stochastic or non-stochastic: the former vary with frequency but not 
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dose and have no threshold, the latter vary in severity but not frequency with dose and 
may exhibit a threshold1. 
 
1.4 Pathogenesis of radiation injury 
For many years it was considered to be the direct cytotoxic effects of radiation on cells 
which produced the lesions that developed after tissue was irradiated. The prevailing 
‘target-cell’ hypothesis in the late 1980s and 90s suggested that the main effect of 
ionizing radiation on tissues and organs was a direct consequence of cell killing, 
resulting in the depopulation of crucial cell populations and subsequent functional 
deficiency18. However, it became apparent from cellular radiobiology studies that cell–
cell communication was vitally important in the processing of cellular radiation damage. 
Irradiating single cells in culture flasks with high-precision microbeams cells led to the 
death of nearby cells in the vicinity of an irradiated cell even though the neighbouring 
cells had not been irradiated themselves - the so-called 'bystander effect'20. It is 
becoming clear now that the direct cellular effects of radiotherapy are not the main 
reason for subsequent tissue injury. It also became more obvious because local cells and 
progeny effects caused by signalling pathways also show changes after irradiation of 
neighbouring or parent cells. These bystander cells – cells not in direct contact - also 
show gene rearrangements, chromosome aberrations, sister chromatid exchanges, 
deletions, duplications, mutations, amplifications and cell death. Many of the changes 
observed previously after whole cell irradiation could be induced in vitro by 
cytoplasmic irradiation alone. Therefore the theory was proposed that this was because 
of gap junction transmission by soluble factors especially reactive oxygen species and 
cytokines26. Later, this was also recognised in vivo. For example, lungs irradiated with 
apical shielding showed similar changes in the apex to the rest of the lung 
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parenchyma27; similar changes were observed in liver tissue protected from the 
radiation source28. 
Recent interest has concentrated on epigenetic changes such as methylation status and 
histone injury5. These areas, together with RNA associated silencing, have all became 
fashionable areas of interest. These are especially interesting as they provide additional 
clues as to how radiation induced changes may be passed onto cellular progeny and 
subsequent cells are consequently genetically unstable5. 
When the focus of interest shifted away from direct cell injury during the 1990s, it 
became clear that the latent period between irradiation and the clinical expression of late 
normal-tissue injury is a highly active interlude. Soon after irradiation many cytokine 
cascades are activated, and these remain active throughout the phase of overt damage 
expression. Although radiation-induced cell killing might have a role as a triggering 
event, it is now clear that there is an orchestrated, active biological response brought 
about by the early release of cytokines17. This response is mediated by various cell 
types, including inflammatory, stromal, endothelial and parenchymal cells actively 
responding through the release or activation of downstream cytokines, growth factors or 
chemokines20. 
Direct cellular injury may be an important component of the early effects of 
radiotherapy, but studies of late side effects and, in particular, radiation-induced fibrosis 
indicate that this cannot be the only route for subsequent tissue remodelling. Clinically, 
radiation-induced fibrosis is characterized by reduced tissue flexibility, reduced 
compliance or strictures. Fibrosis is often associated with pain, neuropathy, reduced 
strength or restricted motion of joints and distal lymphoedema. The corresponding 
histopathological picture typically shows that the normal tissue is partly atrophic, partly 
replaced by mesenchymal cells, and that there is excessive collagen deposition21. It has 
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long been clear that fibroblasts are the main cell involved in the deposition of the 
extracellular matrix; but it was less obvious how the fibroblasts could also be the 
putative target cell for radiation-induced fibrosis. It seems counter-intuitive that killing 
fibroblasts would lead to increased collagen production. Other important observations 
came from clinical studies that showed that non-cytotoxic drugs such as tamoxifen 
could also increase the incidence of late radiation-induced fibrosis after radiation29. 
Many studies have also shown that radiation induced changes may become manifest 
clinically many years after treatment (reviewed in 21). 
 
1.5 Pathobiology of radiation fibrosis 
 
Among the late effects of radiation therapy, radiation-induced fibrosis is probably the 
most extensively studied. This is partly due to the importance of this reaction after 
clinical radiotherapy and partly because a lot has been learned from molecular 
pathology studies of wound healing and of human diseases characterized by the 
excessive formation of fibrous tissue. Mechanistically, the early phases of fibrogenesis 
after irradiation can be seen as a wound-healing response characterized by an almost 
immediate upregulation of pro-inflammatory cytokines such as tumour-necrosis factor-α 
(TNF), interleukins 1 and 6 (IL1 and IL6) and many growth factors in the irradiated 
tissue30 (Fig. 1). Chemokines are released and these recruit inflammatory cells from the 
surrounding tissue into the irradiated volume. The interactions between the many 
proteins involved in the fibrogenic process are still not completely understood. 
However, useful insights into the in vivo function of the more than 100 proteins 
involved in wound healing have been gathered from genetically modified mouse 
models, gene knockouts or mice that transiently or permanently overexpress one of 
these proteins30.  
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Normal wound healing is regulated by a complex balance between profibrotic proteins 
such as transforming growth factor-β (TGF)31 and its downstream effector connective 
tissue growth factor (CTGF, also known as CCN2)32 on the one hand and antifibrotic 
proteins such as TNF and interferon-γ (IFN) on the other33. The pro-inflammatory TNF 
is expressed in macrophages during wound healing but downregulates the expression of 
matrix genes34. In addition, IFN is a pro-inflammatory cytokine released by T cells after 
irradiation, that has been shown to downregulate TGF and suppress collagen synthesis35-
37. 
The molecular processes underlying rectal radiation injury have been investigated and 
inflammation-related proteins are clearly important. Reduced amounts of endothelial 
thrombomodulin have been observed in normal rectum and tumours after irradiation, 
which may lead to increased fibrin deposition and associated upregulation and release of 
inflammatory and fibrogenic cytokines38. Increased concentrations of mRNA for TGFβ1 
and TNFα have been found in colorectal tissues of fibrosis-susceptible and fibrosis-
resistant strains of mice 6 months after irradiation39. In the ileum of rats, increases in 
TGFβ1, TGFβ2, and TGFβ3 were observed 2 weeks after a radiation dose of 12 or 21 
Gy, but after 26 weeks, only TGFβ1 remained high40. TGFβ1 was particularly 
prominent in areas with chronic fibrosis, in smooth muscle, mesothelium, endothelium, 
and fibroblasts. 
In the lung, the pathogentic link between pneumonitis early and the development of 
fibrosis later on is still being unravelled. Animal and human studies indicate that 
vascular injury and the coagulation cascade, cellular adhesion molecules, 
proinflammatory and profibrotic cytokines, and oxidative stress all seem to have vital 
roles in the development of radiation pneumonitis41. It is interesting to note that mice 
lacking the gene for the endothelial cell adhesion molecule ICAM1 do not develop 
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pneumonitis or show infiltration of inflammatory cells after irradiation42. The mice 
without ICAM still develop fibrosis, but only at high radiation doses, suggesting that an 
inflammatory response is not the only factor underlying the development of radiation 
fibrosis. Furthermore, individuals with high plasma concentrations of the 
proinflammatory cytokine interleukin 1, or the profibrotic cytokines interleukin 6 and 
TGFβ, before or during radiotherapy have a higher risk of developing pneumonitis 41,43 
and patients with increased concentrations of TGFβ at the end of their course of 
radiotherapy have a higher risk of symptomatic radiation-induced lung injury 6 months 
to 2 years after radiotherapy44. In a fibrosis-prone strain of mice given a single dose of 
20 Gy to the thorax, increases in interleukin 1 were observed during the early post-
irradiation period and were associated with pneumonitis, whereas increases in TNFα, 
TGFβ1, and TGFβ2 occurred later and were associated with the development of 
fibrosis45. Fibrosis-prone mice express more and different chemokines and chemokine 
receptors 6 months after irradiation than fibrosis-resistant mice46. These results clearly 
point towards the recruitment and activation of monocytes, macrophages and 
lymphocytes in the development of fibrosis in irradiated lung tissue. Gene therapy with 
manganese superoxide dismutase (MnSOD) reduces fibrosis in these mice47, suggesting 
a role for oxidative stress in the development of radiation injury as described previously. 
The antifibrotic action of the related compound copper and zinc-containing superoxide 
dismutase (Cu/ZnSOD) could well be mediated by a reduction in the expression of 
TGFβ by myofibroblasts48. The renin-angiotensin system also appears to be involved in 
the development of pulmonary injury after irradiation. However, although angiotensin-
converting enzyme inhibitors or an angiotensin receptor blocker protected rat lungs 
from both pneumonitis and fibrosis after radiation exposure49, patients taking these 
drugs for their hypertension did not have a reduced incidence of pneumonitis50.  
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Figure 1. Mechanisms of fibrogenesis 30 (with permission) 
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In general, immediately after damage has occurred to the epithelial/endothelial barrier, 
there follows a release of TGF with the recruitment of inflammatory cells and the 
induction of reactive oxygen species. This leads to recruitment and activation of 
collagen producing cells, matrix activation of myofibroblasts and collagen deposition. 
The source of the fibrogenic cells is quite interesting. Some are indigenous fibroblasts 
(or local fibroblast like cells such as myofibroblasts). Others are produced by epithelial 
to mesenchymal transition of local epithelial cells30. There is still further recruitment of 
fibrocytes from the bone marrow51. 
Normal wound healing is a precisely orchestrated response to tissue injury, from the 
initial platelet response immediately after the trauma, to the final remodelling of the scar 
tissue more than a year later. Radiation activates wound-healing machinery, but in 
addition to these processes the unique nature of radiation damage initiates a series of 
processes that are distinct from those involved in normal wound healing. These 
processes span the whole timescale of normal wound healing, and it is probable that it is 
this continued interference with the normal control of wound healing that leads to the 
excessive deposition of extracellular matrix (ECM) and collagen that is characteristic of 
radiation fibrosis51.  
In contrast to normal wound healing, the radiation fibrogenic process can be perpetuated 
over periods of many years. This has led to some labelling radiation fibrogenesis as a 
'wound that does not heal'51. Understanding the homeostatic feedback control of normal 
wound healing — and why this is dysfunctional in radiation fibrogenesis — would 
clearly represent a breakthrough in the attempts to develop interventions to dampen, or 
possibly even reverse, radiation fibrosis. 
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1.6 Some of the key players in radiation fibrosis 
 
There are numerous proteins and other components involved in the process of fibrosis 
which could be discussed at this point. The focus of this thesis is PDGF. Chapter 6 is 
devoted to this growth factor. Amongst the others, some of the crucial key players will 
be outlined here, in particular TGF(β). 
 
1.6.1 Transforming growth factor β (TGF)  
 
TGF is a multi-functional cytokine, a 25 kDa polypeptide that is strongly profibrotic. 
When TGF was discovered it was classified as a growth factor, a term that reflects its 
involvement in the proliferation and differentiation of cells31. At that time, the term 
cytokine was used to refer to signalling proteins in the haematopoietic and immune 
systems, but as cellular molecular biology evolved it was realized that the same kind of 
cell–cell signalling also has a fundamental role in solid tissues. TGF can usefully be 
classified as a cytokine and a growth factor. It has attracted much interest in fibrosis 
research, and there is a large and rapidly growing body of knowledge on this protein and 
its biological action. TGF belongs to a superfamily comprising over 60 proteins in 
multicellular organisms, with at least 29 of these encoded by the human genome and 
more than a dozen related molecules in invertebrates33. These proteins regulate a wide 
range of processes, including embryonic development, homeostasis, cell-cycle control 
and wound healing33. Dysfunction of the TGF system seems to be involved in various 
severe human diseases, including immunodeficiency, cancer, defective wound healing 
and a long list of fibrotic diseases in the kidney, liver and lung, as well as 
arteriosclerosis, rheumatoid arthritis and scleroderma. TGF has a dual role in tumour 
suppression and tumour promotion52,53. TGF is a potent inhibitor of endothelial cell 
proliferation, in the mammary gland for example54. It has been proposed that during 
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malignant progression breast cancer cells might become refractory to the growth-
inhibitory effect of TGF, and that TGF, through its effect on the extracellular matrix, 
might promote invasion and metastasis in patients with advanced disease54-56. 
TGF(β) exists in three isoforms (TGFβ1–3), and these show a high degree of homology 
between various species33. TGF is secreted in latent form and requires dissociation of 
the active mature TGF from a latency associated peptide (LAP) to bind its receptor57. 
This means that a large extracellular pool of latent TGF can be rapidly mobilized after a 
triggering event. Ionizing radiation is one of the few exogenous factors that have been 
shown to induce TGF activation, and this happens within an hour or less of giving doses 
as low as 0.1 Gy58,59. The active TGF binds to pairs of two distinct transmembrane 
receptors, TGFR1 and TGFR2, and it has been shown that TGFR1 is unable to bind 
TGF in the absence of TGFR2, and conversely, that the binding of TGF to TGFR2 does 
not activate the signalling pathway in the absence of TGFR160. The biological 
advantage of this relatively complex — compared with other similar ligand–receptor 
systems — activation of the signalling pathway is not clear, but it probably contributes 
to the versatility of the transcriptional response to TGF. The signalling pathway itself is 
rather simple: the only established intracellular signalling effectors are the Smad 
proteins, of which there are five R-Smads (receptor-regulated Smads; SMAD1, 2, 3, 5 
and 8) that are directly phosphorylated by the type I receptor, a co-Smad (SMAD4) that 
forms heteromeric complexes with the R-Smads and two inhibitory Smads (SMAD6 
and 7) that antagonize TGF signalling61. The final transcriptional response of a specific 
target gene is determined by a number of DNA-binding transcription factors and various 
co-activators and co-repressors51. 
Ionizing radiation directly activates TGF through the dissociation of the latency-
associated peptide (LAP) from the active mature form of TGF. Furthermore, radiation 
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damages endothelial cells, which in turn initiate a cellular response that also leads to the 
release of pro-fibrotic cytokines, including TGF. A third main effect of radiation is that 
it perturbs the homeostatic control of the reactive oxygen and nitrogen species (ROS 
and RNS), which again leads to the activation of TGF and directly interferes with the 
Smad signalling pathway. These extracellular events activate the TGF signalling 
pathway, which in turn produces various transcriptional responses, all of which lead to 
increased extracellular matrix (ECM) and collagen deposition33. The radiation-induced 
vascular damage and uncontrolled tissue remodelling can lead to tissue hypoxia, which 
could be one of the mechanisms perpetuating the fibrogenic response. 
One of the many effects of TGF is that it promotes terminal differentiation along a 
lineage from proliferation-capable progenitor fibroblasts to postmitotic functional 
fibrocytes62-65 and it has been suggested that the ratio between the number of colony-
forming late and early progenitor fibroblasts would be correlated with the incidence of 
clinical fibrosis after radiotherapy. Two studies found some support for this 
hypothesis66,67 but concluded that the association was too weak to be used as a potential 
predictive assay in the clinic. 
One puzzling aspect until recently was where the fibroblasts originated. Epithelial–
mesenchymal transition (EMT) of cells has long been recognized as an important part of 
embryonic development, but more recent data suggest that EMT occurs during wound 
healing and fibrogenesis in adult tissues, including radiation fibrosis68. In the case of 
renal fibrosis it has been estimated that more than a third of all disease-related 
fibroblasts stem from tubular epithelia69. It is probable that EMT has an important role 
in radiation fibrogenesis, and studies have shown that the loss of SMAD3 blocks EMT 
and reduces fibrogenesis70. There is also a strong experimental case for the mobilization 
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of bone-marrow stem cells71,72 and human mesenchymal stem cells73 as an important 
element in the processing of radiation injury. 
Although some of the signalling pathways are known in detail, it is still not clear why 
these cytokine cascades are continually perpetuated. One suggestion is that endothelial 
cell killing, which leads to vascular damage and subsequent tissue hypoxia, could drive 
radiation fibrogenesis74,75. This model is supported by experimental studies of fibrosis in 
the mouse lung showing that moderate hypoxia is present in the lung at 6 weeks after 
irradiation — long before pathological signs of restrictive lung injury become 
manifest76. There is also evidence in other fibrotic diseases that hypoxia is involved in 
their progression at least in the final stage of disease77-79. 
 
1.6.2 Reactive oxygen and nitrogen species (ROS and RNS) 
Another key element in fibrogenesis seems to be the homeostatic control of reactive 
oxygen and nitrogen species (ROS and RNS) in the cell. It has long been appreciated 
that ionizing radiation creates ROS in the cell1, but after the discovery of the biological 
role of nitric oxide and its interaction with the superoxide radical O2-, oxidative and 
nitrosative stress are now seen as two sides of the same coin. It has been proposed that 
O2- is the initiator and NO and its derivatives the effectors of the activation of 
cytoplasmic signalling pathways20. However, it has been shown that the total 
concentration of ROS is dwarfed by the contribution from cell metabolism and other 
sources: a 1 Gy radiation dose produces less O2- averaged over the cell volume than a 
human cell produces in 20 seconds80,81. Therefore, it would seem that it is the 
perturbation of the homeostatic control of ROS and RNS rather than the radical species 
themselves that drives the active biological response to oxidative and nitrosative stress. 
Superoxide dismutase (SOD) is the most important antioxidant enzyme, effectively 
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catalysing the conversion of O2- to H2O2 and thereby controlling the concentration of 
superoxide80. There is direct evidence that the SOD enzymes have an important role in 
the molecular pathology of fibrosis74,82-84. The ROS and RNS pathways as 
interventional targets in fibrotic disorders is described below. 
 
1.6.3 The renin–angiotensin system  
The renin–angiotensin system (RAS) regulates blood volume, arterial blood pressure 
and cardiovascular function. Although research into hypertension has traditionally 
focused on haemodynamic regulation by the RAS, more recent research points to the 
role of angiotensin II in vascular remodelling and fibrosis as a pathogenic factor in this 
disease85,86. The RAS has been known for some time to be implicated in kidney injury 
after irradiation, and studies in the early 1990s showed that the angiotensin-converting 
enzyme (ACE) inhibitor captopril reduced the level of kidney damage20. Captopril 
contains a thiol group, and could therefore potentially function as a free-radical 
scavenger, but it has become clear that ACE inhibitors without a thiol group also 
work20. Furthermore, it has been shown that these drugs are effective at doses that do 
not lower blood pressure and that other blood-pressure lowering drugs have no effect on 
radiation-induced kidney damage. Recently, Robbins and Diz87 have reviewed the 
evidence that indicates that RAS might contribute to the development of radiation 
effects in other organs, for example the lung and the brain. As ACE inhibitors seem to 
decrease the risk of radiation effects irrespective of any systemic effects, it has been 
proposed that they act on locally generated angiotensin II, perhaps generated in 
response to oxidative stress. Angiotensin II has several functions, including an ability to 
upregulate TGF, and could therefore contribute to the fibrogenic response in irradiated 
tissue. 
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1.7 Summary of relationship between mechanism and effects of radiation injury 
Acute radiation damage most commonly involves tissues with rapidly proliferating 
cells, such as in epithelial surfaces of the skin or alimentary tract. Symptoms develop 
after functional cells are lost as part of normal tissue turnover and are not replaced. This 
is because of impairment to the stem-cell compartment. In tissues such as the skin and 
gut, there is compensatory proliferation in the stem cell population, often involving the 
stem cell niche, which appear to be more tolerant to radiation than other types of cells. 
Subsequent replacement of functional cells leads to a degree of recovery. Symptoms 
tend to subside thereafter, usually during the course of radiotherapy.  
The ionisation events and free radicals produced by radiation cause damage to various 
components of the cell, including vital cellular structures and processes. DNA damage 
from radiation commonly leads to cell death in the first cell division after irradiation or 
certainly within the first few divisions. Cell death during mitosis (mitotic death) is 
generally caused by unrepaired or improperly repaired chromosomal damage. Cell death 
may also occur by apoptosis. In some cell types (especially lymphocytes, 
spermatogonia, and salivary gland serous cells) undergo apoptosis during interphase 
after irradiation. This type of death is rapid. Cells may also leave the reproductive pool 
by differentiation rather than proliferation. This senescence may be a particularly 
important response of fibroblasts, resulting in excess collagen deposition and fibrosis. 
Radiation also activates various cellular signalling pathways that lead to expression and 
activation of pro-inflammatory and profibrotic cytokines88-90 vascular injury91, and 
activation of the coagulation cascade92. These changes are involved in the development 
of oedema, inflammatory responses, vasculopathic processes and the initiation of 
wound-healing. Sometimes the acute reaction fails to resolve and it may persist for 
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some time. The resulting lesions, often called consequential late effects can contribute 
to the overall damage93.  
The late effects of irradiation develop many months or years after treatment. The 
symptoms may be mild or severe, self-limiting, or progressive, and may develop 
gradually or suddenly. In some instances there may be progression of the late effects for 
20–34 years after therapy94,95. Late effects tend to occur in tissues with a slow turnover 
of cells, such as subcutaneous tissue, fatty tissue, muscle, brain, kidney and the liver, 
including neighbouring sites of slow turnover within tissues that contain rapidly-
proliferating cells, such as the wall of the intestine. The resulting lesions can be quite 
variable, but usually include fibrosis, necrosis, atrophy, and vascular damage.  
Clinical and experimental animal data show that the fibrogenic pathway is heavily 
involved in the development and expression of many types of late side effects of 
radiation therapy, and it does seem to be a universal response to irradiation. Under the 
target-cell paradigm, the most important pathogenic mechanism was thought to be 
parenchymal cell depletion, and it is probable that this does have a role not only in early 
but also in late side effects of radiotherapy. However, in many cases this will be 
accompanied by a fibrotic–atrophic response, and it might not be possible to separate 
the relative contributions of the two in a given setting. 
Late effects develop through complex interacting processes that appear to include cell 
death during proliferation. Cells co-exist in a complex community and all members 
depend on each other for the welfare of the whole tissue. Irradiation of tissue activates a 
rapid molecular response. Part of this response is the production of cytokines, which 
leads to an adaptive response in the surrounding tissue and cellular infiltration. Direct 
vascular damage and indirect release of vasoactive cytokines enables fibrin to leak into 
the tissues, thereby promoting local collagen deposition. In many ways, the response 
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has the features of general wound healing; except that the process often persists due to 
waves of cytokine production89,96. Leukocyte adhesion to endothelial cells and thrombi 
can block local vessels, as can endothelial-cell aggregates during vascular regeneration, 
which can lead to down-stream loss of cells dependent on those vessels97-99. 
Additionally, death of parenchymal cells can lead to atrophy of the vessels supplying 
the tissue they make up100. The response is often perpetuated by cell loss, dysregulated 
cell-cell interactions and hypoxia101. In some tissues accelerated senescence of stromal 
cells and their infiltration into sites of damage results in further fibrotic consolidation 
whilst in others it is necrosis that is the most serious complication. This is almost 
certainly a result of the reparative capacity of the tissue involved and the cell type 
injured – tissues composed predominantly of permanent cells most affected by necrosis 
whereas labile or stabile cell populations either regenerate well or may be replaced by 
fibrous tissue. 
 
1.8 Non-fibrotic late effects 
1.8.1 Radiocarcinogenesis  
 
Carcinogenesis is an important consequence of radiation exposure, which is considered 
here. As mentioned previously epidemiological studies have documented a definite 
increase in a range of cancers after irradiation exposure, particularly at higher doses. 
The higher the linear energy transfer (LET) the higher the rate of tumours1. Important 
clues to the effects of radiation and radiation-related carcinogenesis have come from 
patients who appear to lack the normal DNA repair apparatus alluded to above. Patients 
with ataxia telangiextasia (AT), Fanconi’s anaemia and xeroderma pigmenstosa (XP) 
and similar inherited disorders fall into this category and develop increased numbers of 
tumours after exposure13. Also mutant mammalian cell lines defective in repair of 
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double strand breaks are more radiosensitive than parental cell lines from which they 
were derived. The dose required for tumour formation appears to be important as 
extremely high doses seem to cause cell death and very low doses seem to have limited 
effects (we will come back to this later). At intermediate doses there is a peak incidence 
for tumour formation and several theoretical models have been developed in order to 
estimate the risk and discover whether low dose exposure is associated with an 
increased risk. The present models do not always reflect the epidemiological evidence 
and the negative studies do not rule out the possibility that cancer is induced by low 
doses as the effect may be so small that at present it is undetectable102. Radiation has 
been described as a universal carcinogen as it may produce tumours in virtually all 
tissues of all species at all ages. The mechanisms however are poorly understood, but 
with the obvious role of DNA/chromosome damage and alteration following radiation it 
seems likely that these structures are significant. In addition the production of proto-
oncogenes and other tumour promoting proteins plus the downregulation or loss of 
tumour suppressor genes/proteins probably all have a role. For example it has been 
shown that p53 mutations may occur after irradiation although this protein does not 
seem to play a general role in radiocarcinogenesis8. Other possible influences include 
the inability to repair DNA damage due to lack of the relevant proteins, and autocrine 
effects of growth factors. There is also evidence that there is prolonged genetic 
instability and long term mutagenic events after irradiation thereby linking the well-
known phenomenon of latency with DNA damage13. Whatever the mechanism, it seems 
likely that it follows at least some of the pathways now established for non-radiation 
induced cancers103.  
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1.9 Factors affecting response 
 
These are often separated into the physical, biological and chemical factors of each 
radiation episode. The physical characteristics of the radiation, total amount delivered 
and time in which it is given are important determinants of the response. The type of 
cell is also important as indeed is the tissue make-up and architectural arrangement. The 
tolerance of normal tissue depends upon its functional reserve and its structural 
organisation. For example, the lung is able to tolerate a high dose in a small volume, but 
is less able to tolerate a low dose to the whole lung18. Conversely, a high dose to a small 
volume in the spinal cord could be hazardous, but a low dose to a large area may be 
innocuous18. 
There are several chemical factors that can either sensitise tissue to irradiation damage 
or actually protect it. Oxygen serves as a substrate for the production of free radicals 
and therefore increases damage, utilized in hyperbaric enhanced therapy. In fact this is 
the main reason for using hyperbaric therapy. Halogenated pyrimidines (DNA base 
analogues) are also tissue sensitizers. Protective chemical substances include sulphydryl 
amines, cysteine and cystamine which act as free radical scavengers and therefore limit 
damage. Growth factors are not only stimulated by irradiation, but their presence has 
also been shown to affect the response to irradiation, and they play a role in 
radioprotection. This radioprotective role is established for haematological growth 
factors such as GMCSF and GCSF and it has been shown that bFGF increases the 
radioresistance of endothelial cells by stimulating damage repair17. 
Biological factors include the phase in the cell cycle, with cells being more susceptible 
in G2 and mitosis than G1 and S phase. This may be because the repair proteins are 
present in the more resistant phases. Rapidly dividing cells are therefore more 
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radiosensitive than slowly dividing ones (the Bergondie/Tribondeau Law) and slowly 
proliferating tissues show their signs of damage months or years after exposure13. 
The incidence and the severity or grade of a specific side effect depends on the details 
of how therapy is delivered but shows large variability among patients, even after 
delivery of identical treatment. Recently, the importance of this topic has been 
highlighted by the flurry of new radiation-treatment strategies in various stages of pre-
clinical or clinical development. Experimental radiotherapies are not always better than 
the standard therapy — but they are often more toxic as they typically represent 
attempts to intensify therapy. Some divide the factors that influence the outcome of the 
radiation therapy into those related to the treatment, those associated with the patient 
and those related to the tumour. 
 
1.9.1 Treatment-related factors 
 
The effects of irradiation seem to depend on the dose and type of radiation (ionising 
versus UV radiation) and also the stage in cell cycle when irradiation is encountered. As 
noted above, cells in G2 and mitosis are more susceptible to the damaging effects of 
radiation. Treatment related factors are usually a reflection of the total and fractional 
dose and schedule; late changes appear to be associated more with changes in fraction 
size and less with changes in overall treatment time than early changes. Chemotherapy 
can exacerbate reactions, whether given at the same time or metachronously. Other 
drugs or compounds which alter cell dynamics can also increase radiosensitivity if given 
appropriately, and this is one mechanism being explored for enhancing the effects of 
radiotherapy for the treatment of tumours. The volume of tissue irradiated is also 
important.  Larger volumes carry a higher risk of subsequent organ-function 
impairment.  
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Appreciation and manipulation of the dose-response curves for radiotherapy, together 
with the limited capacity of tumour cells for repair has led to the development of 
alternative models for radiation delivery, apart from single large doses. Methods include 
accelerated (standard fractions, but several in one day) and hyper-fractionation (lots of 
mini doses).  Both can deliver the same overall dose but they allow one to focus a 
higher dose on the tumour rather than the surrounding normal tissues. Conformal 
radiotherapy uses the same radiotherapy machine as the normal treatment (this is called 
a linear accelerator) but uses metal blocks placed in the path of the x-ray beam to alter 
the shape of the beam104. This means that the metal blocks can be carefully arranged for 
each patient to shape the treated area more precisely. More recently a device called a 
multi-leaf collimator has been produced as an alternative to the metal blocks. This 
consists of a number of layers of metal sheets, which are fixed to the linear accelerator. 
Each layer can be adjusted to a different position and so alters the shape and intensity of 
the beam of x-rays reaching the patient. A further development has been the ability to 
move the layers of the multi-leaf collimator whilst the actual treatment is in progress. It 
has been argued that this can give even more precise shaping of the treatment areas to 
the contours of the tumour that is being treated. This method of moving the collimator 
during the radiotherapy treatment is called intensity modulated therapy. There is 
evidence that conformal treatments reduce the number of side effects. NICE (the 
National Institute for Clinical Excellence) produced a manual in September 2002 
('Improving outcomes in urological cancers') which recommends conformal 
radiotherapy as the best type of external radiotherapy for prostate cancer105. At present it 
is not known how intensity modulated therapy compares with standard conformal 
treatment. 
In addition to dose and method of delivery, an appreciation of the effects of time 
fractionation has allowed radiation schedules to try to discriminate between tumour and 
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normal tissue. It has been found that around 6 hours is ideal for normal tissue to recover 
after a dose of radiation. However, some tumours repopulate extremely quickly and 
tumours are said to become tolerant. The current practice of fractionating radiotherapy 
treatments arose from observations that late effects were less severe and better local 
tumour control rates could be achieved with multiple, small radiation fractions than with 
one or a few large fractions. 
 
1.9.2 Patient-related factors 
Patients vary in their response to a specific course of radiotherapy106. There are many 
reasons for this, as everyone is unique in terms of their individual anatomy, tissue and 
cellular composition. In fact, tissue type is an important determinator in the outcome of 
radiation delivery. As discussed previously, cells and tissue have different integral 
tolerances; in some areas of the body small volume high dose delivery is better tolerated 
than low dose to a wider area. The severity of response depends very much on the 
radiosensitivity of the target cell(s) and the architectural arrangement (functional 
subunits) of the tissue being irradiated. 
There are also important general factors which influence the response to irradiation, in 
addition to the make up of the tissue. These include local and systemic features such as 
the presence of recent trauma, diabetes mellitus, vascular disease and medication 
(including anti-inflammatories and steroids) which will be familiar determinants of all 
wound healing processes. Age can also be considered an influencing factor, but age by 
itself must not be considered a reason for avoiding the use of a curative regimen. 
As late effects of irradiation can be associated with significant human suffering and 
direct health-related costs, even costly treatment modifications would be justified in 
patients at high risk of developing late toxicity if they could be reliably identified by an 
  50 
assay. At the same time, the identification of predictive markers could point to new 
interventional targets for ameliorating late effects. In addition, any break-through could 
be broadened to include the early detection and repair of cellular damage and the tissue-
remodelling response in general, not only that caused by irradiation. 
Genetic susceptibility has been mentioned before. This genetic influence can be readily 
appreciated with conditions which interfere with DNA damage repair such as AT. These 
patients develop severe radiation reactions because of defects in the repair of DNA after 
radiation damage. Furthermore, LOH studies have shown that many other genetic 
alterations which involve proteins that impact on inflammatory and fibrotic cytokine 
production and function could also influence the ability of an individual to tolerate their 
radiotherapy. Such alterations have been observed in patients with lung cancer and in 
tissues adjacent to breast and bladder tumours. This has fuelled research into phenotypic 
or genotypic predictive assays with the perspective of modifying therapy in 
radiosensitive individuals and perhaps intensifying therapy in relatively resistant cases.  
It is clear that genetic variations have a role in determining radiosensitivity as observed 
in the hyper-radiosensitivity associated with some rare genetic syndromes such as 
Nijmegen breakage syndrome, Fanconi anaemia and ataxia telangiectasia (AT). Is it 
possible that anything could be learned from detailed study of these conditions which 
could be extrapolated to the general population? AT is a rare autosomal recessive 
disorder characterized by progressive neuronal degeneration, immunological deficiency 
and an increased incidence of cancer. The gene mutated in AT (ATM) encodes a kinase 
that amplifies the DNA-damage signal induced by DNA double-strand breaks. ATM 
and its downstream kinase CHK2 phosphorylate several targets that regulate DNA 
repair, cell-cycle checkpoints and apoptosis. The in vitro radiosensitivity of skin 
fibroblasts from AT homozygous patients is typically threefold higher than that of 
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normal human fibroblasts107, and clinical case studies show that these patients have an 
extreme normal-tissue reaction to radiotherapy and might achieve local tumour control 
at a fraction of the radiation dose used normal108-110. However, protein-truncating ATM 
mutations do not seem to be more prevalent among patients with breast cancer who 
have a pronounced reaction to radiotherapy than among patients who have a normal 
reaction111-113. Among the downstream targets of ATM and CHK2 is the tumour-
suppressor gene BRCA1114,115. One might speculate that germline mutations in BRCA1 
might lead to increased risk of early or late radiotherapy toxicity in the cases with 
mutated BRCA, but this does not appear to be the case. 
Radiogenomics is the study of genetic differences in the response to radiation116. This is 
an emerging field of research in which attempts at investigating a possible genetic 
background for variations in clinical radio-responsiveness have concentrated on single 
nucleotide polymorphisms (SNPs) in selected candidate genes and the screening of 
multiple genes using gene-expression arrays either by genome-wide or candidate-gene 
studies117-119. 
In a series of 41 patients that received postoperative radiotherapy for breast cancer, 
Andreassen et al. assessed 17 specific SNPs in TGF1, SOD2, XRCC1, XRCC3 and 
APEX, and found that 7 of these were associated with a significantly increased risk of 
developing severe subcutaneous fibrosis120. However, applying a Bonferroni correction 
to the published data in their paper shows that only one of these (XRCC3 codon 241 
Thr/Met) remains significant after the correction. ICAM deficient mice do not appear to 
develop fibrosis after pulmonary irradiation and patients with high TGFbeta, IL1 and 
IL6 levels have all been found to be at a higher risk of developing pneumonitis than 
those without120. The early experience in this research field is sufficiently positive to 
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warrant further studies to try to arrive at true-positive SNPs associated with 
radiotherapy side effects. 
The transcriptional response of normal cells and tissues to radiation has been the subject 
of a few studies using cDNA microarrays121-123. Although these are also powerful 
discovery tools in radiation research124 there is still a long way to go before we have a 
gene signature of value in clinical response prediction.  
In summary, determination of the radiosensitivity of cells isolated from individual 
patients has not yet proved to be a reliable predictor for clinical use, except in rare cases 
of extreme radiosensitivity. Studies of the comparison of early and late responses in 
individual patients have shown that patients who have severe acute responses do not 
necessarily or predictably develop significant late reactions. This finding may be a 
reflection of differences in underlying mechanisms involved in the development of 
these types of injury. 
 
1.9.3 The role of the tumour 
 
In addition to the contribution of radiation itself, the presence of the tumour may 
predispose the surrounding normal tissue to injury. Tumours can alter or influence their 
surroundings in a number of ways. The presence of the tumour can physically distort 
normal tissue architecture resulting in defects that can add to damage produced by 
therapy. Tumours also release proteolytic enzymes that facilitate invasion and 
metastasis and which may alter the ‘normal’ radiation response1. Tumour vessels are 
leaky. They allow fibrinogen to escape into the surrounding tissues, which is converted 
to fibrin, and which results in collagen deposition and fibrosis30.  
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1.10 Clinical and tissue manifestations of radiation injury 
Radiation injury varies from organ to organ, as described above. However, radiation is 
usually delivered to a localised area with consequent injury and symptoms. These are 
primarily the thorax (lung and breast tumours), head and neck, and pelvis (prostate and 
cervical tumours)18. In the following sections the general changes associated with 
locality irradiation will be outlined, followed by a more in depth description of organ-
specific changes. 
 
1.10.1 Radiation to the thorax 
The lung is one of the most radiosensitive organs, yet one or both lungs are frequently 
irradiated as part of treatment programmes for cancers of the lung, oesophagus, breast 
and haematopoeitic system. The early effects of radiation to the throax become 
clinically apparent soon after radiotherapy (about 1–3 months) with congestion, cough, 
dyspnoea, fever and chest pain caused by pneumonitis (pneumopathy). The histological 
changes in the lung at this time include reactive changes and hyperplasia of type II 
pneumocytes with a decrease in parenchymal cells and surfactant secretion together 
with oedema and inflammatory cell infiltration and hyaline membranes97. Radiographic 
studies show changes which reflect these findings with an infiltrate within the irradiated 
field. The same changes can also be caused by systemic or inhaled toxins, various 
drugs, infections, and tumour recurrence and these need to be differentiated clinically as 
the pathological and radiological features can be identical, whatever the underlying 
cause97. The dyspnoea is variable and rather unpredictable, it can be mild or severe. In 
severe cases, hypoxaemia and signs of right-sided heart failure may be present. Partial 
lung irradiation occasionally induces a bilateral, immunologically-mediated 
pneumonitis that generally resolves without treatment125. 
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The inflammation induced by radiation generally subsides after a few weeks. In many 
cases it is followed by a phase of chronic inflammation and fibrosis that develops 
months or years after irradiation, and which can progress for a considerable time 
afterwards. In this phase, vascular damage and collagen deposition become more 
obvious97,126,127. If the volume affected is small, the patient may be asymptomatic and 
the scarring may be detected as an incidental finding radiographically. If a larger 
volume has been irradiated, the patient may develop symptoms due to a reduction in the 
diffusion capacity and respiratory volume caused by pulmonary fibrosis and scarring 
with surrounding tissue retraction127. A positron emission tomography (PET) scan may 
help to distinguish radiation injury from tumour recurrence because the latter may be 
more metabolically active. 
Current treatment approaches for severe acute radiation pneumonitis (assuming there is 
not an alternative cause for their acute respiratory distress) include the use of systemic 
corticosteroids127. Supplemental oxygen, and even mechanical ventilation, may 
occasionally also be necessary. In the future it may be possible to predict patients at 
high or low risk by measuring profibrotic or proinflammatory cytokines (or both) in the 
circulation, thereby enabling individualisation of treatment fields and dose on the basis 
of a risk profile for normal tissue injury128. Overall, strategies to prevent radiation injury 
to the lung are likely to be more effective than subsequent treatment of the problem 
when it arises. Recent improvements in imaging and computer technology have 
contributed to the development of 3-dimensional conformal radiotherapy (3DCRT) and 
intensity-modulated radiotherapy (IMRT), which enable more precise delivery of the 
dose distribution to the tumour, with deliberate avoidance of sensitive normal tissues129. 
The normal tissue within the treatment field should be able to tolerate these higher doses 
because of the smaller volumes involved. In the case of thoracic tumours, gating 
techniques are being used to minimise or accommodate tumour movement during 
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breathing130. However, these methods are relatively new and the long-term 
consequences are not yet known. 
 
1.10.2 Radiation to the head and neck 
The skin, mucosa, subcutaneous tissues, bone and salivary glands are often affected 
when radiotherapy is used in the treatment of head and neck cancers. In the skin, the 
early responses include erythema and dry or moist desquamation, the latter resulting 
from loss of proliferating cells with subsequent failure to replace functional cells131. The 
reaction is commonly accompanied by itching, hypersensitivity and/or local pain. 
Symptoms usually develop during a course of treatment and often subside before the 
end of the treatment, but dermatitis may not resolve until weeks later. 
Mucositis is caused by a similar process as dermatitis, resulting from loss of functional 
cells with a temporary lack of replacement from the pool of rapidly proliferating 
cells132. If mucositis is severe, the patient may have difficulty eating and a feeding tube 
may be necessary to provide adequate nutrition. This is especially common with very 
intensive combined modality treatment or multiple daily fractions. A temporary 
interruption in treatment may be required. 
Similar microscopic changes are seen in the skin and mucosa with typical inflammatory 
features such as vascular congestion, vasodilation, and plasma leakage, with denudation 
of the epithelium. Later effects in the skin include alopecia, pigmentory alterations, 
telangiectasia, atrophy, fibrosis and ulceration. Although acute effects occur mostly in 
rapidly proliferating cells of the epidermis and mucosa, these later changes largely 
reflect damage to the vascular and connective tissues. Microscopically there may be 
atrophy, atypical epithelial cells, vascular lesions and fibrin exudates leading to collagen 
deposition97. Again there may be individual differences between patients with high 
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concentrations of salivary epidermal growth factor before and during radiotherapy 
apparently be associated with less oral mucositis133.  
The salivary glands, particularly the parotid glands, are frequently irradiated during 
treatment of tumours of the head and neck. The parotid glands contain serous cells that 
are radiosensitive and die by apoptosis134. The more resistant submandibular and 
sublingual glands contain mucous and serous cells. Damage occurs primarily in the 
parenchyma of the salivary gland, rather than in the ducts, but inflammation, vascular 
changes and oedema all contribute to the damage135. Functional impairment correlates 
well with the volume exposed and the radiation dose136. Clinically, swelling and 
tenderness often develop after the first treatment, but they generally subside within a 
few days. Xerostomia is the most common and distressing symptom because saliva 
becomes scant, sticky and viscous during a course of radiotherapy. It makes eating, 
speech and wearing dentures difficult. It may take months or years for this to improve 
and return to normal, if it occurs at all135.  
Xerostomia can cause the patient to become more susceptible to fulminant dental caries. 
Carious teeth can result in infection of the underlying bone leading to 
osteoradionecrosis. This complication is more common in the jaw bone than in the 
upper jaw bone, because of the relatively poorer blood supply of the former137. 
Osteoradionecrosis may be prevented in most patients by removing unsalvageable teeth 
before treatment and initiating a programme of aggressive prophylactic dental care, 
including daily fluoride rinses. Antibiotic therapy and resection of devitalised bone may 
be necessary. Xerostomia can be treated by saliva substitutes, sialogogues water, and 
sugarfree sweets and gum. The radioprotector amifostine, given before each fraction of 
radiotherapy, reduces the incidence of xerostomia138. Treatment plans using 3DCRT and 
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IMRT can be designed to reduce the dose of radiation to the salivary glands, particularly 
the volume exposed to high doses (conformal avoidance) 129.  
 
1.10.3 Radiation to the pelvis 
 
The rectum is the area most often affected by pelvic irradiation for treatment of prostate 
and cervical cancer. Acutely, diarrhoea results from loss of integrity of the epithelium 
and increased secretion of mucus. The tissues develop oedema and hyperaemia. The 
most common late effects include increased stool frequency, urgency, spotting of blood 
and partial incontinence. Less commonly mucosal ulceration, severe bleeding, pain, 
strictures, severe incontinence and fistulae may develop139. Fibrosis and ischaemia in 
the submucosa and muscularis, accompanied by telangiectasia and other vascular 
abnormalities lead to collagen deposition and abnormal fibroblasts which causes the 
mural changes described above140. The risk of complications depends chiefly on the 
total dose and the amount of rectum in the treatment field. Brachytherapy (radioactive 
implants) techniques, 3DCRT and IMRT, have been used so that an escalation of dose 
to the tumour can be accomplished without an increase in normal tissue injury141,142.  
Treatment of rectal complications includes oral anti-inflammatory agents, pain 
management, stool softeners, intrarectal steroids, blood transfusions (for bleeding) and 
dilatation of strictures. For serious or refractory complications, hyperbaric oxygen or 
surgical intervention with temporary or permanent colostomy may be required. 
 
1.11 Specific tissue effects of radiotherapy 13 
 
It will become clear that many of the following represent a combination of the 
general effects outlined above and specific tissue effects, together with 
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functional/symptomatic effects that may not correlate with tissue changes. 
Functional disturbances may also occur but they will not be documented in any 
depth here.  
 
1.11.1 Nervous system 
 
Radiation damage occurs to the brain, spinal cord and peripheral nerves. Neurons 
are very radioresistant but the supporting cells are less so. The acute changes 
manifest as increased vascular permeability with vasogenic oedema and a rise in 
intracranial pressure. If severe, areas of necrosis that are either focal or diffuse 
may be produced predominantly affecting the white matter, but with some 
extension into the deeper layers of the grey matter (a feature said to be specific for 
radiation injury143). These areas are surrounded by demyelination (possibly due to 
oligodendrocyte damage), macrophage infiltration (but fewer than in ordinary 
cerebral ischaemia) and astrocyte changes. In fact radiation may accelerate 
demyelination in multiple sclerosis and irradiation may produce transient 
disruption of myelin synthesis. The necrotic areas may lead to cystic degeneration 
and subsequent calcification. Later changes also include reactive astrocytosis and 
gliosis, astrocyte atypia with nuclear vacuolation and hyperchromasia and 
radiation vasculopathy (Fig. 2). The latter comprises endothelial cell proliferation, 
luminal narrowing, fibrinoid necrosis, medial hyaline thickening and luminal 
thrombosis. In children mineralising microangiopathy may be seen143. These 
vascular changes often result in coagulative necrosis. Cerebral radionecrosis may 
present as a space occupying lesion which can mimic post therapy relapse due to 
its latency144. It should be remembered that radiation injury to the brain may not 
only produce morphological disturbances but a combination of 
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leukoencephalopathy and cerebral atrophy will lead to intellectual and functional 
problems.   
 
 
 
Figure 2. Vasculopathic changes in the brain after irradiation. Picture of MS 
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The changes in the spinal cord are similar but they manifest earlier due to shorter 
latent period145. Areas of necrosis with surrounding demyelination represent acute 
transient myelitis which occurs 2-4 months after exposure. This is probably due to 
transient demyelination of ascending sensory neurons and it usually recovers. 
However delayed myelitis tends to be more permanent, occurs at around 20-30 
months and affects the lumbar and thoracic areas predominantly. The lower motor 
neurons (LMN) may also be secondarily affected by vascular damage, but the 
subsequent atrophy of these cells may just reflect their very slow dividing times 
and hence manifestation take some time to appear. 
Peripheral nerves are one of the most resistant structures to irradiation but a 
peripheral neuropathy may occur. It is difficult to establish the direct role of 
radiation in this, and to exclude other factors such as surgery or drugs. Perineural 
inflammation and thickening has been described around the peripheral nerves in 
the pelvis after irradiation with ganglionitis24.  
The association of radiation with intracranial tumour formation has long been 
known with gliomas and meningiomas both being more common after radiation. 
 
1.11.2 Cardiovascular system  
 
There is an extensive literature describing the effects of radiation on the heart as 
the heart  is frequently included in the radiation field of thoracic and breast 
tumours. Irradiation of mediastinal tumours appears to have the greatest effects. It 
is said to affect 2-9% of patients who receive mediastinal irradiation and 3-4% for 
breast cancer146. In addition to the heart itself changes in peripheral vessels have 
been appreciated for a long time and it is now clear that the changes are not only a 
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morphological marker of irradiation, but they are a vital component in the 
mechanism of delayed injury25. The most consistent acute event after cardiac 
irradiation is the production of a pericardial effusion (rarely producing 
tamponade). This is associated with a fibrinous pericarditis which if protracted 
may organise and form fibrous adhesions. In fact radiation is now one of the most 
common causes of chronic constrictive pericarditis in the USA146. Early 
myocardial functional changes are also observed with transient decrease in left 
ventricular function. Myocardial fibrosis results from a combination of myocyte 
necrosis and repair, diffuse capillary damage with secondary fibrosis and 
ischaemic fibrosis from coronary artery narrowing.    This fibrosis is pericellular 
and perivascular and a moderate/severe degree was found in 50% of hearts 
examined in one study146. The administration of cardiotoxic chemotherapeutic 
drugs may exaggerate these myocardial changes. The cardiac myocytes may be 
hypertrophic. As there is virtually no inflammatory cell infiltrate it has been 
suggested that radiation-induced cardiomyopathy is a better term for this than 
myocarditis146. Later consequences in the endocardium are thickening that 
commonly involves the valves. The left sided valves show fibrosis and 
calcification more often than the right and functional regurgitation may occur. It 
is not clear why pulmonary valve changes are seldom seen although this valve is 
the most anterior. ECG changes may reflect conducting abnormalities which may 
be secondary to conducting system fibrosis. Radiation induced changes in the 
coronary arteries are well established with intimal thickening, foam cell 
accumulation and medial fibrosis resembling atheromatous plaques. It is not clear 
whether these changes reflect potentiation of atherosclerosis, but similar changes 
may be seen in medium sized arteries at any irradiated site. A helpful 
differentiating feature may the less frequent presence of cholesterol clefts25. 
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Obviously similar changes elsewhere lead to vascular occlusion and delayed 
ischaemia.  
Small peripheral arteries seldom show significant acute changes but endothelial 
swelling and hyperchromasia may be seen. In the longer term there may be 
intimal fibroplasia and hyaline change to the media similar to systemic 
hypertension with possible fibrinoid necrosis, thrombosis, subendothelial fibrosis, 
accumulation of foam cells, adventitial fibrosis and even rupture. In medium sized 
arteries again delayed changes predominate and are similar to those in smaller 
vessels although intimal thickening may be more prominent and late medial 
fibrosis is likely to reflect earlier inflammatory changes. Obviously the earlier 
changes need to be differentiated from differentiate from systemic vasculitis. 
Large arteries are the least affected probably because the vessel wall provides 
strong support for the damaged endothelium and the lumen is larger thereby 
preventing occlusion. Although uncommon with severe injury the consequences 
may be the most dramatic with occasional rupture which is usually fatal. This is a 
result of transmural necrosis of the wall and may reflect vasa vasorum injury. The 
capillaries are the most sensitive vessels to acute injury and may show 
postirradiation endothelial cell swelling with narrowing or occlusion of the lumen. 
Subsequent platelet and fibrin thrombimay be seen and possible rupture of 
capillary wall occurs with microhaemorrhage. There may be compensatory 
proliferation but vascularisation remains reduced and is an important factor in 
radiation heart disease, pneumonitis and nephropathy. Later on a consistent 
feature of these small vessels is telangiectasia. 
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Veins appear more resistant to radiation damage than arteries but fibro-
obliterative changes may occur and are an important feature in hepatic radiation 
damage25 (see liver section). 
 
1.11.3 Respiratory system 
 
Irradiation of head and neck tumours and upper respiratory lesions may lead to 
laryngeal complications in as many as 23% of patients1. One of the most common 
features of laryngeal or tracheal irradiation is early transient oedema which may 
be followed by fibrin deposition in the stroma. Later evidence of irradiation 
manifests as telangiectasia, subepithelial fibrosis, epithelial cell atypia and the 
vessel changes described above. Other changes include vocal cord fibrosis, 
ulceration and the presence of granulation tissue with bizarre fibroblasts. 
Glandular atrophy occurs late occasionally with a histological appearance similar 
to necrotising sialadenopathy147. The latter is thought to result from ischaemic 
compromise. A fairly specific change in this region is asceptic necrosis of the 
cartilage.   
Radiation damage to the lung and pleura commonly follows irradiation of lung, 
mediastinal or breast tumours. The effects depend on any coexisting lung disease 
such as COPD. The lungs are very vascular and therefore very susceptible to 
irradiation injury. Again the effects depend on the dose and volume of lung 
exposed. If the whole lung is irradiated then 10-15% will develop radiation 
pneumonitis defined as decreased lung function, dyspnoea and dry cough 
appearing 3-16/12 after irradiation with X-ray changes in the field exposed18. 
Histologically the early changes comprise interstitial and intra-alveolar oedema 
(due to increased capillary permeability), endothelial swelling, scanty 
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inflammation with foamy macrophages. Later changes are dominated by fibrosis 
(Fig.3). 
Epithelial cell damage occurs some time after with necrosis of type I 
pneumocytes followed by hypertrophy and hyperplasia of type II pneumocytes. In 
more severe cases hyaline membranes may form and the histological picture is 
that of ARDS. After around 8-15/12 there is delayed fibrosis with atelectasis and 
occasionally bronchiolitis obliterans. Vessel changes are once again present with 
myointimal proliferation, intimal foam cells and with fibrosis leads to increased 
pulmonary artery pressure. There may be coexisting infection. Pleural effusions 
and similar changes to those seen in the pericardium may be seen in the pleura. 
Radiation is associated with lung cancer and the latent period is over 9 years. The 
most common type in uranium miners is small cell carcinoma. Smoking has at 
least an additive effect. 
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Figure 3. Fibrosis and chronic inflammation in the lung many years after 
thoracic irradiation. Picture of MS 
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1.11.4 Gastrointestinal system 
The changes throughout the gastrointestinal tract follow a similar pattern, but the 
severity and timing of the effects vary depending on the site and the mobility of 
the particular segment involved, and additional factors such as recent surgery or 
coexisting diabetes mellitus, hypertension or vasculitis. The small bowel and 
stomach are more sensitive than oesophagus and rectum; predominantly a 
reflection of rate of cell turnover. Post-radiation carcinomas have been described 
at all sites in the body. 
The early changes seen in the oropharynx are epithelial depletion with erosive 
mucositis and vascular dilatation. Later this may progress to chronic ulceration 
and submucosal fibrosis. Delayed vessel changes may be conspicuous and lingual 
necrosis has been observed148. A picture resembling necrotising sialadenopathy is 
occasionally seen. Salivary gland changes have been well studied with early 
oedema and swelling, epithelial necrosis and desquamation accompanied by mild 
inflammation. The latter includes many eosinophils. Serum amylase is usually 
raised. Delayed manifestations include interstitial fibrosis with telangiectasia, 
squamous metaplasia, atrophy and residual inflammation. Arteriosclerosis is once 
again a feature. 
The oesophagus shows similar mucosal injury with early erosive mucositis 
followed by fibrosis, ulceration, stricture formation, fistulae, perforation and 
either atrophic or thickened epithelium. The latter may show radiation-induced 
cellular atypia. Functional disturbances may result with abnormal motility and 
dysphagia. Candidal infection may be superimposed. 
Radiation therapy used to be employed to treat gastric ulcers. However it is now 
recognised that irradiation is associated with chronic inflammation and epithelial 
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degeneration leading to ulcer formation. In the long term, gland atrophy and 
chronic atrophic gastritis may occur with any of the other complications of 
vascular compromise seen elsewhere in the gastrointestinal tract. 
The small intestine is the most sensitive section of the tract. The crypt cells 
proliferate and move to the tips of the villi to replace effete epithelial cells at the 
surface. Radiation impairs this process and leads to surface erosion which allows 
bacterial colonisation and fluid loss. Villous atrophy follows and malabsorption 
may occur. In the lamina propria there is a variable increase in fibrous tissue with 
inflammation and telangiectasia. There may be subepithelial collagen deposition 
mimicking collagenous colitis/sprue. In the submucosa vascular changes 
predominate. Progressive damage leads on later to chronic ulceration, stenosis, 
haemorrhage and adhesions. Other complications include fistulae, mucosal 
atrophy and vascular intimal thickening. A recent study indicated that the 
incidence of chronic irradiation enteropathy is significant with 18-30% of patients 
receiving between 50-60Gy having manifestations. This appears to be 
increasing149. These authors found moderate to severe submucosal oedema in 
86% of cases, intramural or serosal fibrosis in 76%, vascular injury (including 
foam cell plaques) in 57%, mucosal degeneration in 81%, atypical fibroblasts in 
81%, subepithelial collagen in 10% and enteritis cystica profunda in 38%. 
Epithelial cell atypia was seen in 33% of cases149. Ulceration was significantly 
more common in the long term group. Vascular changes alone do not account for 
many long term effects such as ulceration seen in the gut and the histology is 
distinct from ischaemic colitis. Therefore it is proposed that chronic injury results 
from a combination of vascular compromise together with other tissue 
components such as fibroblasts, smooth muscle cells or epithelial cells. 
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In the colon, sigmoid and rectum an early feature is inflammation with prominent 
eosinophils and eosinophilic abscesses150. The epithelial cells may show atypia. 
There may be peritoneal fibrin deposition with subsequent organisation and 
fibrous adhesions. Mucosal ulceration may occur late with the formation of 
strictures or fistulae. Chronically there is shortening and fibrosis of colon with 
mucosal atrophy. Colitis cystica profunda may be seen. Vessel changes resemble 
those at other sites within the tract. The development of adenocarcinoma 
following atypia of the epithelium has been described many years after radiation 
exposure. 
The liver has an intermediate sensitivity to radiation. The effects are more 
pronounced in children and in the regenerating liver. There may be direct 
hepatocyte necrosis, but as the liver has a large regenerative capacity it is usually 
the vascular effects that predominate. Early after irradiation one can see a mild 
hepatitis with sinusoid congestion, hyperaemia, central haemorrhage, fibrin 
deposition and intravascular coagulation leading to secondary necrosis and 
atrophy of central hepatocytes. There is central vein dilatation with progressive 
liver cell plate atrophy and decreased reticulo-endothelial cell function. In the 
subacute period, at about 3-6 months, fibrosis begins around the small central 
veins, lobular or sublobular veins and sinusoids forming a coalescent net leading 
to hepatic veno-occlusive disease. Later, after six months the liver is markedly 
less congested but atrophy is worse with increased collagen and parenchymal 
replacement. There is little information on the ductal epithelial cell changes.  
Thorotrast (thorium dioxide - an alpha emitter) was introduced for diagnostic 
radiology in the 1950s. This localised to phagocytes and was associated with 
several benign and malignant conditions. In the liver storage in Kupffer cells led 
to peliosis, cirrhosis, hepatocellular carcinoma, cholangiocarcinoma and 
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angiosarcoma. The latent period was long (15-40years). There is very little 
information about radiation changes in the gallbladder, but it is likely that the 
changes can be predicted from other mucosal sites.  
In the pancreas there may be evidence of necrosis and lymphocytic infiltration 
followed by atrophy of the exocrine pancreas, fibrosis and vessel changes. The 
degree of fibrosis appears to be less in the islets although the endocrine cells are 
more sensitive than the exocrine. 
 
1.11.5 Skin  
 
Acute post-irradiation changes include epidermal intracellular oedema, appendage 
degeneration, dermal inflammation, erythema and oedema of the dermis due to 
capillary dilatation and increased vascular permeability with red blood cell 
extravasation. Epidermal necrosis may be seen with ulceration extending into the 
upper dermis. Less severe damage results in bulla formation which may heal or 
may lead to wet desquamation and pigmentation. Epilation may occur due to 
follicular necrosis with dry desquamation following sebaceous unit necrosis. 
Vascular injury may be seen in the subacute phases. 
Chronic radiodermatitis shows epidermal atrophy with variable hyperkeratosis 
which is dry and shows hyper and hypo-pigmentation. The former results from 
increased melanocyte enzyme activity. Keratinocytes may show atypical nuclear 
features and individual cell keratinisation. The dermis becomes less cellular and 
develops homogeneous and hyaline collagen fibrosis with scattered plump 
fibroblasts. The superficial vessels are dilated, but the deeper ones show 
thickening of the vessel walls with luminal narrowing with possible occlusion by 
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thrombus. Secondary ulceration may develop. This damaged skin is susceptible to 
traumatic injury with poor healing and a propensity to dysplasia or malignancy. 
The finger nails may show ridging. 
As early as 1902 an x-ray tube worker developed a squamous cell carcinoma on 
his hand and since then several studies have shown a link between irradiation and 
cutaneous neoplasia151. One unfortunate example is the development of basal cell 
carcinomas on the scalp of children treated with radiotherapy for tinea capitis152. 
As is the case with radiation-induced tumours there was a significant latent period 
of around 20 years. It appears that the tumorigenic effects are enhanced by prior 
or subsequent UV exposure. 
 
1.11.6 Bone marrow and lymphoid tissue 
 
Following irradiation of the bone marrow there is a decrease in the nucleated cells 
(myeloid more than erythroid) with necrosis and panhypoplasia resulting in 
cytopenia. Repopulation occurs early and in fact there may be compensatory 
hyperplasia in the early stages. If repopulation is not complete (for example with 
high doses, large fields of exposure or coexisting marrow disease) there may be 
fatty replacement with an increase in loose fibrous tissue. A relative increase in 
plasma cells may be observed due to hyocellularity of the other cell lines (Fig. 4). 
In 1911 the leukaemogenic effects of irradiation were first noted and now it has 
become established that haematological malignancies are the most common 
radiation-induced malignancies with a latency of at least 3 years153. All types of 
leukaemia have been described including multiple myeloma except for CLL and 
many cases followed spinal x-rays for ankylosing spondylitis. 
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Lymphocytes are extremely radiosensitive and are unusual in that they die in 
interphase. In addition to cell death, functional disturbances in homing and 
recirculation have been described. Any lymphoid aggregate including the thymus 
suffers the same fate of lymphocyte necrosis and subsequent atrophy, although 
subpopulations of lymphocytes appear to have differing sensitivities. In the lymph 
node there is cortical depletion with capsular and trabecular fibrosis, calcification, 
atrophy and fatty replacement. Obliterative endarteritis may be seen. With 
metastatic disease, there may be tumour necrosis or susequent hyalinisation of a 
necrotic area. Radiation may be associated with lymphoid neoplasia due to 
immune surveillance damage as there were increased lymphomas in pioneer 
radiologists. However this association has not been identified in atom bomb 
survivors. 
In the spleen early features include large atypical cells, prominent plasma cells 
and eosinophils and focal haemorrhage. This is followed by parenchymal 
collapse, atrophy, red pulp fibrosis and capsular thickening. The almost universal 
vascular changes may be seen here also. 
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Figure 4. Bone marrow after irradiation with loss of haematopoietic components 
and occasional plasma cells remaining. Picture of MS 
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1.11.7 Locomotor system 
 
Changes in the bone and cartilage are obviously very dependent upon age. 
Asymmetrical growth is produced by radiation to the growing skeleton. In the 
adult skeleton severe radiation damage results in radionecrosis of bone or 
cartilage with osteoblast and osteocyte necrosis154. The maxilla, femur and pelvic 
bones are the most commonly involved. This is usually accompanied by the 
marrow changes described above and vessel changes leading to ischaemia. 
Radiation induced fractures have been described. With large doses 
chondrocalcinosis, skeletal muscle oedema, necrosis, atrophy and fibrosis have 
also been described. Radiation is associated with the development of several 
skeletal tumours including osteochondromas and osteosarcomas along with soft 
tissue tumours such as malignant fibrous histiocytoma and angiosacroma155. 
 
1.11.8 Eye and ear 
 
The eye of a child is more susceptible to radiation damage than that of an adult 
and exposure in utero (especially first trimester) is associated with significant 
ophthalmic complications. Damage may occur to the retina, lens or neurovascular 
supply. Fetal exposure may lead to microophthalmia, retinal pigmentation and 
cataract formation156. Lens opacities also follow irradiation of the eye after birth 
with degeneration of lens fibres beginning posteriorly and leading to cataract (Fig. 
5). Other structures damaged include optic neuropathy and retinal and ciliary 
artery damage. The epithelial changes resemble those seen elsewhere with 
keratitis and iritis and possible scarring. Retinal damage reflects vascular damage 
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and manifests as haemorrhages, exudates and microaneurysms with subsequent 
atrophy. Diabetes mellitus and chemotherapy add to these effects. 
 
 
 
Figure 5. A cataract which had developed after radiotherapy to the eye region. 
(Courtesy of Professor C Berry) 
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Acute hearing loss with tinnitus has been described after irradiation with the 
predictable capillary hyperaemia, exudate, vascular damage and sequelae, and 
otitis media. Ossicle necrosis due to vascular damage is also sometimes seen157.  
 
1.11.9 Endocrine system 
 
The endocrine organs are remarkably radioresistant when one considers how 
vascular they are. This obviously reflects the variable sensitivity of endothelial 
cells in different sites25. In general the changes in the endocrine glands are early 
degeneration with secondary vascular changes and necrosis or atrophy. Although 
the glands are relatively radioresistant, endocrine abnormalities are commonly 
documented after irradiation158. This probably reflects functional disturbances that 
may not be associated with morphological abnormality. The parathyroid is said to 
show hyperfunction after irradiation and atrophy if it is embedded in the thyroid 
gland159. The adrenals show a limited biological response to stress after 
irradiation and most effects are secondary to vascular damage. Damage to the 
pituitary gland results in necrosis (growth hormone producing cells most 
sensitive), fibrosis and cystic atrophy. Functional hypopituitarism may take years 
to manifest but secondary effects on target organs should be predictable. Pituitary 
hypofunction may also result from hypothalamic damage (the hypothalamus is the 
most radiosensitive area in the brain; even more than the surrounding white 
matter) and in children growth retardation may result. A late complication of 
pituitary irradiation is tumour formation with most documented cases being 
astrocytomas. Other tumours include meningiomas, oligodendrogliomas, 
osteosarcomas and fibrosarcomas. 
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Within 2 weeks of irradiation of the thyroid follicular destruction can be seen with 
epithelial cells shed into the lumen. Multinucleated cells may be present and 
vessel changes comprising thrombosis and haemorrhage are often seen. There is 
interstitial oedema and a lymphocytic infiltrate. Later changes again result from 
vascular sclerosis with ischaemic fibrosis and atrophy, especially at the centre of 
the gland. Irradiation of  young children is associated with a range of thyroid 
disease such as solitary or diffuse nodular formation with goitre, thyrotoxicosis 
(including thyroid storm), hypothyroidism, chronic lymphocytic thyroiditis, 
adenomas and carcinomas (especially papillary)160. 
 
1.11.10 Breast and female genital tract  
 
In the acute phases after irradiation of the breast, skin changes predominate. 
These have been outlined in the skin section and will not be repeated here. In the 
deeper tissue there may be evidence of fat necrosis and the common early events 
described for many other tissues above. Later changes include glandular atrophy, 
epithelial cell atypia, intralobular and interlobular fibrosis, telangiectasia and 
other vascular changes. It is the atypical epithelial cell changes that make the 
differentiation between radiation effect and recurrent tumour so difficult on 
occasion. It should be noted however that these radiation-induced changes are 
restricted to the terminal duct lobular unit and that atypical epithelium in the 
larger ducts should be viewed with considerable suspicion161. Other features of 
late irradiation injury to the breast include acinar loss and architectural disarray, a 
dense collagenised stroma and occasional abnormal mitoses (although the latter 
may be misleading in isolation). A range of benign and malignant breast disease 
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may be seen after radiotherapy with carcinomas developing after at least 10 years, 
peaking at around 15-20 years162. The age at exposure is an important factor. 
The uterus is extremely radioresistant, but with high dose exposure endometrial 
gland necrosis may be seen in the early post-irradiation period, with areas of 
haemorrhage and fibrin deposition.  Longer term changes include endometrial 
atrophy and epithelial cell atypia. There may be ulceration and scarring with 
scattered lipid laden macrophages and telangiectatic vessels. Rather surprisingly 
the myometrium does not appear to develop significant fibrosis or atrophy. 
Similar blood vessel changes to those described elsewhere may be see. In the 
cervix early changes again include oedema and an inflammatory exudate. 
Ulceration with scarring (including atypical fibroblasts) occurs later with atrophic 
changes, and epithelial cell atypia may present many years after radiation 
exposure163. The changes in the vagina are like those of other mucosae. 
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Figure 6. Wrinkling and altered pigmentation of the breast after radiotherapy to a 
breast cancer. (Courtesy of Professor C Berry) 
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1.11.11 Gonads  
 
The germinal epithelium is extremely sensitive, particularly in the young. After 
irradiation of both testis and ovary, there is early suppression of meiosis followed 
by germ cell necrosis. Spermatogonia B are more sensitive than spermatogonia A, 
spermatocytes and spermatids. All may show nuclear vacuolation and susequent 
apoptosis. Delayed effects on the testis include seminiferous tubular sclerosis, 
basement membrane thickening and stromal hyalinization (Fig. 7). Radiation 
vascular changes may be prominent. The Sertoli and Leydig cells are relatively 
more resistant, but with severe damage Sertoli cell loss and Leydig cell 
dysfunction or loss may be seen. Radiation to the ovary leads to an increase in 
atretic follicles within a few days. This follows follicular and corpora luteal 
degeneration. The granulosa cells are particularly sensitive. A temporary fertile 
period is seen followed by temporary sterility. Some follicles are spared however 
and may mature normally. Chronic damage manifests as atrophy with few 
maturing and the ubiquitous vessel changes. The latter may be more exaggerated 
in the ovary than elsewhere126. Again radiation may play a role in the aetiology of 
some cases of ovarian cancer. 
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Figure 7. Testicular atrophy after irradiation of the testis. There is no 
spermatogenesis in the tubules. (Courtesy of Professor C Berry) 
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1.11.12 Genitourinary system 
 
The kidney is moderately radiosensitive and once again the effects of irradiation 
depend on the administered dose and patients’ age. In addition the amount of 
perinephric tissue, any preexisting renal disease and individual susceptibility all 
affect outcome. Frequently there are no discernible changes in the kidney but 
macroscopically the cortical atrophy and irregular subcapsular surface may look 
like any end stage kidney.  
Microscopically, in the acute phase one may see a combination of interstitial 
oedema and small vessel endothelial damage164. After 6-12 months the changes in 
the glomeruli consist of segmental necrosis with occasional small crescents and 
‘soft swellings’ followed by segmental sclerosis or global scarring. The capillary 
walls are thickened and increased mesangium may extend into the peripheral 
loops producing a double contour appearance. The tubules are atrophic and many 
are lost. Tubular basement membrane thickening may be seen due to a direct 
radiation effect as well as a result of vascular ischaemia. Interstitial fibrosis may 
be accompanied by a lymphocytic infiltrate. The smaller arterioles and 
interlobular arteries show generalised radiation features already mentioned 
including dilatation, intimal thickening, fibrinoid necrosis, foam cell 
accumulation and thrombosis (Fig. 8). There is no distinctive 
immunohistochemical or fluorescence pattern. Electron microscopy reveals 
effacement of the epithelial cell foot processes and subendothelial zone 
thickening. New basement membrane material is deposited with swollen 
mesangial cells extending into the capillary loops. Clinically, early proteinuria 
and increased blood pressure may lead to progressive decrease in function, 
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anaemia and malignant hypertension (in fact the microscopic features may 
resemble any form of thrombotic microangiopathy). 
 
 
Figure 8. Thrombotic microangiopathy is a common feature of radiation injury to 
the kidney. Picture of MS 
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The bladder is highly susceptible to acute radiation injury with patients 
developing acute cystitis. The changes are usually transient and comprise 
epithelial cell loss, mucosal oedema, vascular dilatation and a variable 
inflammatory infiltrate. Ureteritis and urethritis may also develop. The 
inflammatory cell infiltrate contains nymerous eosinophils and mast cells and 
commonly lies perineurally165. Surface erosion may follow with submucosal 
fibrosis, continued inflammation and vascular damage. The latter is thought to 
lead to the later complications of ulceration, bleeding, fistulae, stricture 
formation, smooth muscle fibrosis and contraction. Coexisting infection may also 
be present. An important long term effect is the role of radiation in urothelial 
carcinogenesis. There will be a more detailed discussion of the effects on the 
bladder (and prostate gland) in the following chapters. 
 
1.11.13 Prostate gland 
 
The prostate is commonly irradiated either specifically to treat prostatic 
adenocarcinoma or indirectly in the treatment of transitional cell carcinoma of the 
bladder. The usual changes seen in such glands include exaggeration of the well-
known features of benign prostatic hyperplasia24. In addition giant cell reaction to 
ruptured glands and corpora amylacea, mild chronic inflammation, squamous 
metaplasia, atrophic glands with cytological atypia and stromal fibrosis with 
plump fibroblasts are commonly present. Vascular alterations already described 
are frequently identified. The possibility of prostatic carcinoma being radiation-
induced is controversial. 
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1.11.14 Implications for pathological practice 
 
The main implications for the pathologist are obvious. The effects of radiation on 
the architecture and nuclear appearance of many epithelia such as breast and 
prostate may mimic neoplasia extremely closely and the pathologist should be on 
his/her guard to get all the relevant info before confidently diagnosing malignancy 
in these situations. A search for further evidence of radiation injury is essential in 
such cases with particular note of radiation fibroblasts and the characteristic but 
non-specific vessel changes126. Mimicry of neoplasia need not only apply to 
routine histological specimens, but is equally relevant to cytological specimens 
particularly those from FNA such as thyroid, breast166, serous effusion167 and 
urine, as well as exfoliative cytology168. There are several publications 
highlighting the difficulties in interpretation of cytological material after 
irradiation which document that nuclear enlargement, hyperchromasia and atypia 
are frequently seen (Fig.9). Helpful points in the differentiation from recurrent 
tumour include degenerative features such as nuclear and cytological vacuoles 
and more importantly homogeneous staining of the nuclear chromatin without 
malignant characteristics. Occasionally it may not be possible to differentiate with 
any degree of confidence. 
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Figure 9. Atypical squamous cells often appear in post-radiation cervical smears 
and these can cause difficulties in differentiating therapy related changes from 
residual or recurrent cancer. 
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It should also be realised that specimens may be received which show the 
complications of previous irradiation without evidence of residual or relapsed 
tumour. These can obviously be seen many years after treatment and because of 
this latency differentiation from relapsed or recurrent tumour may not be possible 
without biopsy or more definitive surgery. Surgery may well be the appropriate 
treatment in such situations. In some instances the reason for the symptoms may 
not be totally clarified by the pathological specimen and functional effects should 
always be remembered. Lastly the pathologist may be involved in the diagnosis of 
a radiation-induced tumour that occurs many years after exposure. There is no 
difference in the morphology of such tumours to help identify aetiology168. 
  87 
 
1.12 Tumour therapy and clinical measurement of toxicity 
 
Radiation is used to treat tumours by killing the component tumour cells. A distinct 
proportion of cells will be killed with each dose administered. Tumours with high 
proliferative activity obviously suffer a high rate of cell loss. Tumour cells retain some 
capacity to repair their radiation damage, but this is limited compared to the surrounding 
population of normal cells. When designing radiation therapy fields for the treatment of 
cancer, the radiation oncologist must take into account several important biological and 
technical factors. These include: likely patterns of regional tumour spread, to ensure 
coverage of local tumour extensions not detectable with current imaging techniques; 
uncertainties in positioning the patient for each treatment; and tumour and organ 
movement during and between treatments. To achieve these aims, normal tissues 
surrounding the tumour are irradiated, which may result in symptomatic injury. The 
tolerance of these normal tissues to radiation dictates the dose that is prescribed in the 
treatment of most malignant diseases. 
Fractionation amplifies the differential between normal and tumorous tissue because the 
former is better able to repair its damage before the next insult. Fractionation also 
exploits the differential in tumour repopulation (although some tumours accelerate their 
repopulation after irradiation), allows for redistribution in the tumour cell cycle to a 
more sensitive phase and allows a degree of reoxygenation. With more recent protocols 
such as hyper-fractionation a higher overall dose can be given with no increase in the 
long term side effects. Chemotherapy may alter the cell dynamics and increase 
radiosensitivity if given appropriately. 
When a new cancer therapy is evaluated, the toxic effects on normal tissues must be 
assessed and compared with standard therapy. A new scoring system has recently 
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become available: common terminology criteria for adverse events v3·0 (CTCAE, 
http://ctep.cancer.gov/reporting/ctc.html). It was developed from two earlier scoring 
systems, the common toxicity criteria (CTC), developed by the National Cancer 
Institute (NCI) for evaluating acute toxicity of new chemotherapeutic agents and acute 
effects of radiation, and the late effects normal tissue/subjective objective management 
analytical (LENT/SOMA) for assessing late normal tissue effects and their 
management169-171. The merged scoring system includes early and late responses, and is 
applicable to chemotherapy, radiotherapy, surgery, other treatment modalities, and 
combinations of therapies. It also includes quality-of-life measures. The new scoring 
system will be useful for assessing the effectiveness of new approaches for preventing 
or reducing injury to normal tissue. 
 
1.13 Therapeutic possibilities and prospects for the future 
 
Radiation therapy remains a cornerstone of modern cancer management, with an 
estimated half of all newly diagnosed cancer patients receiving radiotherapy at some 
point in the course of their disease1. Compared with surgery, radiation therapy has the 
advantage of being non-invasive and potentially organ preserving, although the 
functional outcome might be negatively affected by late side effects. Even in the era of 
molecular oncology, radiation therapy remains an attractive component of multi-
modality therapy because it can be precisely modulated in time and space and provides 
effective tumour de-bulking in many cases. 
All effective cancer therapies that have been developed so far are associated with a risk 
of various side effects and, as an increasing number of people are cancer survivors, 
preventing or reducing late side effects has increasingly become a priority. In the United 
States the National Cancer Institute and the Center for Disease Control estimate that 9.8 
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million people (3.5% of the population) were alive in 2001 after a diagnosis of non-skin 
cancer172. The number of cancer survivors in the United States more than tripled 
between 1971 and 2001, and this has further stimulated interest in the quality of life of 
this population. Relatively little is known about this issue, but it has been documented 
that the burden of late side effects on the physical and social functioning of the 
individual can be considerable173-175. 
There is an intimate relationship between radiation-dose fractionation, spatial dose 
distribution and the clinical outcome of radiation therapy. Effective normal-tissue 
response modifiers or reliable predictive assays of normal-tissue effects would enable 
the intensification of tumour dose and/or the application of dose distributions with a 
higher probability of achieving loco-regional tumour control. This second perspective is 
becoming particularly exciting owing to the improved technologies for radiation therapy 
planning and delivery176,177. 
It is important to focus research efforts on studying molecular and cellular changes in 
pathways leading to overt damage and to develop interventions that lessen the incidence 
and severity of normal tissue injury without compromising tumour control. It is obvious 
that more must be discovered about the process of wound healing (especially after 
radiation) if techniques aimed to prevent or repair damage from ionising radiation and 
other anticancer therapies are to be developed. Also, research to identify molecular 
targets for the development of new anticancer agents must verify whether those targets 
exist in normal tissues as well as tumour tissue. 
Under the target-cell hypothesis, the most important means of creating a differential 
between tumour and late normal-tissue effects is modulation of the dose-fractionation 
schedule. Pharmacological interventions concentrate on cytoprotective compounds such 
as the free-radical scavenger amifostine178. Clearly, for this kind of drug to convey a 
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therapeutic advantage it would require some selectivity for the protection of normal-
tissue cells relative to tumour cells. In fact, in the US, the Food and Drug 
Administration (FDA) has approved amifostine, "to reduce the incidence of moderate to 
severe xerostomia in patients undergoing post-operative radiation treatment for head 
and neck cancer, where the radiation port includes a substantial portion of the parotid 
glands." However, the use of amifostine remains controversial. It is not without side 
effects of its own, namely hypotension, vomiting and allergic reactions. Furthermore, a 
substantial body of preclinical data suggest that amifostine induces some degree of 
tumour protection in addition to normal-tissue protection179.  
As our understanding of the pathogenesis of late radiation effects improves, specific 
interventional strategies are being developed that target all the contributing pathogenic 
pathways for late effects180-182. Early intervention during the initial phase of the 
cytokine cascade might be highly effective in modulating the subsequent cell and tissue 
response. One obvious target for the prevention of late radiation complications is the 
TGF pathway because of its key role in radiation fibrogenesis and its proposed dual role 
as a suppressor and promoter of malignant progression54,56,183. This makes TGF a high-
risk target for intervention on the one hand, but a target with anticancer potential on the 
other. Several TGF-targeting strategies are in clinical trials as cancer therapies52,183,184, 
and these include TGF antisense oligonucleotides, TGF antibodies and small-molecule 
inhibitors of the signalling pathway. Other strategies currently in pre-clinical 
development involve the silencing of the TGFR2 receptor using a dominant-negative 
receptor, or inhibiting TGF signalling using the extracellular soluble domain of the 
TGFR2 receptor. 
There is some evidence that this strategy for the prevention or amelioration of radiation 
fibrogenesis through TGF targeting has some promise. In the pre-clinical study of Giri 
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and colleagues it was shown that the administration of an antibody against TGF could 
reduce the severity of bleomycin-induced lung fibrosis185. Other studies have 
established that the delivery of soluble TGFR2 receptor by gene therapy with an 
adenoviral vector186 or by intra-tracheal instillation187 reduces the risk of bleomycin- or 
radiation-induced lung injury in rodent models. Furthermore, the TGF signalling 
pathway constitutes an alternative or additional potential target: SMAD3 knockout mice 
show resistance to radiation-induced fibrosis188, and the Smads constitute potential 
targets for drug therapies184. Finally, there are several new small-molecule inhibitors in 
various stages of development such as SM305189 and halofuginone190 that have shown 
promise in pre-clinical models. Several of these strategies are in clinical trials as 
potential interventions in fibrotic disease or as prophylaxis against excessive scarring 
after surgery191. Other cytokines and growth factors will inevitably be investigated as 
potential targets for radiation induced injury (and other fibrosing conditions for that 
matter). This includes VEGF and PDGF. 
Another logical target to prevent radiation injury include the ROS and RNS pathways. 
Both Mn SOD delivered by an adenovirus vector192 and inducible NO synthase 
inhibition193,194 reduce fibrogenesis. Furthermore, there are a number of clinical studies 
that suggest that radiation-induced fibrosis can be reversed using antioxidants180. 
Initially, liposomal Cu and Zn SOD were used but more recently significant regression 
of clinically marked fibrosis has been seen with pentoxifylline and vitamin E195,196. 
Treatment could be continued for several months or even years, as necessary for the 
individual patient, and it was well tolerated. On the other hand, although most patients 
obtained at least some regression of their fibrosis, few obtained a complete remission, 
and there was evidence of a rebound effect after the end of treatment195. 
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The degree of collagen deposition is a result of the balance between extracellular matrix 
synthesis and degradation, and the degradation step might be as interesting as the 
synthesis step as a potential interventional target in fibrogenesis197. Studies on 
metalloproteinases and similar proteins should be considered in the future.  
In summary, although much of the emphasis over the past 5–10 years has been placed 
on tissue remodelling as a crucial element in radiation pathogenesis, the damage-
induction step (the initial cellular processing of damage) remains relevant as a target for 
intervention. Interventions that aim to reduce the initial cell killing would also reduce 
the cellular and tissue-damage response. Several compounds are in clinical trials, 
including free-radical scavengers, as a means of preventing the side effects of 
radiotherapy. In fact, the NCI Radiation Research Program sponsored a workshop on 
this topic and recommended further study in: renin–angiotensin system inhibition (ie, 
use of ACE inhibitors and angiotensin II receptor antagonists), growth factors and 
cytokines (particularly TGFβ, basic fibroblast growth factor, and keratinocyte growth 
factor), proteases and their inhibitors, vitamin E and pentoxifylline, penicillamine, 
eicosanoids, COX2 inhibitors, Cu/ZnSOD and MnSOD, hyperbaric oxygen, and stem-
cell transplants. Treatments given before irradiation such as amifostine and expanders of 
stem-cell populations can also protect normal tissues from acute and late effects198.  
There is also a need to identify surrogate molecular markers such as patterns of gene 
expression, genetic polymorphisms and imaging patterns that will accurately predict 
patients at risk for normal tissue injury (such as TGFβ and pneumonitis) and to 
investigate appropriate timing of interventions to arrest or prevent complications. 
Mechanisms of damage are likely to be tissue specific and may be under genetic 
control. Efforts to develop and evaluate new therapies to prevent or reduce injury to 
normal tissue will be facilitated by increased understanding of the mechanisms by 
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which treatments for radiotoxicity work, and from greater knowledge of why radiation 
damage does or does not heal. It is obviously crucial on the other hand to ensure that 
these treatments are effective in the clinical setting and do not protect or give a survival 
advantage to tumour cells. 
 
1.14 Conclusion 
 
The medical use of radiotherapy to treat cancer inevitably involves exposure of normal 
tissues. As a result, patients may experience symptoms associated with damage to 
normal tissue during the course of therapy for a few weeks after therapy or months or 
years later. Symptoms may be due to cell death or wound healing initiated within 
irradiated tissue, and may be precipitated by exposure to further injury or trauma. Many 
factors contribute to risk and severity of normal tissue reactions; these factors are site 
specific and vary with time after treatment. Treatments that reduce the risk or severity 
of damage to normal tissue or that facilitate the healing of radiation injury are being 
developed. These could greatly improve the quality of life of patients treated for cancer. 
Radiation therapy has curative or palliative potential in roughly half of all incident solid 
tumours, and offers organ and function preservation in most cases. Unfortunately, early 
and late toxicity limits the deliverable intensity of radiotherapy, and might affect the 
long-term health-related quality of life of the patient. Recent progress in molecular 
pathology and normal-tissue radiobiology has improved the mechanistic understanding 
of late normal-tissue effects and shifted the focus from initial-damage induction to 
damage recognition and tissue remodelling. This has stimulated research into new 
pharmacological strategies for preventing or reducing the side effects of radiation 
therapy with emerging strategies now approaching clinical practice. 
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Chapter 2. Effects of radiation on the prostate gland 
2.1 Introduction 
Prostate cancer is the commonest cancer of men in the US and is the second most 
common male cancer worldwide199. In 2007 there were 218890 new cases of prostate 
cancer in the United States of America causing 27050 deaths200. This made it the most 
common malignancy in men and second leading cause of cancer death in the US200. In 
England and Wales the number of cases registered and death rates have increased and 
prostate cancer is the second leading cancer related death in men after lung cancer201. 
Treatment of prostate cancer depends on the grade and stage of the disease and in 
appropriate men hormone manipulation, chemotherapy, surgery, high energy ultrasound 
or radiation therapy will be used solely, sequentially or in combination. All of these 
treatments can lead to alterations in the neoplastic and non-neoplastic gland which have 
been investigated by many authors over the years but few studies have looked at the 
effects of radiation on the prostate gland that does not harbour a cancer202-207. This first 
major description of radiation changes in the neoplastic and benign prostate gland was 
published in 1982 but this included few non-neoplastic cases and no-one has studied the 
radiation induced changes in the normal prostate gland in any systematic way208. 
There are many reasons why it is important to document and understand the changes in 
the prostate gland associated with radiation. Firstly, prostate biopsies are the mainstay 
of diagnosis and it is crucial that a full knowledge of the radiation induced changes is 
appreciated in order to avoid overcalling cancer. Secondly, symptoms after radiation to 
the lower urinary tract are common and sometimes the reasons for the symptoms cannot 
be explained. It may be that radiation changes in the prostate or neighbouring structures 
may provide possible explanations for these symptoms. 
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The prostate gland is intimately related to the base of the bladder. We therefore looked 
at prostates in cystoprostatectomy specimens removed from patients who had been 
treated with radiotherapy for transitional cell carcinoma. For a comparison, prostate 
tissue removed at TURP for benign prostatic hypertrophy/hyperplasia was used as a 
control, with age matched cases. 
 
2.1.1 Anatomy of the normal prostate gland 
 
 
Figure 10. The position and local anatomy of the prostate gland209 
 
The prostate gland develops from epithelial invaginations of the posterior urogenital 
sinus in utero. It enlarges continuously to reach 20g by around 25-30 years of age. 
There have been several anatomical descriptions of the internal anatomy of the gland 
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but currently the most popular depicts several zones encased in a capsule. The zones are 
useful anatomically and pathologically as the most common disorders of the prostate are 
frequently found in particular zones. The zones are the peripheral zone, the central zone 
and the transition zone. Most cancers are found peripherally. The urethra runs through 
the prostate and the seminal vesicles contribute their secretions to the urethra through 
gland (Fig. 10). The gland is well innervated.  
 
2.2 Materials and methods 
The files of the Pathology Archive of RLH were searched over a 10-year period (1983-
1993) looking for all patients who had undergone a radical cystoprostatectomy for the 
treatment of their bladder cancer. A total of 39 radical samples were identified where 
there was a specimen available for review. All patients had originally been diagnosed 
with transitional cell carcinoma of the bladder. The case notes, and in some instances 
the radiotherapy schedule, were reviewed and all patients had been through the same 
course of radiotherapy at the London Hospital. The treatment course consisted of 20 
daily treatments of 55Gy each day for 5 days over a 4-week period. The protocol was 
similar for all patients and involved three beam irradiation, one anterior and two 
posterior oblique beams. The field was determined using CT scan image based planning 
to build up a three dimensional map of the area to be irradiated. As per convention, the 
protocol intentionally included a 10-15mm margin of surrounding tissue which would 
have incorporated the prostate gland. Surgery was necessary because of symptom 
control or resistant, recurrent or progressive tumour. No patient had had a pre-treatment 
biopsy of their prostate gland although it was thought that the prostate gland was not 
involved by the tumour pre-operatively. In each case the time between irradiation and 
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surgery was known (1week to 17 years). All cases were male and the age ranged from 
41-84 years. 
The specimens were all handled in the Department’s routine manner. All had a similar 
assessment at cut-up with a gross description and appropriate block sampling. The 
pieces of prostate gland tissue retained were random and not directed to any particular 
area. Between two and five blocks were taken for each case. The tissue was fixed in 
10% formalin, processed routinely and embedded in paraffin wax. Sections were 
subsequently cut at 4-5 microns and stained with haematoxylin and eosin.  
The slides from each case were examined by two observers who scored the changes as 
being either present or absent. If appropriate, the features were graded according to a 
predetermined scale. The scale was subjective and comprised 0 when the feature was 
absent, + when there was a mild change, ++ for a moderate change and +++ for a 
conspicuous, widespread alteration. Changes within glands, stroma, vessles and 
surrounding structures were all inspected. In particular we looked for glandular atrophy, 
epithelial cellular changes (especially the nuclei), metaplastic epithelial alterations, 
stromal inflammation, mural fibrosis, vessel changes and changes within and around 
nerves. Slides which showed direct involvement by tumour were purposely excluded 
from the study. In some cases, where present, the seminal vesical was also assessed. In 
the majority of cases the scores for both observers were identical. When there was a 
discrepancy however, the cases were re-examined and a final agreed score was given. 
In order to relate the findings to a control group, we also looked at 40 TURP specimens 
removed for benign myoadenomatous hyperplasia. None of these cases included 
patients with either tumours (known or found at surgery) or re-operations. None had had 
previous pelvic irradiation. We chose cases from the same time period and same age 
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range. We did not specifically exclude any cases above or below a certain size/weight of 
chippings; there was no attept to correct for this. 
For statistics, a Chi-squared test was performed and results showing a p value of less 
than 0.05% were considered significant. 
 
2.3 Results  
The results are outlined in Table 1. The most frequent changes identified within the 
prostate gland were acinar atrophy (Fig. 11), squamous metaplasia (Fig. 12), epithelial 
cell cytological and/or nuclear atypia (Fig. 13) and basal cell hyperplasia (Fig. 14). All 
four of these features were also found in the control group but not as frequently as in the 
irradiated set. Changes that were much more frequently found in irradiated prostate 
glands included a foreign body reaction with spillage of corpora amylacea from the 
ruptured glands into the surrounding stroma (Fig. 15). Inflammation and fibrosis were 
frequently found in both populations but these were much common in the radiation 
group (Fig. 13). Intra-prostatic vascular changes were expected but these were 
surprisingly very common. Some changes such as endothelial cell hypertrophy, foam 
cells in the intima, intimal hyperplasia/fibrosis, medial hyaline thickening, thrombosis 
and luminal occlusion were quite common and this combination was rarely seen in the 
control group (Figs. 14-17). Inflammation, with mononuclear cells, was regularly 
identified within and around ganglia both within and around the gland itself (Fig. 18). 
Perineural thickening and inflammation was also conspicuous (Fig. 19). However these 
types of changes could not be compared with the control group as periprostatic tissue 
was not regularly represented. The same problem prevented comparison of the seminal 
vesicle fibrosis which was seen in most of the radiated group patients. It should be 
pointed out here that the case selection (cystectomy cases) may bias our results to more 
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exaggerated changes than those that occur in the majority of patients undergoing 
radiotherapy who do not develop symptoms that require such radical surgery. 
 
Feature Prostates after 
irradiation n = 39 (%) 
Non-irradiated 
prostate glands n = 40 
(%) 
P-values 
Glandular atrophy 31 (80) 9 (23) <0.001 
Nuclear atypia in 
glands 
30 (77) 6 (15) <0.001 
Basal cell hyperplasia 30 (77) 17 (43) 0.0018 
Squamous metaplasia 23 (59) 3 (8) <0.001 
Foreign body /giant 
cell reaction to 
corpora amylacea 
17 (44) 2 (5) 0.001 
Arterial intimal 
hyperplasia 
36 (92) 9 (23) <0.001 
Marked arterial 
luminal narrowing 
24 (62) 2 (5) <0.001 
Arterial medial 
thickening and/or 
hyalinisation 
33 (85) 2 (5) <0.001 
Stromal inflammation 35 (90) 23 (58) 0.0012 
Marked stromal 
fibrosis 
35 (90) 8 (20) <0.001 
 
Table 1. Changes in the prostate gland following irradiation 
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Figure 11. Gland atrophy after prostatic irradiation 
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Figure 12. Squamous metaplasia in a prostatic gland after radiotherapy.  
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Figure 13. Inflammation and epithelial cell atypia typical of radiation induce 
changes in the prostate gland. 
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Figure 14. Basal cell hyperplasia is commonly seen in the irradiated prostates. 
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Figure 15. In addition to epithelial hyperplasia and atypia, there was often rupture 
of corpora amylacea into the periglandular stroma with an associated giant cell 
response. 
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Figure 16. Vessels sometimes show endarteritis obliterans, often quite a long time 
after irradiation. 
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Figure 17. Endothelial cell swelling/hypertrophy was a common finding. 
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Figure 18. Sometimes atheroma-like accumulation of foamy macrophages was seen 
beneath the endothelium of small arteries. 
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Figure 19. Infrequently cholesterol emboli were noted. 
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Figure 20. Lymphocytic ganglionitis was frequently seen. 
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Figure 21. Perineural inflammation (with eosinophils) was often seen. 
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2.4 Discussion 
 
Radiotherapy is often employed for the treatment of localised prostate cancer and it is 
also used in advanced, disseminated cases. Radiation therapy is now well established as 
a key treatment for prostate cancer and there have been many reviews of the types of 
radiation delivery and suitability of patients for the particular protocols available. 
Recognised methods include external beam, brachytherapy, IMRT and many other 
varieties of radiation delivery. The relative benefits of and preference for each of these 
modalities is beyond the scope of this study but there have been many reviews of this 
topic210-215. Whilst radiotherapy may be used alone in the treatment of prostate cancer, 
some advocate a multidisciplicary approach  and many patients will benefit from such 
an approach with radiation as part of the treatment plan in addition to surgery, 
chemotherapy, hormone therapy or some other method of combination treatment216. 
Each patient undergoing radiation treatment will require a risk-benefit assessment to 
establish whether the treatment with radiation is likely to be worthwhile in terms of 
prognosis and morbidity. The unwanted effects of radiation will factor into this 
assessment. Toxicity includes of urine retention and proctitis. Most outcomes are 
measured in terms of symptoms produced and there are scoring systems for this169.  
There is a fairly comprehensive literature on the histological effects of all sorts of 
treatment (including radiation) on prostate carcinoma but little has been documented on 
the radiation changes in the normal prostate gland. Knowledge of these changes is of 
vital importance since one must know the non-neoplastic changes to avoid overcalling 
cancer. This is especially important when one appreciates that follow up biopsies are 
frequently performed when assessing response to treatment and predicting tumour 
progression. It has been suggested that cases with poor outcome prediction from the 
biopsy morphology may be due to misinterpretation of the biopsy appearance.  
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There was limited information on the effects of radiation on prostate cancer until fairly 
recently.  In one of the studies performed in 1999217, the authors did investigate the 
changes within benign glands adjacent to prostate cancers but the numbers were very 
limited. In their cases, they showed that the changes included gland atrophy, cytological 
atypia and basal cell prominence. Paneth cell like change was seen in 32% of cases, 
mucinous metaplasia in 21% and blue tinged luminal secretions in 10%. Squamous 
metaplasia was only found  in 6%. Changes in cancerous glands were very variable. 
Nilsson and colleagues have looked at the morphological effects of radiation on prostate 
cancer218. This study was primarily focussed on whether their 40 patients with prostate 
cancer, who were treated by radiation, had evidence of residual tumour and whether this 
could be differentiated from radiation atypia. They compared their findings to those 
identified in 10 patients irradiated for non-prostatic pelvic tumour. They found a 
decreased ratio of tumour glands to stroma, gland atrophy and squamous metaplasia of 
non-neoplastic glands with or without cytological atypia of the lining epithelial cells. 
They also identified stromal fibrosis, arterial lumen narrowing due to myointimal 
proliferation, foam cells in vessel walls, fibrosis and atrophy of the seminal vesicle. 
Prominent inflammation was noted but this was not helpful in predicting whether the 
patients had undergone radiation therapy. 
Other studies on prostate cancer cases have also specifically looked at the changes 
within the prostate tissue itself after a variety of local and systemic treatments. For 
example Bostwick and Meiers looked at a range of at therapy related changes to prostate 
cancer histology, including a few cases of radiation219. Roznovanu and colleagues 
looked at the hormonal and radiation induced changes in prostate cancers220. They 
found similar changes to Nilsson with increased number of atrophic acini, squamous 
metaplasia and atypical glands. They stated that radiation induced atypia in non-
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neoplastic glands after radiation for prostate cancer may persist for many years and 
therefore be a pitfall for overcalling recurrent cancer.  
Magi-Galluzzi’s group also described atypia in non-neoplastic prostate glands and have 
devised a scoring system based on a numerical score 0-3 for nuclear atypia, stromal 
fibrosis and vascular hyalinization221. When they separated their cases into three groups, 
depending on the time since irradiation (less than 24 months, 24-48 months and more 
than 48 months), they found more atypia in interstitial (brachytherapy) and combined 
cases rather than sole external beam therapy. They also identified more stromal fibrosis 
in these groups. Vessel changes were the similar in both groups of patients.  No change 
in atypia over time was identified in interstitial and combined although they seemed to 
show less atypia in the group examined more than 48 months after external beam 
radiation. 
In the study presented here, my aim was to identify and record changes in the non-
neoplastic gland where we know a local primary prostatic tumour would not be 
influencing the appearances. The changes we observed are very similar to those 
described in the early paper from the Bostwick group208. For example, nuclear atypia in 
glands was present in 77% of cases studied here and 78% of Bostwick’s cases. 
Squamous metaplasia was present in 59% of our cases and  63% of Bostwick’s. A 
granulomatous reaction to gland rupture and displaced corpora amylacea was identified 
in 50% of the American cases and 44% of ours. Bostwick did not appear to compare his 
results to any form of control group. 
Many of the changes found in the non-neoplastic glands were seen in both the irradiated 
and non-irradiated groups including atrophy, chronic inflammation, corpora amylacea 
and basal cell hyperplasia. This is not particularly surprising as we purposely chose age-
matched controls who inevitably included an older population. However, the changes 
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were more frequently observed in the radiation group than control and they were often 
more exaggerated. It is possible therefore that the changes observed after radiation 
reflects acceleration of regular degenerative changes seen in the normal physiological 
ageing processes. These latter clearly involve apoptosis1, atrophy222 and 
atherosclerosis223,224, all of which are very commonly found in tissues generally after 
radiotherapy. It could be therefore that radiation induces changes which are similar to, 
or even identical to, generalised degenerative phenomenon in epithelial and stromal 
cells, involving nuclear and cytoplasmic structures.  
Radiation is also known to be associated with inhibition of DNA synthesis in prostatic 
epithelial cells225. In fact, as discussed in Chapter 1, the effects of radiation are 
generally brought about by direct nuclear injury, free radical induced damage or 
cytokine induced changes. These are all processes that are implicated in ageing and 
senescence, which is after all basically an accumulation of structural cellular/system 
damage over time. Therefore radiation may be inducing premature ageing. It is difficult 
however to tease out the direct effects from indirect changes associated with ischaemia 
from vascular injury and it may be the latter which has a more significant effect on the 
tissues. 
It is well recognised that radiation can induce vascular changes in many organs, 
including changes in large/medium sized arteries such as atherosclerosis. The full 
spectrum of vascular changes described in many tissues after radiation was observed in 
the prostate gland. These changes are also found in the prostatic vessels, with 
conspicuous atheroma-like foam cell accumulation within the intima, endarteritis, 
medial thickening and intimal hyperplasia all being observed (these are also features of 
ageing226). Some of these changes were seen in small vessels as well as medium sized 
arteries. In the thorax, it is well recognised that atheroma of the coronary arteries is 
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accelerated and/or increased after radiation to the chest227. Other vascular changes 
included thrombosis (presumably due to provocation of the coagulation system by 
endothelial cell injury).  
Stromal fibrosis was especially conspicuous after irradiation (as indeed it was in the 
prostates examined by Bostwick). This is not surprising since radiation is followed by 
fibrosis in most organs studied. In the lung this has been shown to be associated with 
growth factor expression, including release by alveolar macrophages89. Similar changes 
are described in the intestine after irradiation. In culture, endothelial cells have been 
shown to produce growth factors after irradiation74. Such growth factors are potent 
mitogens and chemotactins for fibroblasts and they increase their production of 
collagen. It is logical, therefore, that growth factors are involved in the production of 
radiation-induced fibrosis. We have gone on to show that PDGF expression is increased 
in the bladder after irradiation and suggest that it may be involved in the contracted 
bladder that is sometimes seen after radiotherapy (see Chapters 6-8). It is also possible 
that PDGF may be relevant for some of the vascular injury observed after radiation – 
there are theories suggesting that local PDGF production may be important in 
atherogenesis and endothelial cells express PDGF.  
Inflammation is a conspicuous feature of early radiation injury. The inflammatory cell 
profile is unusual in that eosinophils are especially common in a lymphohistiocytic 
background. Eosinophils were present in the prostate after irradiation but their 
population was not as florid as in the bladder (see Chapter 5). Mast cells also 
accumulate after radiation228 and increased numbers of mast cells were identified in the 
prostate gland suggesting that radiation provoked this pattern of inflammation rather 
than it reflecting a local infection/dysfunction.  
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The presence of mast cells is interesting.  These cells contain vasoactive amines and 
growth factors. The latter includes TGFβ. We also describe immunoreactivity for PDGF 
in mast cells in the bladder and prostate gland after irradiation. Others have also 
suggested that mast cell contain PDGF229,230. It is tantalising to speculate that the 
presence of mast cells, with their cytoplasmic fibrogenic factors, may be an important 
part of the fibrotic process seen after irradiation. After all, mast cells are also increased 
in other fibro-inflammatory conditions such as scleroderma, interstitial cystitis and 
atherosclerosis and this surely supports a role for mast cells and their cytokines/growth 
factors in the pathological manifestations and symptoms encountered in these lesions.   
Another particularly interesting finding of this study is that radiation appears to be 
associated with a range of neural changes. In particular, inflammation was seen around 
nerves and within ganglia. This time the inflammatory cell population included mainly 
lymphocytes mainly but again occasional mast cells and eosinophils were admixed. 
Such changes have been described before in a few superficial bladder mucosal 
biopsies231 but our study shows that it is a frequent finding not only in mucosal nerves 
but also in deeper nerves and nerves outside of the pelvic organs themselves. 
Furthermore, we also found prominent perineural thickening which was more often seen 
in the irradiated group rather than the control group. The statistical significance of this 
finding could not be established due to the limited number of cases with nerves outside 
of the bladder/prostate gland in the control arm. Some growth factors are also present in 
nerves and the surrounding cells and the relevance of this remains undetermined. The 
neural changes may be particularly important in the symptoms patients who have 
undergone radiotherapy complain of, since often no anatomical change is found 
macroscopically232. 
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One of the more common complications of radiotherapy to the pelvis is cystitis, either 
associated with infection or unassociated. Patients also complain of haematuria often 
associated with ischaemic injury233. However, when specifically asked about these 
issues, patients report that their quality of life is not greatly affected234. There may also 
be other local and related anatomical problems like rectal injury, strictures, lower limb 
oedema, nerve injury, incontinence and maintenance of erectile potency. Post 
radiotherapy pain is also seen and this could be related to the neural changes described 
above. It would be worth pursuing the possibility that neural injury is an important 
factor in the symptoms patients suffer.  
 
2.5 Summary and conclusion 
The prostate gland will inevitably be exposed to radiation when tumours of the pelvic 
region are irradiated. The subsequent changes include a combination of inflammatory, 
fibroatrophic and reactive features which may be significant clinically either by 
producing symptoms or inducing abnormalities that provoke an alteration in subsequent 
management. Most of the changes are fairly predictable but this study has identified 
changes that have not previously been recognised and which are crucial to appreciate 
for two main reasons. Firstly, the findings help to explain some of the morphological 
changes that have been described by previous studies and secondly, some of the changes 
may account for some of the post-radiation symptoms suffered by many patients who 
have undergone pelvic irradiation. This could lead to novel methods of symptom relief 
and control and deserves more attention in the future. 
  118 
Chapter 3. Effects of radiation on the human bladder 
3.1 Introduction 
 
Radiation is widely used to treat tumours of the pelvis, most frequently cancers of the 
bladder, prostate and cervix. Radical radiotherapy is associated with a good response 
rate when used for transitional cell carcinoma of the bladder, but occasionally salvage 
cystectomy is required235. Approximately 80% of patients with bladder cancer treated 
by external beam radiotherapy have long-term survival with intact, well functioning 
bladders236. In many cases, however, there is unavoidable injury to the surrounding non-
neoplastic tissue. In some cases this includes the structures that make up the lower 
urinary tract including the bladder itself, the urethra and ureter. Patients develop 
symptoms soon after, or some considerable time following, radiation treatment and 
although over 70% of people may develop clinically relevant complications237 there is a 
limited amount of pathological data on human tissue with occasional studies on few 
cases. Despite the extensive literature on the clinical aspects of radiation injury in this 
area, even with the development of scoring systems, pathological information is limited. 
In most instances the material relies on superficial biopsies of tissue obtained 
transurethrally. It is essential therefore that a thorough examination of irradiated bladder 
tissue be made in order to extend our knowledge of this area and also to search for 
potential features that might explain the variety of symptoms patients have after pelvic 
irradiation. There is a large archive of tissue in the files of the Department of Pathology, 
Royal London Hospital which includes a number of surgical specimens removed and 
examined as part of the management for bladder cancer. The bladders were removed 
(cystectomy) for either locally advanced disease, recurrent disease or symptomatic 
control of complications of radiation. 
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3.1.1 Structure of the normal bladder 
 
The internal epithelial lining of the bladder (urothelium) consists of 3-7 layers of 
urothelial or transitional cells resting on a thin connective tissue basement membrane. 
The cells replicate and proliferate from the base towards the luminal surface. As they 
migrate superficially, they become larger and take on a more voluminous appearance. 
At the surface they form ‘umbrella cells’ with tight junctions between them. There is a 
polysaccharide layer on the luminal aspect to protect the epithelium and underlying 
tissue and form a waterproof barrier238. 
Beneath the basement membrane there lies a lamina propria composed of loose 
connective tissue with occasional smooth muscle cells. Deep to this there is a more 
prominent muscle layer; the detrusor muscle. This layer of muscle converges near the 
neck of the bladder to form a more structured arrangement of three circular layers, an 
inner, an outer and a middle which extend along the urethra in females and end at the 
limit of the prostate in men. This acts as an involuntary sphincter. The inner layer 
extends further, along the urethra in men and women.  
The bladder is under autonomic control by motor innervation which provides efferent 
impulses. This occurs through parasympathetic fibres from spinal cord to the detrusor 
muscle via sacral and pelvic nerves. The trigone, seminal vesicle and ampulla of vas 
deferens are all under sympathetic control. The pelvic floor and external sphincter are 
innervated from S2-3 via the pudendal nerve. Afferent or sensory nerves travel via the 
pelvic nerve and sympathetic pathways to T11-L1. 
The bladder’s main function is to store urine for voluntary release when required. 
Storage is accomplished by compliance and requires competent sphincters. There is also 
an ureteral anti-reflux mechanism to prevent urine passing back into the ureters. The 
normal bladder capacity is around 400-500ml. On reaching appropriate compliance 
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afferent fibres send messages to the spinal cord which produces a suitable voiding 
mechanism. Damage to the bladder may result in reduced capacity to store or void urine 
and may lead to urinary incontinence. Prorioceptive nerves are also present in the 
bladder and therefore insult to the bladder may be associated with pain and/or 
contractions. 
 
 
Figure 22. The anatomy and structure of the normal bladder282 (permission for use 
granted) 
 
3.2 Materials and methods 
 
The files of the Pathology Archive of the Royal London Hospital were interrogated 
looking for patients with cystoprostatectomy for treatment of their urothelial carcinomas 
of the bladder for a 10-year period (1984-1993). The database search was then refined 
to identify those patients who had undergone pre-operative radiotherapy. This originally 
produced a total of 39 cases. All of the patients had been through the same course of 
radiotherapy consisting of 20 daily treatments of 55Gy each, over a 4-week period. The 
age range was 41-84 years. The protocol was similar for all and involved three beam 
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irradiation, one anterior and two posterior obliques. The field was determined using CT 
scan image based planning to build up a three dimensional map of the area to be 
irradiated. The map intentionally included a 10-15mm margin of surrounding tissue 
which would have incorporated the prostate gland. Subsequent surgery was necessary 
because of symptom control or resistant, recurrent or progressive tumour. In each case 
the time between irradiation and surgery was known (1week to 17 years). 
The surgical specimens were all handled in the same routine manner. Briefly, the 
specimens were fixed in 10% formalin, processed routinely and blocked into paraffin 
wax. The blocks of tissue were sampled as per our local Department protocol which 
follows the recommendations outlined in Ackerman160. Between eight and twenty 
blocks were taken per case, of which 2-5 contained bladder wall (distant from tumour 
where possible). Sections were cut at 4-5 microns and stained with haematoxylin and 
eosin (H&E).  
Each case was examined by two observers who scored the changes either present or 
absent. Changes within the epithelium, lamina propria, stroma, vessels and surrounding 
structures were looked at and recorded. In particular we looked at epithelial cellular 
changes, epithelial metaplasia, stromal inflammation, mural fibrosis and vessel changes 
together with changes within and around nerves. Blocks and slides with direct tumour 
involvement were excluded. The changes were scored present or absent. Where possible 
the changes were related to the time since irradiation to see which alterations were seen 
early, which were late and which were present continuously. In every case there was 
agreement between observers either individually or after consultation. The alterations 
were compared with autopsy bladder tissue and cystectomies from patients with 
interstitial cystisis. However, there were too few of these ‘control’ cases to perform 
meaningful statistics. Mnay of the changes searched for were the same as those 
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examined in the prostate glands. The bladder wall is a more complicated structure with 
more anatomical relationships to surrounding tissues that the prostate and therefore 
there were additional features to study (see Table 2). 
 
3.3 Results  
 
The overall results are presented in Table 2. 
The dominant early changes (less than 1 year after irradiation) were eosinophils rich 
inflammation (Figs. 23 and 24), ulceration, urothelial hyperplasia, transitional cell 
nuclear atypia, endothelial cell enlargement and smooth muscle cell necrosis. Later 
changes (over 1 year after radiotherapy)  included  prominent numbers of mast cells 
(Fig. 25), fibrosis of the mural smooth muscle, perineural thickening, serosal fibrosis 
and vessel changes including myointimal inflammation and thickening, and endarteritis 
obliterans with subintimal foam cells (Figs. 26 and 27). Some of the more common 
findings throughout included the presence of eosinophils, vascular thrombosis (Fig. 28), 
perineural inflammation and serosal fat necrosis. The tumour was viable in the majority 
of cases where residual or recurrent tumour was present. 
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Feature Early Late 
Ulceration + + 
Urothelial hyperplasia + - 
Urothelial cell atypia + + 
Squamous metaplasia + + 
Endothelial cell enlargement  + - 
Arterial intimal hyperplasia + + 
Fibrointimal thickening - + 
Endartieritis obliternas - + 
Subintimal foam cells - + 
Thrombosis  + + 
Marked arterial luminal 
narrowing 
- + 
Smooth muscle cell necrosis  + - 
Arterial medial thickening 
and/or hyalinisation 
- + 
Stromal inflammation + + 
Marked stromal fibrosis - + 
Smooth muscle fibrosis - + 
Eosinophils + + 
Mast cells + + 
Perineural inflammation + + 
Perineural thickening + + 
Serosal fat necrosis + + 
Serosal fibrosis - + 
 
Table 2. Features seen in the bladder after local irradiation (listed in no particular 
order but from inner to outer aspect of the balder wall). 
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Figure 23. Inflammation was commonly seen in irradiated bladders.
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Figure 24. The inflammation was often eosinophil rich. Note the stellate 
fibroblasts. 
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Figure 25. Mast cells were frequently observed in the bladders after radiotherapy. 
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Figure 26. Intramural vessels showed intimal fibrosis.
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Figure 27. There was sometimes an intimal arteritis as well as fibrosis.
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Figure 28. Occasionally the vessels within the bladder wall were thrombosed.
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3.4 Discussion 
 
Radiation is frequently used in the treatment of a range of pelvic tumours including 
transitional cell carcinoma of the bladder. The optimal and most appropriate use of the 
various techniques in the treatment of bladder cancer has been outlined fairly recently 
by an International Committee after critical review of the literature available236. The 
panel looked at studies describing the use and effectiveness of external beam therapy, 
interstitial radiotherapy and therapy combined with surgery and/or chemotherapy. They 
concluded that radiotherapy was an effective treatment for bladder cancer, producing 
long term disease control and preservation of normal bladder function. Choice of 
appropriate treatment for the correct individual case was considered paramount with all 
newly diagnosed patients being assessed in a multidisciplinary setting where the relative 
merits of surgery, radiotherapy and chemotherapy can be considered. Others have 
reviewed the most appropriate role and type of radiotherapy for urinary bladder 
cancer239. When compared with surgery some suggest that there is no benefit of pre-
operative radiotherapy although radiation has the advantage that it can palliate tumour 
related symptoms in bladder cancer239. 
Others have outlined the usefulness of radiation therapy for the treatment of bladder 
cancer but all remind us that radiotherapy is often associated with unwanted side 
effects235,240. The latter looked at 163 patients who were treated with radiotherapy and 
found that 61% achieved a complete response, depending on T stage, varying from 90% 
for T1 tumours to 53% for tumours stage T3. A few relapsed in the bladder. There were 
18 (11%) partial responders of whom 7 required subsequent salvage cystectomy. All of 
the patients who did not respond died relatively quickly with a median survival of only 
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10 months. Their results suggested that radiation before surgery was beneficial in many 
cases. 
Marks and colleagues reviewed the usefulness of radiotherapy and chemotherapy in 
lower urinary tract lesions and discussed the complications and morphological changes 
produced by radiotherapy241. They reviewed the clinical syndromes associated with 
radiation treatment of the lower urinary tract and tabulated the complication rates for 
radiotherapy directed at the pelvis, including urothelial tumours. They also outlined the 
tolerance doses, options for treatment of side effects and scoring systems for the 
unwanted effects encountered. Between 3 and 47% of patients treated in a range of 
studies by radiotherapy for bladder cancer, were reported to have developed significant 
side effects (greater than or equal to grade 3 in their subjective, objective, management 
and analytic system). Complication rates after radiotherapy for prostate cancer and 
cervical cancer were also provided. 
There are many other publications on the clinical side effects of radiotherapy used for 
pelvic tumours. Tomic described 121 patients with muscle invasive or recurrent 
transitional cell carcinoma who were treated by radiotherapy and cystectomy and found 
clinically relevant complications in 71-78% of patients (many intestinal)237. 
Furthermore, they describe 3% mortality from these complications. On the other hand, 
late toxicity appears to be less of a problem after three-dimensional conformal 
radiotherapy and intensity modulated radiotherapy (IMRT) for prostate cancer242. 
In an Italian series of complications following radiation treatment of bladder cancer, 
Tonoli et al found 459 cases with grade 1-2 toxicity of which the majority were urinary 
23%, and 6% were late and enteric243. It appears that some of the complications, 
including radiation cystitis, can be alleviated by hyperbaric oxygen. Three women with 
radiation cystitis given hyperbaric oxygen were found to cease their macrohaematuria 
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and cystoscopy showed that the macroscopic and microscopic bladder inflammation 
improved but the telangiecatasia did not resolve completely244. 
There is a fairly well established history of animal studies of radiation injury in the 
bladder including investigations on dogs, rabbits, mice and rats.   In the dog, 
complications of irradiation for pelvic tumours were seen in 20 of 51 dogs irradiated 
(39%)245. The complications included skin necrosis (7), chronic colitis (4), strictures (4), 
osteopaenia (2), rectal perforation (1), bladder thickening (1), iliosacral osteosarcoma 
(1), and one each of pelvic limb oedema and perianal pain.  
In rabbits, epithelial and muscular changes were found to be dose dependent, but the 
submucosal and extramuscular changes were not246. The transitional epithelium was 
either atrophic or hyperplastic, umbrella cells were always present and there was 
fibrosis in the submucosa and muscle layers. Blood vessel and lymphatic changes were 
seen in some of the animals. Rabbits studied by angiographic, microangiographic and 
tissue microscopy showed similar changes with atrophy of mucosa, epithelial 
desquamation, cellular atypia and ulceration and that these irradiation changes appear 
earlier when increased doses of radiation are used247. 
Antonakopoulos et al. looked at changes in the rat bladder after X-irradiation248. By 
light and electron microscopy they detected basal cell damage in the urothelium early 
on which extended to the intermediate cells a little later and by 6 months the epithelium 
was generally hyperplastic. The blood vessels showed changes with endothelial cell and 
smooth muscle cell damage. Fibroblasts appeared to show increased secretion with 
abundant collagen deposition leading to severe fibrosis of bladder wall. After a few 
months muscle cells degenerated, became disorganised and some were even necrotic. 
By 20 months nearly 60% of surviving animals developed transitional cell carcinomas. 
In another rat model of post-radiation bladder dysfunction, two phases of reduced 
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bladder compliance were noted, the first at 4 weeks and the second at 6 months. 
Histologically, at 6 months after irradiation, increased mast cell density was identified 
with fibrosis in around half of the cases. Electron microscopy showed smooth muscle 
cell injury and selective degeneration of unmyelinated axon profiles249. Similar changes 
were observed in mouse bladders, which could be reversed by acetylsalicylic acid which 
suggested that prostaglandins may be involved in the radiation response250. 
In humans, the histological changes associated with radiation injury in the bladder are 
generally poorly documented and most of the studies previously performed have only 
looked at superficial bladder mucosal biopsies. Consequently, the pathogenesis of many 
radiation related symptoms remain unexplained251. Superficial biopsies have been 
investigated previously because the easiest way to take samples for histology is 
obviously via cystoscopy. One of the largest series of cases is described in the article by 
Suresh et al.231. They investigated the changes in superficial biopsies of 15 patients 
together with 3 cystectomies. All patients had received radiotherapy as part of their 
treatment for cervical and uterine cancer. The time interval varied from 6 months to 4 
years. Symptoms included urinary frequency, dysuria, incontinence and haematuria. 
Histological changes on the surface included ulceration, cellular atypia, proliferation, 
squamous metaplasia, cytoplasmic vacuolation. In the stroma and/or submucosa there 
was oedema, fibrosis, atypical stromal cells, vascular changes, deep epithelial inclusions 
(cystitis cystica) and a conspicuous inflammatory cell infiltrate. When the authors 
compared the differences in specimens taken before and after 12 months from the date 
of radiotherapy, they found that the epithelial changes were prominent in the early cases 
and the stromal changes dominated the later cases. However, there was a continuing 
spectrum of epithelial changes which persisted many years after initial radiation. 
Inflammation was present throughout, but there was ‘no predeliction for eosinophils in 
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infiltrate’. The inflammation was thought to be the cause of the fibrosis which 
developed quite early, but which persisted into later stages. 
Some post-radiation changes can cause confusion with recurrent or residual tumour. A 
review of such radiation and chemotherapy related changes described the issues with 
clues to avoid confusion with urothelial carcinomas252. One particular clue for 
differentiation between the two is the finding of characteristic chemotherapy and/or 
radiotherapy changes nearby which can help to avoid misinterpretation. Furthermore, 
‘polypoid’ or ‘papillary cystitis’ is another mimic of transitional cell carcinoma that has 
been described in 41 of 155 cases originally diagnosed as neoplasms by Lane and 
Epstein253. Two of these cases followed previous radiotherapy. These changes were not 
seen in our cases. 
In order to enhance the current literature on radiation changes to the bladder, we 
reviewed a large series of cystectomy specimens removed after a standard course of 
radiotherapy. Many of the findings described in previous animal and human studies 
were confirmed, but alterations in deeper structures were also identified. Some of these 
might explain some of the symptoms experienced by patients after radiotherpay, others 
are novel. The significance of some of the changes is uncertain. Furthermore we were 
able to categorise our cases into arbitrary groups on the basis of time since irradiation. 
We found differences between changes seen early and late phases. Additionally, the 
progression of many of the changes from the early period to later could be 
demonstrated.  
The changes found in the bladder wall are outlined in the results section and will not be 
repeated here. Briefly however, there were consistent epithelial changes, such as 
hyperplasia, cellular atypia and metaplasias; almost universal necro-inflammatory 
changes throughout the bladder wall; frequent vascular changes and also changes in the 
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nerves of many of the cases. The early post-radiation period was dominated by the 
inflammation, ulceration and necrosis (although these were frequently seen to a lesser 
extent throughout the study period) and later the picture was dominated by the vascular 
compromise associated with arterial narrowing and obstruction. Some features were 
seen in virtually every case, such as conspicuous eosinophils, vascular changes and 
perineural changes. 
The presence of cellular atypia is well described after irradiation, especially within 
epithelial cells. Radiation is also known to cause tumours, usually after a significant 
latent period of several years. It is likely that these two are related although it is 
interesting to note that cellular atypia is a frequent finding after bladder irradiation but 
development of urothelial carcinomas is not254. Researchers following a group of people 
exposed to radiation after the Chernobyl incident have demonstrated DNA damage in 
urothelial cells of those exposed255. They found significant activation of DNA damage 
repair mechanisms (base and nucleotide excision repair) which were thought to be 
induced by oxidative stress generated by ionising radiation. Some patients developed 
chronic proliferative atypical cystitis, others had multifocal dysplasia and carcinoma in 
situ. Ten of their cohort developed transitional cell carcinoma, although all were small 
and superficial. All of the findings were significantly higher than in their control group. 
The morphological changes described integrate well with the current theories of the 
pathogenesis of radiation injury, including that seen in the bladder. This has been 
illustrated fully in the previous chapters. The role of the inflammation, with a range of 
inflammatory cytokine including eicosanoic acid derivatives and growth factors is a 
fundamental part of the process. Whether eosinophils have a special relevance in 
radiation injury remains unknown but they appear to be a consistent feature of the 
reaction of tissues to irradiation. Furthermore, direct and indirect nucleic acid damage is 
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also important and it introduces the concept of radiation inducing accelerated ageing as 
discussed in the chapter on the prostate gland. The key features of radiation changes and 
the pathogenesis of these changes is leading to realistic treatment options for patients 
who develop complications after radiotherapy such as cytokine inhibitors and growth 
factor influencers. In some, but not all, bladders, the tumour was persistent and viable 
after radiotherapy. Clearly it is impossible to determine whether some of the changes 
observed were related to the presence of the tumour. Another potential contributor to 
post-radiation effects on the bladder is drug-related injury although this is reported not 
to increase the risk of clinical complications, above radiotherapy alone256. The clinical 
and pathological effects of radiotherapy are said to be dose related although this could 
not be determined in this study since all patients have received the same standard course 
of therapy. 
Two potentially important new findings from this study included the changes to pelvic 
nerves and the presence of mast cells. The latter may go some way to explaining the 
unresolved symptoms that some individuals suffer, in particular the local pain. The 
pelvic nerve changes included perineural fibrosis and perineural inflammation with 
ganglionitis. Mast cells have been described in a range of fibrosing conditions around 
the body including scleroderma and scar tissue. Mast cell numbers were increased in the 
bladder after irradiation. They also appear to be sources of growth factors, in particular 
PDGF257. The latter is a potent chemotactic agent and activator of fibroblasts, leading to 
stromal fibrosis. Increased mast cell density has previously been described in 
association with bladder irradiation in animals249. This rat model of radiation injury to 
the bladder found that half of the rats irradiated had a reduced index of bladder 
compliance beginning at 4 weeks after treatment which progressed at 3-4 months and 
persisted at 6 months. Biopsy at 6 months showed increased numbers of mast cells in 
the irradiated group with degenerative changes in smooth muscle cells and selective 
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degeneration of unmyelinated axons. The results suggest a link between mast cells and 
post-radiation fibrosis and also subsequent neuronal injury. 
Increased mast cells have also been described in the detrusor muscle of patients with 
spina bifida where recurrent infections lead to mural fibrosis258.  These patients also had 
evidence of mast cell degranulation and increased collagen deposition, which were 
thought to be directly related.  
 
3.5 Summary and conclusion 
 
Radiation is commonly used to treat cancers of the pelvic organs. Complications and 
relatively common and sometimes these involve the lower urinary tract. Many of the 
complications can be explained by the necro-inflammatory and fibro-atrophic processes 
seen within tissues exposed to irradiation anywhere in the body.  Others may be related 
to the neurological changes and other novel findings discovered during this 
investigation. The pathogenesis of radiation related injury to the bladder is very likely to 
be similar to radiation injury in general and reflect cellular toxicity followed by a series 
of inflammatory and growth promoting events which lead to the processes described 
above. In some unfortunate individuals radiation may also be carcinogenic. A better 
understanding of the progressive changes that are involved in radiation injury will pave 
the way for targeted therapy which could reduce or even reverse the unwanted effects of 
radiation on the bladder. 
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Chapter 4. Fibrosis and fibronectin in the bladder after irradiation 
 
4.1 Introduction 
 
Most superficial bladder tumours can be treated by chemotherapy or removed by minor 
surgical procedures, muscle invasive tumours often require radiotherapy.  This not only 
has an effect on the tumour but also damages the surrounding normal tissue.  Early 
(reversible) or late (irreversible) side effects may develop259. The primary role of the 
vasculature in the development of these effects has been known for some time260,261, and 
the degeneration of the smooth muscle cells in the tunica media and its replacement by 
hyaline material is a common finding in human radiation pathology, as is the 
development of fibrosis to the irradiated urinary tract262. The latter is due to the 
excessive synthesis of ECM components, including collagen types I and III, elastin, 
glycosaminoglycans, and the basement membrane constituents (fibronectin, collagen IV 
and laminin).The latter three components provide structural support for bladder mucosal 
cells and influence cell migration, attachment, differentiation and proliferation.  
More than 30 years ago the World Health Organization proposed to define fibrosis “as 
the presence of excess collagen due to new fiber formation” 263. The same is true for 
radiation fibrosis that was classically considered as a chronic and progressive process in 
which normal tissue is replaced by fixed and irreversible fibrotic tissue. This view has 
however been challenged and fibrosis has been recently redefined as a dynamic process 
resembling chronic wound healing264-266.  
Fibronectin is a large multifunctional high molecular weight glycoprotein which is 
bound to cell surfaces by integrins. It is an important participant in tissue 
morphogenesis and repair and exists in several forms created by both alternative 
splicing and post-translational modifications.  The ED-B+ (extra domain B) form is 
restricted to embryonic tissues, but it has been shown to subsequently reappear in 
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granulation tissue, liver cirrhosis, fibromatosis and in tumour stroma267-270. Its 
expression is stimulated by TGF-β and has been linked with  tumour angiogenesis and 
behaviour with regards to invasiveness and metastatic potential271.  More importantly, 
several recent studies have underlined its importance in relation to cell survival after 
radiation damage272-276. 
Historically there have been very few studies concerning the histological changes 
induced by irradiation of the urinary bladder248,277. Other researchers have concentrated 
on the histological changes in the bladder biopsy after irradiation and have been 
descriptive231. Radiation induced late changes have been studied in various animal 
models, but the time after radiation was short (6-12 months) 278. 
This study therefore aims to quantify the degree of fibrosis in the bladder wall at various 
times after irradiation, and to compare it with a range of control groups. Furthermore, 
given its close involvement with repair and fibrosis in other situations, and more 
recently determined roles in modulating cell cycle arrest and survival after radiation, the 
expression of fibronectin in the various components of the irradiated bladder wall will 
be examined.  
 
4.2 Materials and methods 
 
Ninety-four cystectomy specimens were included in this study group and comprised: 56 
pre-operatively irradiated bladder tumours, 18 non-irradiated bladder tumours, 6 
interstitial cystitis and 14 post-mortem bladder specimens.  The irradiated bladder group 
was further subdivided into 19 cases, 26 cases and 11 cases, each group of which had 
undergone cystectomy 0.25-12 months, 12-36 months and 36-98 months after 
irradiation respectively.   The specimens were obtained from patients attending The 
Royal London Hospital between 1981 and 1995, and ranged in age from 41-84 years 
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(mean 58.7years). All 56 irradiated patients had received a standard course of radical 
radiotherapy (20 treatments of a 55 Gray dose over 4 weeks), and required cystectomy 
because of either recurrent tumour or urinary symptoms.  The time between 
radiotherapy and subsequent surgery ranged from 0.25 to 98 months (mean 23.8).  
 
4.2.1 Immunohistochemical and tinctorial analysis 
 
Cystectomy tissue blocks (distant from the tumour) were retrieved from the archives, 
and 3 micrometer sections were cut and placed on Superfrost slides for 
immunohistochemical localisation of fibronectin and on ordinary microscope slides for 
both haematoxylin and eosin (H&E) and tinctorial staining of collagen.   
Avidin-biotin-peroxidase complex (ABC) method was used in conjunction with 
monoclonal mouse anti-human fibronectin antibody (NCL-FIB, Novocastra, UK) at a 
dilution of 1:200.  Normal kidney was used as a positive control, and the negative 
control had the primary antibody omitted. Picrosirus red was used for collagen 
localisation as it gave greater contrast with the background tissue components than 
haematoxylin van Gieson. Furthermore it has been shown to stain collagen 
stoichiometrically under similar conditions and reflects the amount of fibrosis 
present279,280. Positivity for fibronectin was defined as a convincing brown colouration of 
the component tissue which was clearly different from the background counterstain 
(usually comparing to the smooth muscle present which was negative). All cases were 
assessed by two observers and any cases which were considered particularly difficult 
and agreement was not reached independently were read together and the consensus 
answer was decided to be the final result. 
In order to validate the results, suitable positive control tissues were performed 
alongside each antibody run. Normal kidney tissue was used as a control as per the 
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manufacturers recommendations. Negative controls included omission of the primary 
antibody. 
 
4.2.2 Morphometric image analysis 
 
A JVC 3-CCD Model KY-F55BE video camera mounted on a Zeiss microscope was 
used.  The video output was connected to a microcomputer which contained the Zeiss 
KS400 image analysis software package (version 3). The light source was controlled by 
a photo diode voltage regulator (7.90V), which maintained a light source of constant 
intensity.   Histological images of human urinary bladder were visualised using a x 10 
eyepiece and x 6.3/0.16 objective lens at an Optivar setting of 1.25.  Two dimensional 
Red-Green-Blue (RGB) colour images were acquired using the live video camera 
displayed on screen and optimally adjusted using the focus on the camera and 
microscope.   
The picrosirius stained slides were subjected to morphometric image analysis in order to 
measure the amount of collagen present.  This was used as a marker of fibrosis in all the 
study groups; the distribution of collagen throughout the lamina propria (LP) was 
compared to that within the MP.  For each case, 4 tumour free random sample areas 
within both the LP and MP were analysed.  In order to determine intra and interoperator 
reproducibility the area of interest in 10 random cases was randomly remeasured and 
the analysis revealed consistent results.  The image was thresholded (definition of 
minimal pixel intensity to be included in the calculation) and pointset described 
(definition of the parts of an image to be included in the calculation; Figs 30 and 31).  
The total stained area and field area were measured, the information transferred to an 
Excel spreadsheet and the interactive statistical visualisation package JMP (SAS 
Institute, USA) was used to provide ANOVA (One Way Anaysis of Variance) and 
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Dunnett’s test analysis to compare irradiated and nonirradiated groups against the 
control post mortem groups.  P values less than 0.05 were considered as significant. 
 
 
 
Figure 29. The captured image highlighted with blue to exclude the gaps in the 
tissue associated with processing 
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Figure 30. The blue pixels now show the areas of collagen to be calculated  
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4.3 Results 
 
4.3.1 Fibronectin immunohistochemistry 
 
The general stroma, basement membrane (BM), fibroblasts and endothelial cells of both 
the mucosal and MP layers were analysed.  Immunoreactivity was microscopically 
evaluated in two different areas of the sections and scored as either positive or negative.  
The results are summarised in Table 3 and provided in Appendix 2.   
Of 14 control non-irradiated post-mortem cases 3 (22.4%) showed mucosal stromal and 
4 (35%) showed mucosal fibroblast positivity for fibronectin.  In contrast MP general 
stroma, BM and fibroblasts were negative, as was the BM of the mucosa.  A similar 
finding was seen in the cystitis cases with the MP general stroma, BM and fibroblasts 
again being negative, where as the mucosal general stroma 5(83.3%), BM 1(16.6%) and 
fibroblasts 1(16.6%) were positive. 
One of the key findings was that in the irradiated and non irradiated tumour groups 
there was a diffuse increase in fibronectin positivity (Fig. 31) particularly in the MP 
general stroma, BM and fibroblasts, all three of which were negative in the post mortem 
and control groups. The increase in expression was more prominent in the irradiated 
group. This group showed the highest levels of fibronectin expression in all the four 
components analysed both in the mucosa and the MP (Table 4). 
The other notable feature was the consistently high level of fibronectin expression by 
endothelial cells in all the groups studied, both in the mucosa and MP. Again the highest 
levels of fibronectin expression (92.8% and 94.6% for mucosal and MP endothelial cells 
respectively), are in the irradiated group.  
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Figure 31. Positive staining for fibronectin in the superficial part of the bladder 
wall after radiotherapy. Note the smooth muscle bottom left which is negative. 
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The irradiated bladder tumour group was subdivided according to the timing of the 
cystectomy post irradiation.  Group A included 0.25 to 12months, B 12-36 months and 
C 36-98 months.  The fibronectin expression in the mucosal and MP layers of the 
bladder for each group are detailed in Tables 4 and 5.   Of note again is the consistent 
high expression of fibronectin by the endothelial cells in both sites which does not drop 
below 88.4% at any stage and is 100% in both sites in group A (0.25-12months).  In the 
mucosal and MP basement membrane the percentage of fibronectin expression appears 
to be negatively correlated with the time post irradiation.    
 
4.3.2 Collagen quantification 
 
Although there was a steady increase in the amount of mucosal and MP collagen 
between the three post irradiation time groups (Graph 1), this was not statistically 
significant.However, the degree of MP fibrosis in both the irradiated and non irradiated tumour 
groups was significantly higher (p<0.05) when compared with the post-mortem group, Graph 2.    
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Figure 32. a. Picrosirus red to highlight collagen. b. EVG is not as good in this 
situation 
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Total 
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G
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92 
56 
18 
6 
14 
N
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40(71.4%
) 
13(66.6%
) 
5(83.3%
) 
3(22.4%
) 
G
eneral 
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a 
 
15(26.7%
) 
3(16.6%
) 
1(16.6%
) 
0 
B
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ent 
m
em
brane 
 
20(35.7%
) 
3(16.6%
) 
1(16.6%
) 
4(35%
) 
Fibroblasts 
 
52(92.8%
) 
13(72%
) 
6(100%
) 
13(92.8%
) 
Endothelial 
cells 
 
33(58.9%
) 
5(22.2%
) 
0 0 
G
eneral 
strom
a 
 
10(17.8%
) 
1(5.5%
) 
0 0 
B
asem
ent 
m
em
brane 
 
15(26.7%
) 
2(11%
) 
0 0 
Fibroblasts 
 
53(94.6%
) 
14(77.7%
) 
4(66.6%
) 
11(78.5%
) 
Endothelial 
cells 
Table 3. Number and percentage of cases expressing fibronectin. 
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Mucosal/LP layer 
component 
Time Period 
A B C 
General stroma 15(78.9%) 15(57.6%) 10(90.9%) 
Basement membrane 6(31.5%) 7(26.9%) 2(18.2%) 
Fibroblasts  7(36.8%) 10(38.4%) 3(27.7%) 
Endothelial cells 19(100%) 23(88.4%) 10(90.9%) 
TOTAL (56) 19 26 11 
 
Table 4. Fibronectin expression in mucosal layer of irradiated bladder and its 
positivity at different time periods since radiotherapy.  
 
 
 
 
Muscularis Propria 
Component 
Time Period 
A B C 
General stroma 10(52.6%) 15(57.6%) 8(72.7%) 
Fibroblasts 5(26.3%) 7(26.9%) 3(27.7%) 
Endothelial cells 19(100%) 23(88.4%) 11(100%) 
TOTAL (56) 19 26 11 
 
Table 5. Fibronectin expression in the intermuscular layer of irradiated bladder 
and its positivity at different time periods since radiotherapy. 
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Graph 1: Area fraction of collagen in mucosa/LP and muscularis 
propria of irradiated bladder group and its relation to post-
irradiation time period
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 Graph 2: Comparison of the mean area fraction of collagen in the 
mucosal/LP and muscularis propria of irradiated, non irradiated and 
post-mortem cystectomy specimens.
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This was not the case for mucosal fibrosis, which showed no significant difference 
between the normal post-mortem group and the irradiated/nonirradiated tumour groups.    
When the mean area fraction of mucosal and MP fibrosis was grouped together and 
analysed the difference in fibrosis was again significant (p<0.05), when comparing the 
post mortem group with both the irradiated and non irradiated tumour groups.  Due to 
sample size (six), the intersitital cystitis group was excluded from this analysis.     
 
4.4 Discussion 
 
In this study we have analysed the expression of fibronectin by various components of 
the bladder wall at various times after irradiation. This ECM molecule, a component of 
the basement membrane, has in recent years been recognised to play an important role 
in cellular responses injury.   We have also quantified the amount and location of 
fibrosis in the post irradiated bladder. Fibrosis is characterised by the deposition of 
collagen, fibronectin and glycosaminoglycans by fibroblasts in response to various 
cytokines including platelet derived growth factor (PDGF), transforming growth factor 
Beta (TGF-B), fibroblast growth factors(FGF), interleukin 1(IL-1) and tumour necrosis 
factor (TNF).  Many of the above are produced both by tumours and chronic 
inflammatory states, whether infective, or induced by other insults such as radiation281-
283.  
Cell responses to radiation are modulated in part by cell-ECM interactions with the type 
of ECM component able to influence the percentage of cells that arrest in G1 phase273.  
In the skin, fibronectin has been shown to be upregulated in response to UV light284. 
Others have shown that lung cancer cell lines which are irradiated on fibronectin show 
significantly greater survival when compared with cells irradiated on polystyrene or 
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other substrates. The authors suggest this may be due to the increased time spent in G2 
arrest275. The same lung cancer cell lines grown on fibronectin have been shown to have 
a reduced response to single dose chemotherapy regimens274. Bcr-abl transfected cells 
pre-adhered to immobilized fibronectin have a significant survival advantage after 
gamma irradiation when compared to the same cells grown on laminin, polylysin or 
suspension276. Thus, in each case, fibronectin appears to confer specific survival 
advantages in multiple irradiated cell lines.  
It is not just a radiation insult that has been shown to cause fibronectin upregulation. 
The fibronectin gene may be a natural target for hepatitis surface antigen,via the NF 
kappa B pathway, leading to the accumulation of fibronectin in the liver in Hepatitis B 
infection285. Hepatic stellate cells are known to express many ECM proteins including 
collagen IV, entacin and fibronectin and have been implicated as one of the prime 
culprits in hepatic fibrosis and cirrhosis.  The finding that complement (C5a) 
specifically elevated fibronectin mRNA in these cells286, suggests that fibronectin may 
also be involved in mediating the damage and subsequent fibrosis due to inflammation. 
Based on the above findings one could propose that most tissues may upregulate 
fibronectin expression after irradiation or an infective insult.  To date there is very 
limited literature on this but fibronectin expression has been shown to be upregulated in 
the connective tissue stroma of the irradiated rat submandibular gland287,288. We have 
also demonstrated increased fibronectin expression in the stromal components of the 
bladder wall after radiation particularly in the MP layer. This is not suprising given the 
above previous findings.  However the non-irradiated tumour group also showed a 
diffuse increase in fibronectin expression by all the elements examined.  This may be 
due to factors released by the tumour, such as TGF-B. Paracrine modulation of ECM 
components by tumour cells has been demonstrated in the past289.  
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The relative restriction of fibronectin staining to the mucosa in the normal post-mortem 
and cystitis cases seen in this study, is interesting, and may reflect its continuous role in 
the deposition and remodelling of other matrix proteins290. 
Endothelial cells of all groups exhibited high levels of fibronectin immunoreactivity in 
both the mucosal and MP layers.  This corroborates a previous study which 
demonstrated the presence of FN immunoreactivity in the subendothelial area in 
capillaries, venules and arterioles of the normal human myocardium291. This high level 
of endothelial fibronectin immunoreactivity may reflect their key role in inflammation, 
and the sensitivity of the vascular system to radiation260. Vascular damage may be the 
most consistent pathogenic mechanism in delayed radiation injury and fibrosis.  The 
appearance of fibronectin immunoreactivity in the stroma, basement membrane and 
fibroblasts of the MP may be a step in the process of MP fibrosis. Such a step wise 
cascade post irradiation has been suggested in pulmonary fibrosis292. The mechanisms 
by which FN is up-regulated may, however, be quite different in the irradiated versus 
the non irradiated cystectomy groups as already alluded to. 
The finding of a significant quantified increase in MP fibrosis in the irradiated 
cystectomy specimens when compared with post mortem controls, although not 
previously published, is to be expected given that fibrosis is a known sequelae of 
radiation therapy that has been documented in many different tissues293. Few papers 
have addressed the issue of whether there is a temporal increase in the degree of 
fibrosis. Rubio et al. have looked at this issue in the irradiated distal ileum of the rat294. 
They showed a dose-time dependant increase in the amount of collagen in the all layers 
of the bowel wall, however we have not seen any such papers concerning the human 
bladder, where the clinical problem that fibrosis causes may result in a cystectomy.  
Although we also found a steady increase in the amount of LP and MP collagen 
between the three post irradiation time groups (Graph 1), this was not statistically 
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significant.  This interpretation may be limited by the sample size.  Furthermore, we 
cannot be sure that this steady increase in the degree of fibrosis after irradiation is due to 
the latter alone, as the non-irradiated group also showed a similar steady increase in MP 
fibrosis.  
We found preferential fibrosis in the MP and this significant increase in MP fibrosis was 
also found in the non-irradiated tumour group.  Of further note, was that with regards to 
mucosal fibrosis, there was no statistically significant difference between any of the 
study groups.  The increase in MP fibrosis may be linked to the up-regulation of 
fibronectin by MP constituents, especially fibroblasts that do not normally express the 
molecule.  The lack of a significant increase in mucosal fibrosis is interesting, and may 
potentially be due to local mucosal factors that prevent or inhibit the development of 
fibrosis to a greater extent than in the MP. Interesting in this regard is the suggestion of 
an inverse correlation between BM fibronectin expression and time since irradiation.  
Furthermore the mucosa and lamina propria are less robust and more vulnerable, when 
compared with the MP and do not cope as well in tissue handling and processing.  This 
can be a source of error in morphometry studies295.    
In summary there was an increase in MP fibronectin expression in irradiated and non-
irradiated cystectomy specimens when compared with post mortem and cystitis control 
bladders. Similarly there was a site specific significant increase in MP fibrosis in both 
the irradiated and non-irradiated cystectomy groups. Vascular endothelial cells 
consistently expressed the highest levels of fibronectin in both the irradiated groups and 
also in all of the control groups.  The observed upregulation of fibronectin by fibroblasts 
and other constituents of the MP may be a precursor to susequent fibrosis in this area.   
This may be due to the direct effects of radiotherapy, tumour related factors or most 
likely a combination of both. 
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Chapter 5. Platelet-derived growth factor  
5.1 Introduction 
Platelet-derived growth factor (PDGF) is one of many growth factors found in the 
human body. It is a highly conserved protein, being found throughout the animal 
kingdom.  It was named in 1982 although it was originally identified in 1974 as a 
constituent of whole blood serum that was absent in cell-free plasma296,297.  It was 
subsequently purified from human platelets 298,299and was found to act as a serum 
growth factor for fibroblasts, smooth muscle cells and glial cells300. Soon after its 
discovery it was realised that PDGF protein was composed of two polypeptide chains A 
and B. Mitogenic and active in physiological states  mainly during development, with 
activities in wound healing, angiogenesis, fibrosis, atheroma and carcinogenesis. In the 
first decade of the 21st century it became clear that PDGF was more complex that 
originally appreciated. Researchers became aware of two further chains, C and D. The 
function of these additional PDGF proteins largely remains a mystery in human 
physiology and disease. However it has become clear that PDGFs are closely related 
structurally and functionally to VEGFs. These potent neovascularising agents are 
conserved throughout the animal kingdom and have many similarities to PDGFs. All of 
these growth factors are dimers, formed of polypeptide chains with disulphide 
links/bonds. They are classified according to their receptor binding. Platelet-derived 
growth factor is a family of heterodimeric or homodimeric isoforms of A- and B-
polypeptide chains that are synthesized as precursor molecules undergoing proteolytic 
maturation. The synthesis of PDGF isoforms is carefully regulated, and their action on 
receptors is modulated by interaction with components in the matrix as well as with 
soluble binding proteins. 
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5.2 Structure and expression of PDGFs 
PDGF-A was first characterised by Betscholtz by cDNA cloning in 1986301. At first it 
was thought that most cells secreting PDGF, expressed PDGF-A and secreted PDGF-
AA homodimers296. Later, PDGF-BB homodimers were produced by SSV-transformed 
or PDGF-B-expressing cells and this led to the realisation that the PDGF family 
consisted of at least three proteins—PDGF-AA, PDGF-AB, and PDGF-BB—encoded 
by two genes, PDGF-A and PDGF-B 298. This view lasted for more than 15 years until 
combinations of genomic and biochemical efforts identified two additional PDGF genes 
and proteins; PDGF-C303,304 and PDGF-D305, although relatively little is known 
currently about these more recent additions to the family. All isoforms of PDGF are 
disulfide-linked dimers of two related polypeptide chains, designated A, B, C and D, 
which are assembled as heterodimers (PDGF-AB) or homodimers (PDGF-AA, PDGF-
BB, PDGF-CC and PDGF-DD) 306. 
The genes for the A- and B-chains of PDGF are found on chromosomes 7 and 
22, respectively301,307. Both genes are organized in a similar manner with seven exons. 
In each case exon 1 encodes the signal sequence, exons 2 and 3 encode precursor 
sequences that are removed during processing, exons 4 and 5 encode  most of the mature 
protein and exon 7 is mainly non-coding308. Exon 6 encodes a COOH-terminal sequence 
that may be removed during the maturation of the B-chain; the A-chain occurs as two 
different splice forms, with and without the exon 6-encoded sequence. The C and D 
chains are similar in that they share related CUB domains (Fig.33). 
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Figure 33. The PDGF and VEGF family of growth factors302 (with permission) 
 
 
5.3 Location of PDGFs 
Platelet-derived growth factors can be produced by many different cell types. There 
appears to be no regular expression of PDGFs but synthesis is often increased in 
response to external stimuli, such as exposure to low oxygen tension393, thrombin310,311, 
or stimulation by other growth factors and cytokines312. Expression of PDGF-A also 
increases in human uterine smooth muscle cells during the physiological hypertrophy of 
pregnancy313. Although the α-granules of platelets are a major storage site for PDGF, 
recent studies have shown that PDGF can be synthesized by a number of different cell 
types such as macrophages, epithelial and endothelial cells 314-317. Most cell types 
expressing PDGF are capable of making both A- and B-chains, but the expression of the 
two chains is independently regulated at the transcriptional as well as post-
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transcriptional levels308.  Generally, PDGF B is mainly found in endothelial cells, 
megakaryocytes and neurons. PDGF A and PDGF C are located in epithelial cells, 
muscle and muscle progenitor cells. At present it is unclear where PDGF D is 
predominantly found but it has been seen in fibroblasts and SMCs at certain locations 
(possibly suggesting autocrine functions via PDGFR-β). Therefore PDGFS are 
generally produced by predictable groups of cells and they act locally309. 
 
5.4 Production, secretion and binding of PDGF 
PDGF biosynthesis and processing is controlled at multiple levels and is different for 
the various PDGFs. PDGF-A and PDGF-B become disulfide-linked into dimers and are 
released as propeptides. PDGF-A and PDGF-B are similar in that they contain N-
terminal pro-domains that are removed within the cell by a number of convertases 
including furin318. This N-terminal processing is essential for PDGF-A to acquire 
receptor-binding ability and it is presumed that PDGF-B also requires N-terminal 
cleavage to become active. PDGF-C and PDGF-D have been less studied in this regard 
because of their novelty. However, it is known that PDGF-C and PDGF-D are 
processed differently. They are not altered intracellularly but are instead secreted as 
whole (but inactive) proteins319. Activation occurs outside of the cell and requires 
proteolytic dissociation of the CUB domain. Experimentally, plasmin and tissue 
plasminogen activator (tPA) have been shown to remove the CUB domain in PDGF-C, 
rendering it biologically active 320. The activation factors in vivo remain to be identified, 
but tPA is a likely contender for PDGF-C and plasmin may cleave and activate PDGF-
D. It remains to be established if some of the overlapping expression patterns for 
PDGF-A and PDGF-C result from common transcription regulatory mechanisms. Little 
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is currently known about the transcriptional regulation of PDGF-C and PDGF-D and 
the PDGFRs.  
 
5.5 Extracellular distribution of PDGFs 
PDGF, in common with many other growth factors and cytokines, shows an uneven 
distribution within connective tissue. The precise localisation and retention in the 
interstitium depends on coordinated binding to extracellular matrix components. The 
main trapping mechanism for PDGF-A and PDGF-B appears to be accomplished by the 
positively charged C-terminal motifs (so-called retention motifs) which are rich in basic 
amino acid residues. The presence of the retention motif is determined by alternative 
splicing in PDGF-A and by alternative C-terminal proteolytic processing in PDGF-B. 
Alternative splicing of the PDGF-A transcript is cell type-specific. PDGF-C and PDGF-
D lack basic retention motifs, but the CUB domains described earlier are thought to be 
important in protein–protein and protein–carbohydrate interactions in general. Therefore 
CUB may regulate the extracellular distribution of PDGF-C and PDGF-D.  
Much of the work on PDGF retention has come from studies of PDGF interaction with 
heparan sulfate proteoglycans (HSPGs) and phenotypic analysis of PDGF-B retention 
motif knockout mice. PDGFs bind to heparin and HSPGs in common with other growth 
factors and morphogens with critical functions during development such as hedgehog 
and Wnt signaling pathways321-323. Targeted deletion of the PDGF-B retention motif in 
mice or reduced heparan sulfate (HS) N-sulfation leads to pericyte detachment from the 
microvessel wall. This is probably caused by attenuated PDGF-BB binding to HS. This 
suggests that PDGF-BB secreted from endothelial cells interacts with HS at the 
endothelial surface or in the periendothelial matrix which would lead to local deposits 
of PDGF-BB. PDGF-BB, is thought to be critical for the correct investment of pericytes 
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in the vessel wall. HS on endothelial cells may function to enhance PDGF-BB-mediated 
PDGFR-β signalling in neighbouring pericytes.  
PDGF also binds to several non-HSPG extracellular proteins, but the physiological 
relevance of these interactions is unclear. These include α-2-macroglobulin324, which 
might act as a scavenger for PDGF-B through low-density lipoprotein (LDL) receptor-
related protein (LRP) receptors on macrophages and other cells325. PDGF-B also binds 
to SPARC and adiponectin, which may trap the growth factor to heparin sulphate 
proteoglycans and heparin. Thrombin might also draw PDGF-B to its locality. C-
terminal proteolytic processing of PDGF-B may take place intracellularly or 
extracellularly. The endogenous protease(s) responsible for C-terminal cleavage of 
PDGF-B has not been identified, but it may be thrombin 326. Cells transfected with 
PDGF-B expression vectors secrete soluble PDGF-BB into the conditioned medium. 
However, a major part of endogenously expressed PDGF-B becomes trapped on the cell 
surface or in the extracellular matrix, where it subsequently can be released by 
thrombin. C and D probably bind via the CUB domain and when this is missing the 
factors become soluble. 
 
5.6 PDGF receptors 
PDGFs exert their effects by interacting with two structurally related receptors on the 
target cell surface. These receptors are both proteins with tyrosine kinase activity, 
designated alpha and beta. The α- and β-receptors have similar overall structure with 
molecular sizes of ~170 and 180 kDa, respectively. The extracellular component of each 
receptor contains five immunoglobulin-like domains. The intracellular part of the 
receptor comprises a tyrosine kinase domain that contains a characteristic sequence 
which is different to other kinases327-329. The basic structure of PDGF receptors is 
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similar to those of other growth factor receptors such as colony stimulating factor-1 
(CSF-1) receptor330 and the stem cell factor (SCF) receptor331. The human alpha-
receptor gene is localized on chromosome 4q12, close to the genes for the SCF receptor 
and VEGF receptor-2332, and the beta-receptor gene is on chromosome 5 329 close to the 
CSF-1 receptor gene333. 
Because PDGF isoforms are dimeric molecules, they can bind two receptors 
simultaneously and thus dimerize receptors upon binding334-336. The alpha-receptor 
binds both the A-, B- and C-chains of PDGF with high affinity, whereas the beta-
receptor binds only the B- and D-chains with high affinity. Therefore, PDGF-AA 
induces alpha-receptor homodimers, PDGF-AB alpha-receptor homodimers or 
alpha/beta-receptor heterodimers, and PDGF-BB all three dimeric combinations of 
alpha- and beta-receptors337-339. Theoretically the possible PDGF–PDGFR interactions 
are multiple and complex and include the formation of receptor heterodimers. However, 
in vivo there is functional evidence for only a few interactions; i.e., those of PDGF-AA 
and PDGF-CC via PDGFR-α, and PDGF-BB via PDGFR-β. It is likely that PDGF-DD 
acts through PDGFR-β in vivo, but evidence for this is currently lacking. PDGF ligand 
dimerization of the receptors leads to subsequent autophosphorylation of the PDGF 
receptor tyrosine kinase (RTK). Activated RTK phosphorylates numerous molecules 
that initiate intracellular signalling cascades (discussed later).  
 
5.7 Location of PDGF receptors 
There are differences between α- and β-receptors in their binding specificity of PDGF 
isoforms and in the signals they transduce and so the response of a cell to PDGF 
stimulation will be determined by which of the two receptor types the cell expresses. 
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The classical target cells for PDGF, fibroblasts and smooth muscle cells, express both α- 
and β-receptors, but generally higher levels of β-receptors. Other cell types such as the 
O-2A glial precursor cells and human platelets express only α-receptors whereas other 
cell types express only β-receptors. PDGFR-α is expressed in mesenchymal cells with 
particularly strong expression of PDGFR-α in subtypes of mesenchymal progenitors in 
lung, skin, and intestine and in oligodendrocyte progenitors. PDGFR-β is expressed in 
mesenchyme, particularly in vascular SMCs (vSMCs) and pericytes. 
The distribution of platelet-derived growth factor receptors is not uniform over the 
surface of the cell membrane. They are found mostly in caveolae (distinct membrane 
invaginations) which help endocytosis340. Binding internalizes the ligand-receptor 
complex to produce endosomes341. A small proportion of the PDGF-receptor complex 
subsequently dissociates, and the receptor recycles to the cell membrane. PDGF 
receptors also undergo cytoplasmic degradation in proteasomes after ubiquitination342. 
Most of the ligand-receptor complex however is degraded upon fusion of the endosomes 
with lysosomes. The rate of deactivation of PDGF receptors is an important parameter 
in the regulation of the mitogenic response. The internalization of PDGF receptors is a 
controlled process that is dependent on the kinase activity of the receptor343 as well as 
on the interaction between the receptor and PI 3-kinase344 and other molecules345. 
 
5.8 Cellular Effects Mediated by PDGF Receptors  
Isoforms of PDGF exert their cellular effects by inducing tyrosine kinase receptors, 
resulting in cell growth, chemotaxis, actin reorganization and prevention of apoptosis. 
The level of receptors at the cell surface can be modulated by external stimuli. Most of 
our current knowledge concerns the functional roles of PDGF receptor homodimers. 
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Both α- and β-receptor homodimers transduce potent mitogenic signals and both 
receptors mediate an increase in intracellular Ca2+ concentration. PDGFR activation can 
inhibit gap junctional communication between cells346 and exert an antiapoptotic 
effect347. There is, however, a difference between the receptors regarding their effects on 
the actin filament system and activation of chemotaxis. The α-receptor activates 
chemotaxis whilst activation of the β-receptors inhibits chemotaxis of certain cell types 
including fibroblasts and smooth muscle cells, but stimulates chemotaxis of certain 
other cell types348.  
 
5.9 PDGFR-induced signalling pathways 
Of particular interest to cancer biologist was the discovery in 1983 that B chain of 
PDGF had close homology with v-sis SSV oncogene302. Subsequent investigations led 
to the discovery that c-sis was in fact PDGFB. Scientists found that PDGF could act in 
an autocrine way to transform SSV in virus and this introduced the important concept of 
a fundamental relationship between growth factors and neoplastic cell transformation. 
This exciting discovery provided the impetus for much of the subsequent research on 
which our current theories of carcinogenesis are based. Both PDGFR-α and PDGFR-β 
both tyrosine kinase type receptors which engage several well-characterized signalling 
pathways such as Ras-MAPK, PI3K, and PLC-γ; all of which are involved in multiple 
cellular and developmental responses. PDGFRs attach to Ras-MAPK mainly through 
the adaptor proteins Grb2 and Shc. Grb2 binds the activated PDGFR through its SH2 
domain and complexes Sos1 through its SH3 domains. Sos1 in turn activates Ras, 
leading to downstream activation of Raf-1 and the MAPK cascade. MAPK signaling 
activates gene transcription, leading to stimulation of cell growth, differentiation, and 
migration349,350.  
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PI3K is a family of enzymes phosphorylating phosphoinositides. Effectors of PI3K 
signalling include serine/threonine kinases such as Akt/PKB, some members of the PKC 
family, p70 S6 kinase and small GTPases of the Rho family. Activation of the PI3K 
pathway by PDGFRs promotes actin reorganization, directed cell movements, 
stimulation of cell growth and inhibition of apoptosis351. When PLC-γ binds PDGFRs it 
results activation through phosphorylation, leading to mobilization of intracellular 
calcium ions and the activation of PKC352. The effects of PDGFR-mediated PLC-γ 
activation include stimulation of cell growth and motility353.  
PDGFRs also engage several other signalling molecules, including enzymes, adaptors 
and transcription factors. For instance, activation of the Src TK promotes Myc 
transcription and mitogenic responses354. In addition, members of the Fer and Fes TK 
family bind to PDGFRs and PKC-δ is phosphorylated by PDGFR-β, leading to its 
activation and translocation to the cell membrane. This signal may be involved in cell 
differentiation. The adaptors Nck and Crk bind to PDGFRs through their SH2 domain 
and are involved in activation of JNK355. The adaptor Grb7 contains a SH2 domain and 
binds PDGFR-β356. STAT transcription factors may bind to PDGF receptors, leading to 
their phosphorylation and activation357.  
PDGF receptors interact also with integrins, which promote cell proliferation, migration 
and survival358. This interaction helps localizing PDGFRs and interacting molecules at 
focal adhesions, which are sites where several signalling pathways initiate and cross-
talk359. Recently, Na+/H+ exchanger regulatory factors (NHERFs) were shown to bind 
PDGFR-β and link it with focal adherence kinase and the cortical actin cytoskeleton360, 
as well as to N-cadherin361 and the phosphatase PTEN362.  
Overall, the best characterised mechanisms by which PDGF down-streaming signalling 
mediates cellular responses involve the activation of the ras/MAPK pathway, which can 
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functionally increase cellular proliferation, migration and differentiation363, and the 
PI3K/Akt pathway, which promotes cell survival364. Both pathways are of crucial 
importance for tumour resistance to radiotherapy and chemotherapy. Furthermore, 
platelet-derived growth factor (PDGF) exerts its potent mitogen and chemotactic effects 
in a variety of mesenchymal cells such as fibroblasts, vascular smooth muscle cells, 
glomerular mesangial cells and brain glial cells365-368 making PDGF a potential key 
molecule for tissue rebuilding in response to physiological and non-physiological 
conditions. 
 
5.10 Control of PDGFR signaling 
There is an effective negative feedback mechanism by which ligand occupancy 
promotes endocytotic receptor internalisation and lysosomal degradation, thereby 
limiting the duration of PDGFR signalling. Furthermore, stimulatory and inhibitory 
signals arise in parallel and the ultimate response depends on the balance between these 
signals. The SHP-2 tyrosine phosphatase binds PDGFR through its SH2 domain and 
dephosphorylates the receptor and its substrates369. Ras-GAP, which negatively 
regulates Ras, also binds PDGFR-β through its SH2 domain370. Recycling of PDGFR-β, 
but not PDGFR-α, was recently observed in cells deficient for the phosphatase TC-PTP, 
which is a negative regulator of PDGFR-β phosphorylation. However, lysosomal 
degradation of PDGFR-β depends on interactions with c-Cbl and receptor 
ubiquitination. The adaptor protein Alix, which interacts with the C-terminal domain of 
PDGFR-β, facilitates ubiquitination and degradation of c-Cbl, thereby inhibiting 
PDGFR-β down-regulation371.  
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5.11 Other cellular responses to PDGFR-mediated signaling 
Some of the cellular responses to PDGFs take place rapidly (within seconds to minutes) 
of PDGFR activation and are independent of gene expression and protein synthesis. The 
cellular response to PDGFR-α and PDGFR-β activation is similar but not identical. Both 
receptors stimulate rearrangement of actin filaments, but only PDGFR-β promotes 
formation of circular ruffles. PDGFR-β also mobilizes calcium ions more efficiently 
than PDGFR-α372. PDGFR-β inhibits gap junctional communication between cells 
through phosphorylation of the gap junction protein connexin 43373. It is unclear 
whether this ability is shared with PDGFR-α.  
In addition to the rapid post-transcriptional responses, PDGFRs (like other RTKs) 
induce fast transcriptional changes involving immediate early genes (IEGs)374. IEGs are 
direct targets of the transcription factors that get activated (by post-translational 
modification) through various signalling pathways. The IEG responses are probably 
necessary for many of the long-term effects of PDGFs but the extent to which the IEG 
responses contribute specificity to PDGFR signalling is currently unclear. Different 
RTKs induce virtually identical sets of IEGs but different signalling pathways activated 
by PDGFR-β induce overlapping sets of IEGs. It seems that quantitative rather than 
qualitative differences in the IEG responses mediate the specific responses to different 
RTKs and signalling pathways. In contrast, PDGFR-α shows strikingly different roles of 
the different downstream signalling pathways. For PDGFR-β, disruption of signalling 
through PI3K alone has no, or only minor, developmental consequences375. In contrast, 
PI3K is absolutely crucial for PDGFR-α function during development376.  
Different IEGs appear to cooperate in their regulation of downstream cellular and 
developmental events. The large overlap between the signalling pathways, IEGs and 
biological processes suggest that specificity is generated through a combination of 
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quantitative differences in magnitude and duration of the responses occurring at 
different levels in the signalling cascade. On the other hand, a major part of the 
specificity of the PDGFRs in developmental functions depends on cell type- and 
context-specific PDGFR expression. The point in time during development and location 
may be more important than the specificity of the receptor. It is interesting to note that 
knockout mice models show that PDGFR-β signalling can fully substitute for PDGFR-α 
signalling if it is expressed at the right place and time377. Conversely, PDGFR-α 
signalling can only partially compensate for the loss of PDGFR-β signalling. Overall it 
is felt that specificity of PDGFR signalling is achieved through a combination of cell 
type-specific expression and differential engagement of downstream signalling 
pathways.  
 
5.12 Physiological and pathological functions of PDGFs and PDGFRs 
5.12.1 General 
PDGF primarily acts in a paracrine manner on local cells although in tumours it may 
well also take on an autocrine function. PDGFs are generally produced by discrete 
populations of cells that act locally to drive different cellular responses. They do not 
appear to be important for routine homeostatic processes; there is limited evidence that 
they perform a role in normal adult human physiology. However, expression increases 
after inflammation and in culture. PDGF expression in cultured cells is found after 
exposure to a variety of stimuli including hypoxia, thrombin, cytokines and growth 
factors, including PDGF itself302. Several factors induce PDGFR expression, including 
TGF-β, oestrogen (probably linked to hypertrophic smooth muscle responses in the 
pregnant uterus), interleukin-1α (IL-1α), basic fibroblast growth factor-2 (FGF-2), 
tumour necrosis factor-α, and lipopolysaccharide.  
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On the other hand many investigators have described increased expression and/or 
activity of PDGF in basic pathological or disease processes, including fibrosis, wound 
healing, atherosclerosis, glomerulonephritis and fibromatosis. Moreover, aberrant 
production of PDGF and autocrine stimulation may be an important mechanism in the 
neoplastic conversion of PDGF receptor-positive cells302. This opens a door for 
pharmacological exploitation using anatagonists PDGFR targetting with inhibitors. 
Currently, pharmacological studies of PDGF and R inhibition are ongoing looking at 
gene inactivation, blocking antibodies and receptor blockers such as imatinib (Gleevec) 
in GISTs, and AML but the action of such compounds is currently non-specific. 
 
5.12.2 Development and embryogenesis  
PDGF is particularly important in cell migration, organogenesis and epithelial-
mesenchymal intreractions. The developmental roles of PDGFs and PDGFRs have been 
unravelled mainly through experiments with gene-targeted mice. A large number of 
knockout, knock-in, or transgenic mutants have been used to identify specific cell types 
that are primary targets of PDGF signalling during development. This has led to many 
important discoveries. The critical roles of microvascular pericytes378, lung alveolar 
smooth muscle cells379 and gastrointestinal villus cluster cells380 were all identified by 
analysis of PDGF-B and PDGF-A knockout mice. PDGF signalling is vital for directing 
various populations of cells in developmental processes such as the movement of 
oligodendrocyte precursors in the spinal cord, of neural crest mesenchymal cells toward 
the branchial pouches and cardiac outflow tract, and of pericytes along newly formed 
angiogenic sprouts. The exact mechanisms by which the cells manouevre, and how 
PDGF regulates this process, remains obscure, however.  
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PDGF-B expression by endothelial cells recruits local pericytes381. Pericytes expressing 
PDGFRs migrate along steep gradient of PDGF-B in the peri-endothelial compartment 
to endothelial cells and thus initiate intimate association with the abluminal surface of 
the endothelial cells381. Pericyte-deficiency promotes a range of microvascular changes, 
such as endothelial hyperplasia, vessel dilation, leakage and rupture, leading to capillary 
microaneurysms, and lethal microhemorrhage378. Despite structural and functional 
abnormalities in the microvasculature, mice embryos deficient of up to 90% pericytes 
are compatible with embryonic and postnatal survival, while loss of more than 95% of 
the pericytes is lethal378,382. This suggests that a rather low threshold density of pericytes 
is required for basal microvascular function. 
During post-implantation development, PDGF-A expression occurs in epithelia, nervous 
tissue, myotome, and vascular and visceral smooth muscle. PDGFR-α, in contrast, is 
expressed by most mesenchymal cell populations; often in a reciprocal pattern 
compared with PDGF-A383. Some epithelial PDGFR-α expression has been identified, 
such lens epithelium384, limb apical ectodermal ridge and the early epithelial somite385. 
PDGF-A appears to be the epithelial-derived factor promoting proliferation and 
movement of nearby PDGFR-α-positive mesenchymal cells. PDGF-A/PDGFR-α is a 
common signalling partnership in epithelial–mesenchymal interaction, acting in concert 
with other signalling molecules such as hedgehogs, FGFs, BMPs and Wnts.  
PDGFR-β appears to be the dominant PDGFR involved in vascular pathology, whereas 
the literature suggests a pivotal role for PDGFR-α signalling in various types of 
mesenchymal cell/fibroblast-driven pathologies. These differential pathological roles for 
the two PDGFRs resemble the developmental roles summarized above, in which 
PDGFR-β signalling has a key role in vascular mural cell formation, whereas PDGFR-α 
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has both general and specific roles in the development of various mesenchymal and 
fibroblastic cell compartments.  
 
5.12.3 PDGF and disease 
In general, two main types of cell respond in a pathological fashion to PDGFs, smooth 
muscle cells and fibroblasts, promoting vessel wall pathologies and fibrotic tissue 
scarring, respectively. In addition, PDGF appears to be involved in the development of 
several neoplastic lesions. 
5.12.3.1 Neoplasia 
Hanahan and Weinberg assign six capabilities to cancer cells; self-sufficiency in growth 
signals, insensitivity to anti-growth signals, escape from apoptosis, sustained 
angiogenesis, tissue invasion and metastasis, and limitless replicative potential386. 
Numerous studies have demonstrated that such self-sufficiency may be established in 
certain cell types through autocrine growth stimulatory loops involving PDGF-
B/PDGFR-β signalling302. However, autocrine PDGF stimulation in vitro does not seem 
to provide a cell with a fully malignant phenotype. PDGF-B-producing retroviruses 
require cooperation with other genetic changes caused by retroviral insertions in order 
to induce malignant behaviour387,388. Thus, autocrine PDGF signalling can contribute to 
tumorigenesis by driving proliferative expansion of clones of preneoplastic and/or 
genetically unstable cells, which become fully malignant through further genetic 
alteration. Not only can PDGF induce a cell-autonomous proliferative stimulus, but is 
can also play a role in invasion and metastasis of certain epithelial cancers. 
Furthermore, paracrine PDGF signalling is likely to influence recruitment of different 
types of tumour stromal cell, especially fibroblasts and pericytes, which can affect 
tumour growth, survival and metastasis. PDGF can stimulate EMT and may also 
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promote metastasis by secreting CCL5, which induces metastatic behaviour. Tumour 
cell-derived PDGF-B and PDGF-D may promote detachment of pericytes, which may 
facilitate metastasis. Tumour fibroblasts may further produce factors that directly act on 
the tumour cells to promote their proliferation and migration such as HGF, CXCL12, 
FGF2, and FGF7. Tumour fibroblasts may also secrete angiogenic factors that help in 
sustaining tumour angiogenesis. Tumour angiogenesis is crucial to the supply of oxygen 
and nutrients to an expanding tumour mass. Moreover, by regulating stroma cell 
function, PDGF may limit drug delivery to tumours through effects on interstitial tissue 
pressure. PDGF may therefore be implicated causally (and hence constitute a putative 
drug target) in at least three of the six Hanahan/Weinberg’s cancer cell traits—self-
sufficient growth, angiogenesis, and metastasis—and furthermore in resistance to 
cytotoxic therapy.   
Autocrine PDGF loops are thought to be important in different types of malignant brain 
tumour of glial origin (gliomas). Such loops involving PDGF-A or -B and their 
respective receptors have been observed in many malignant and low-grade 
astrocytomas, while the activation of PDGF autocrine loops was suggested to be an 
early event in the pathogenesis of malignant astrocytomas389. Virtually all tested human 
glioma cell lines and fresh tumour isolates express multiple PDGFs and PDGFRs390,391, 
especially PDGF-A, PDGF-C, and PDGFR-α, but also PDGF-B, PDGF-D, and 
PDGFR-β392. In various experimental systems, overexpression of PDGFs has been 
shown to cause the formation of glioma-like tumours388,393,394. Inhibition of 
PDGF/PDGFRs has been shown to slow down glioma cell growth in experimental 
models394,395 which has led to clinical trials of inhibitors of PDGFR signalling (such as 
imatinib) for high-grade glioma patients396. PDGFR antagonists also prevent glioma 
formation in a mouse xenograft model390,397,398. DNA synthesis in meningiomas cell 
lines can also be inhibited through an antagonist of PDGF397. 
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The mechanism by which PDGF expression is activated in gliomas is poorly 
understood. It is possible that TGFβ signalling, through Smad2/3/4, activates PDGF-B 
transcription and secretion, and that the effect of TGFβ on glioma cell proliferation 
depends on PDGF-B/PDGFR signalling399,400. The response to TGFβ appears to be 
correlated with the methylation status of the PDGF-B gene suggesting that the 
proliferative response to TGFβ in human gliomas, and perhaps also the poor prognosis 
associated with TGFβ pathway activation in this disease, is mediated by PDGF-B 
expression and function. Furthermore, glioma tumour stem cells appear to respond to 
PDGFs401. Adult neural stem cells in the peri-ventricular zone, which is capable of 
generating both oligodendrocytes and neurons, were shown to express PDGFR-α and 
respond to PDGF by proliferation, leading to the formation of glioma-like hyperplasias.  
There are several ways by which genetic alterations may lead to overexpression or 
altered function of the gene product in tumours. For example gene amplification, 
translocation and activating mutations have all been described in human tumours with 
high PDGF expression. There are several reports on PDGFR-A amplifications, 
especially in glioblastomas392,401,402. Overexpression of PDGFR-α appears to precede 
amplification of the gene. Up-regulation of PDGFR-α protein is detected in most 
gliomas with the more malignant tumours showing the higher expression. PDGFR-A 
amplifications have also been described in anaplastic oligodendrogliomas403, 
oesophageal squamous cell carcinoma404 and pulmonary artery intimal sarcomas405.  In 
each of these tumours, it is speculated that paracrine stimulation can drive proliferative 
expansion of genetically unstable cells leading to tumour formation rather that PDGF 
directly causing the tumour itself. 
Other non-neurological tumours have been also associated with PDGF and/or receptor 
abnormalities. An activating mutation of PDGF-alpha R has been described in some 
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GISTs, whilst alterations of the PDGFB chain are seen in dermatofibrosacroma 
protruberans (DFSP) and PDGF-beta R can be detected in AML, some 
hypereosinophilic syndromes (HES) and mastocytosis.  
Most GISTs carry activating mutations in the c-kit receptor tyrosine kinase and hence 
imatinib is currently used to treat these patients. In 35% of GISTs with wild-type c-kit, 
gain-of-function mutations in PDGFR-A have been detected406,407. It seems that c-kit 
and PDGFR-α mutations are mutually exclusive and 85%–90% of all GISTs carry one 
of the two mutations. However, the alternative defects lead to similar alterations of the 
downstream signaling cascades and cytogenetic changes. PDGFR-α mutations are found 
either in the juxtamembrane region or in any of the two TK domains and lead to 
constitutive activation of the receptor. Signalling through PI3K and STAT3 is thought 
to be of most importance for this activation408.  
More than 95% of all DFSPs have a unique translocation of the PDGF-B gene, which 
results in a fusion of collagen type 1 α1 chain (COL1A1) and PDGF-B genes. This leads 
to the PDGF-B exon 2 being under the control of the COL1A1 promoter409, resulting in 
over-expression of PDGF-B in skin fibroblasts (which normally strongly express 
COL1A1) This creates an autocrine stimulatory loop that drives cell proliferation and 
fibrosis. Furthermore, when transplanted onto mice, DFSP tumour growth is inhibited 
by imatinib410.  
Most translocations involving PDGFRs result in a constitutively active receptor. At 
least six different translocations of the PDGFR-B gene have been reported in myeloid 
disorders and leukaemias411. One of the most commonly found translocations involves 
fusion of the ETV6–PDGFR-B genes. The ETV6–PDGFR-B fusion results in a protein 
containing the transmembrane and catalytic intracellular part of the receptor, a protein 
that cannot bind to PDGF but is nevertheless constitutively active.  
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Fusion of the FIP1L1 and PDGFR-A genes is found in a subset of patients with 
hypereosinophilic syndrome (HES) 412,413. The FIP1L1–PDGFR-A fusion gene has also 
been identified in systemic mastocytosis414. The FIP1L1–PDGFR-A fusion protein is a 
constitutively active tyrosine kinase that can transform hemaetopoietic cells and lead to 
myeloproliferative disease.  
PDGF production in carcinomas is generally thought to act in a paracrine fashion to 
promote tumour stroma, but it is also possible that autocrine signalling plays a role in 
carcinoma development in conjunction with aberrant PDGFR expression415-417. 
Expression of PDGF has been found to correlate with advanced tumour stages and 
unfavourable prognosis in human breast carcinoma418. Furthermore, increased 
expression of genes of the PDGF pathway has been correlated with EMT419. PDGF-
neutralizing antibodies, dominant-negative PDGFR expression, or imatinib, have 
recently been shown to influence EMT and metastasis in mouse breast cancers420. Thus, 
PDGF expression in epithelial cancers may have a role in EMT and tumour 
dissemination.  
PDGF expression is commonly found in the neoplastic component of different human 
tumours. PDGFR expression is also regularly found in the stromal compartment 
(endothelial cells, pericytes or fibroblasts) of several types of carcinoma such as skin, 
breast, colorectal, lung, pancreas, prostate, and ovarian cancers298,421. Through its effects 
on tumour stroma, PDGF signalling may directly or indirectly promote tumor growth, 
blood perfusion, metastatic dissemination and drug resistance. PDGFR-β expression in 
solid tumours occurs mainly in vascular smooth muscle cells. PDGF-BB or PDGF-DD 
expression in experimental fibrosarcoma or melanoma has been shown to enhance 
pericyte recruitment to tumour vessels, correlating with tumour vessel stabilization, 
tumour cell survival and tumour growth381. Pericyte recruitment in tumour angiogenesis 
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is as important as during development. Pharmacological inhibition of PDGFR-β 
signalling in tumour pericytes of mouse models was synergistic with inhibition of 
VEGFR signalling in endothelial cells leading to suppression of tumour growth422.  
It appears that the quantity of recruited pericytes affects tumour vessel function and 
tumour growth in most cancers, but the quality of the pericyte coating influences 
haematogeneous tumour dissemination. Low pericyte coverage is commonly observed 
in tumour vasculature423-425 and low expression of smooth muscle markers correlates 
with metastatic propensity in human solid tumours426. Based on these findings, it would 
appear dangerous to inhibit pericyte behaviour as part of an anti-tumour angiogenesis 
strategy, as it might simultaneously impair tumour vessel function and increase 
metastasis427 but further experiments are required to establish possible benefits and 
drawbacks of therapy aimed at inhibiting tumour pericyte recruitment.  
Tumour fibroblasts are generally considered a passive component of tumours. However, 
it is becoming clear that these cells may affect the malignant behaviour of the neoplastic 
cells and contribute to tumour progression and resistance to therapy. PDGF-B-driven 
recruitment of fibroblasts increases the progression of immortal human keratinocytes 
from a non-tumorigenic to a tumorigenic phenotype428. It is likely that hepatocyte 
growth factor is the likely mediator of this effect429. In addition, tumour cell-derived 
PDGF-AA promotes recruitment of PDGFR-α-positive fibroblasts, which in turn 
produce VEGF-A which can rescue tumour angiogenesis430. The production of 
angiogenic growth factors such as PDGFB by tumour fibroblasts may lead to prominent 
recruitment of both fibroblastic and vascular stroma components431. In models of human 
lung cancer, PDGF-A and PDGF-C have been shown to recruit PDGFR-α-positive 
tumour fibroblasts and thereby promote tumour growth432. Furthermore, PDGF-driven 
fibroblast recruitment drives tumour cell proliferation in a model of mouse cervical 
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cancer, by the secretion of FGF2 and FGF7 by recruited fibroblasts433. In this model, 
PDGFR inhibition by imatinib or PDGFR antibodies, or inhibition of the stroma-derived 
FGFs through ligand trapping, were both effective in reducing tumour growth. Other 
studies have demonstrated the importance of fibroblast secretion of SDF-1/CXCL12 in 
supporting tumour growth through binding of CXCR4 on tumour cells434. Cancer 
fibroblast-derived CCL5/RANTES may enhance the metastatic potential of tumour 
cells435. It could be that SDF-1- and CCL5-positive stromal fibroblasts are recruited into 
the tumours by tumour cell-derived PDGFs.  
Solid tumours commonly display high interstitial fluid pressure (IFP), which reduces 
fluid convection rate across the capillary wall. Increased IFP has been suggested to 
interfere with drug uptake in malignancies. It has been suggested that PDGFR-β 
signalling regulates IFP in normal tissues375 and PDGFR inhibition by imatinib has been 
shown to enhance the uptake and/or anti-tumour effects of cytotoxic drugs436-440.  
Overexpression of PDGF has been observed in fibromatoses (desmoid tumours), while 
inhibition of PDGF signalling by imatinib is reported to induce an overall 1 year tumour 
control rate of 36.8% in a phase II clinical study441 Thus, inhibition of PDGF may be an 
attractive therapy option, alone or combined with surgery or/and radiotherapy in 
refractory cases. Another example for an important role of PDGF in oncogenesis is 
overexpression of PDGF and c-kit observed in Leydig cell tumours. Treatment with 
imatinib can largely inhibit Leydig cell tumour growth in an allograft mouse model by 
inhibition of PDGF and c-kit signalling with no drug-resistance development during 
imatinib treatment442. The clinical success of imatinib/gleevec, a triple tyrosine kinase 
inhibitor of c-kit, PDGF and c-Abl signalling, in chronic myeloid leukaemia443 and 
gastrointestinal stromal tumours444 has accelerated the development of molecular 
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targeted cancer therapy. It is highly likely that many more antitumoral substances of this 
class will be developed and discovered in the near future. 
Angiogenesis is an important event in tumour growth as tumours require a sufficient 
supply of nutrients and oxygen for sustainance and growth445. Hypoxic tumour cells 
secrete cytokines, including VEGF, PDGF, basic fibroblast growth factor (bFGF), 
insulin growth factor (IGF), to stimulate neovascular formation445. However, the 
neovasculature in tumours is very different from normal physiological vessels. 
Disorganised growth leads to vessel malformations including dilation, tortuosity, 
leakage, rupture and the formation of microaneurysms378. Since small numbers of 
pericytes in tumour vessels may be critical for vessel integrity and function378, targeting 
pericytes in tumours may be an attractive and efficacious way for anti-angiogenic 
therapy. Inhibition of PDGF signalling (and also VEGF signalling) induces tumour 
vessel regression by direct anti-angiogenic effect to endothelial cells and pericytes and 
by inhibiting pericyte mediated endothelial cell survival mechanisms446. Therefore, on 
the one hand PDGF increases survival and proliferation of endothelial cells and on the 
other, PDGF regulates vessel growth via pericyte recruitment and association to newly 
formed vessels. 
PDGF’s crucial role in tumour propagation appears to relate to its inherent angiogenic 
activity447. During angiogenesis, PDGF has been shown to be essential for the stability 
of normal blood vessel formation by recruiting pericytes and smooth muscle cells to the 
developing vessels378. PDGF-B expression by endothelial cells recruits pericytes 
through a short-range paracrine mode381. Pericytes expressing PDGFRs migrate along a 
steep gradient of PDGF-B in the peri-endothelial compartment to endothelial cells and 
thus initiate intimate association with the abluminal surface of the endothelial cells381. 
Pericyte-deficiency promotes a range of microvascular changes, such as endothelial 
  179 
hyperplasia, vessel dilation, leakage and rupture, leading to capillary microaneurysms 
and microhemorrhage378. In animal models, loss of more than 95% of the pericytes is 
lethal while mice embryos deficient in up to 90% pericytes are compatible with 
embryonic and postnatal survival381,382. This is seen in knockout mice models such as 
PDGF-B -/- or PDGFR-β -/-. 
Angiogenesis is critical for tumour survival and growth, since tumours located more 
than 100–200 μm from a blood vessel need neovascular formation to ensure a sufficient 
supply of nutrients and oxygen445. Tumour cells in hypoxia secrete cytokines, including 
VEGF, PDGF, basic fibroblast growth factor (bFGF), insulin growth factor (IGF), to 
stimulate neovascular formation445. However, neovasculature in tumours differs from 
normal physiologic vessels. The rapid and disorganised growth leads to vessel 
malformation including vessel dilation, tortuosity, leakage, rupture and formation of 
microaneurysms identical to thise describd above in pericyte deficient mice378. 
Interestingly, these hallmarks of microvascular malformation in tumors were found to 
be identical with the alterations found in pointing to a pericyte-deficiency in the 
disordered neovascular formation in tumours378. Since small numbers of pericytes in 
tumour vessels may be critical for vessel integrity and function378, targeting pericytes in 
tumours may be an attractive and efficacious way for anti-angiogenic therapy. 
Recent data from experiments in vivo imply that targeting pericytes actually provides 
additional benefits448. Until now, endothelial cells were considered to be the most 
important target for anti-angiogenic therapies449. Inhibiting VEGF in endothelial cells 
reduces endothelial cell survival, proliferation, tube formation and invasion in vitro449. 
However, it has recently been shown that endothelial cells are resistant to the inhibitory 
effect of SU5416 by blocking VEGFR in vivo through pericyte mediated escape 
strategies via the Ang-1/Tie2 pathway 446. Combined inhibition of VEGF and PDGF 
  180 
signaling enforces tumour vessel regression by a direct anti-angiogenic effect on 
endothelial cells and pericytes and by inhibiting pericyte mediated endothelial cell 
survival mechanisms446. Others have also shown that tumour vessels lacking pericytes 
are more dependent on VEGF for their survival than are vessels invested by pericytes448. 
In fact, sorafenib and sunitinib/SU11248 act as anti-angiogenic agents by inhibiting 
VEGFR-2/-3, PDGFR-β, Flt-3, and c-KIT. Both drugs exert clear clinical effects in 
patients with renal cell carcinoma which are most likely mediated via anti-angiogenic 
effects450,451.  
In summary, PDGF has at least two distinct functions in pro-angiogenic signalling. 
Firstly, PDGF increases survival and proliferation of endothelial cells secondly, it 
regulates vessel growth via pericyte recruitment and organisation in newly formed 
vessels. 
As has been outlined previously ionising radiation not only has a direct effect on tumour 
cells but radiation induced damage of endothelial cells plays a major role in tissue 
damage and antitumoral efficacy448. Thus, ionising radiation can be considered as a 
potent anti-angiogenic agent448. On the other hand, tumour cells are capable of 
producing pro-angiogenic cytokines including VEGF, PDGF and FGF in response to 
ionising radiation449-452. These pro-angiogenic cytokines could protect endothelial cells 
and vessels from radiation-induced damage and consequently ensure supply of oxygen 
and nutrients for tumour cells447,448,453. Secretion of PDGF can also be stimulated by 
irradiation of stromal cells, such as endothelial and fibroblast cells454. Elevated 
expression of these growth factors correlates with higher vessel density and negative 
clinically prognosis in various tumours455 and often this type of tumour possesses 
relative resistance to radiation therapy456. Inhibition of pro-angiogenic signaling by 
tyrosine kinase inhibitors can therefore augment the radiation induced damage to 
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endothelial cells and abolishes the tumor cells mediated protection. Moreover, these 
inhibitors can prevent the re-growth of endothelial cells and neovascular formation454. 
Consequently, anti-angiogenic substances targeting VEGF and PDGF may increase 
anti-angiogenic activity of ionising radiation and possess a potent antitumoral synergy 
with radiation. 
This dual role for PDGF signaling in oncogenesis and angiogenesis does seem to be 
genuine and it has been demonstrated in gliomas. PDGFR-α has been detected in 
gliomas using in situ hybridization and immunohistochemistry to indicate the presence 
of autocrine and paracrine loops in glioma cells and in endothelial cells within the 
tumour mass. Therefore, treatment with imatinib/gleevec may disrupt the 
PDGF/PDGFR autocrine loop by specifically inhibiting phosphorylation of PDGFR and 
thereby exerting a synergistic antitumoral effect with ionising radiation (i.e it acts as a 
radiosensitiser457) and it may also inhibit hypoxia-induced angiogenesis and reinforce 
the anti-angiogenic effect of radiation458. 
 
5.12.3.2 Vascular disorders  
5.12.3.2.1 Atherosclerosis  
PDGF expression has been reported in virtually every cell type of the atherosclerotic 
arterial wall, as well as in the infiltrating inflammatory cells459. All PDGFs (A–D) and, 
in particular A and B have been found in atherosclerotic lesions at increased levels 
compared with the normal vessel wall459. PDGFR-α and PDGFR-β are also expressed at 
increased levels in smooth muscle cells of the media of arteries diseased by atheroma. 
The role of PDGF and PDGFR is not completely clear. Several conditions associated 
with cardiovascular disease affect PDGF or PDGFR gene expression, such as increased 
blood pressure and α-adrenergic stimulation of the vessel wall (which enhances vascular 
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PDGF-A expression460,461),  reduced endothelial shear stress (which induces both 
PDGF-A and PDGF-B462) and hypercholesterolaemia (which dramatically increases 
PDGF-A and PDGF-B expression in circulating mononuclear cells462).  
In the response-to-injury hypothesis of atherosclerosis, PDGF released from aggregating 
platelets at sites of endothelial injury was thought to be important in the migration of 
smooth muscle cells from the media into the intima, as well as in the subsequent 
proliferation of the smooth muscle cells at this site463,464. The current view of 
atherogenesis is more focussed on local chronic inflammation. Lipoprotein retention 
and the infiltration and activation of different types of immune cells are believed to play 
key roles465. PDGF may still be important as one of many factors secreted in the vessel 
wall by activated immune cells. In fact, in different animal models of acute arterial 
injury by balloon catheterization, neointimal smooth muscle cell accumulation was 
reduced by the administration of various PDGF pathway inhibitors, including 
neutralizing PDGF (AB) antibodies466, PDGFR kinase inhibitors467,468 and PDGFR-
neutralizing antibodies469. Restenosis following angioplasty of atherosclerotic vessels in 
animal models and chronic cardiac transplant rejection-induced atherosclerosis in rats 
can also be inhibited by PDGFR- inhibitors. Atherosclerotic lesions can be inhibited in 
ApoE-deficient mice by neutralizing PDGFR-β antibodies470 and a PDGFR inhibitor471. 
On the other hand, infusion of PDGF-BB, PDGF-C or PDGF-D, or local transfection of 
a PDGF-B expression vector can produce increased smooth muscle cell proliferation 
and intimal thickening in models of arterial injury472,473. There is currently no evidence 
for a role for PDGFR-α in neointimal proliferative responses to acute or chronic arterial 
injury.  
There is support for a functional role for PDGF-B and PDGFR-β in 
atherogenesis/restenosis from genetic models of PDGF-B or PDGFR-β deficiency. 
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Carotid ligation experiments in pdgfrb+/+ and pdgfrb−/− chimeras demonstrated a low 
proportion of pdgfrb−/− cells in the neointima but an increased contribution to the media. 
This suggests impaired migration of medial smooth muscle cells to the intima in the 
absence of functional PDGFR-β474. Furthermore, bone marrow transplantation of 
PDGF-B-deficient marrow into lethally irradiated, ApoE-deficient recipients and the 
subsequent lack of PDGF-B production by infiltrating inflammatory cells led to a small 
and transient inhibition of neointimal fibrous cap formation471. The reason for the 
relatively modest effect may be that PDGF-B has the opposing effects (on 
atherosclerosis) by being both anti-inflammatory and stimulatory to smooth muscle cell 
proliferation in the vessel wall475.  
Additional support for PDGF-B and PDGFR-β’s central role in atherogenesis comes 
from studies of LRP1476-479. LRP1 is a multifunctional transmembrane receptor, which 
is expressed by many cell types and binds a biologically diverse array of ligands. LRP1 
is tyrosine phosphorylated in response to PDGF-BB. It seems that LRP1 normally limits 
PDGFR-β expression and function in medial smooth muscle cells by inhibition of 
thrombospondin-mediated TGFβ activation and signalling through Smad2/3, leading to 
decreased PDGFR-β expression480 and LRP1-dependent endocytosis and c-Cbl-
mediated ubiquitinylation of PDGFR-β481.  
 
5.12.3.2.2 Pulmonary hypertension 
Primary pulmonary hypertension (PH) is a severe condition that can lead to right 
ventricular failure and death. The etiology and pathogenesis of PH is not well 
understood although pulmonary artery smooth muscle cell hyperplasia is a hallmark of 
the disease and increased expression of PDGFs and PDGFRs has been described in 
various experimental animal models of PH482,483 and in humans484. The basis for 
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increased PDGFR signalling in PH is uncertain but it is possible that there are links 
through ApoE and adiponectin. The combined action of ApoE deficiency and insulin 
resistance can promote development of PH in mice. In this model, ApoE and 
adiponectin suppressed proliferation of and inhibited PDGF signalling in pulmonary 
artery smooth muscle cells485. ApoE promotes down-regulation of PDGFR-β479, 
possibly by binding to LRP1 (see above). Adiponectin appears to bind PDGF-B and 
scavenge it486,487.  The cellular origin of the proliferative lesion in PH remains unclear. 
Increased expression of PDGFR-β in PH has been observed in perivascular fibroblast-
like cells, suggesting that these cells may differentiate into smooth muscle cells in 
conjunction with pulmonary hypertension488.  
Imatinib has recently been shown to reverse experimental hypertension in two animal 
models of PH484 and early results of imatinib in a human case of PH are promising489. 
Imatinib reversed pulmonary arterial smooth muscle cell proliferation and neointimal 
formation and these effects may reflect inhibition of PDGFR signalling. On the other 
hand, imatinib is not a completely specific inhibitor of PDGFRs. However, other targets 
of the drug such as Abl, Kit, and Flt3 are not currently implicated in medial smooth 
muscle cell growth.  
 
5.12.3.2.3 Retinal vascular disease 
PDGF-B has been implicated in ischaemic retinopathies such as proliferative diabetic 
retinopathy, proliferative vitreoretinopathy and choroidal neovascularization. 
Intraocular injection of PDGF-B-inhibiting aptamers can protect against retinal 
detachment in a rabbit model of proliferative retinopathy490. Inhibition of PDGFR 
signalling either using antibodies or imatinib has been shown to enhance the therapeutic 
effect of anti-VEGF-A treatment in multiple mouse models of ocular 
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neovascularization491. Focal neovascular retinal disease resembling proliferative 
diabetic retinopathy has been reported in two different mouse mutants with PDGF-B 
deficiency with an accompanying loss of retinal pericytes492,493. In diabetic mice, loss of 
one copy of the pdgfb gene also enhanced retinal pericyte loss and endothelial death494. 
Overall, it appears that PDGF-B may play a role in the pathogenesis of 
vitreoretinopathy, while pericyte loss (caused by PDGF-B deficiency) may lead to the 
development of a diabetic retinopathy-like condition. Pericyte loss is a hallmark of 
human diabetic retinopathy495 and may be causally involved in its pathogenesis, but it is 
not known if diabetes-induced pericyte loss reflects PDGF signalling in the retina. 
 
5.12.3.3 Diseases associated with fibrosis 
PDGF signalling has been implicated in several fibrotic conditions and is assumed to 
play a role in driving proliferation of cells with a myofibroblast phenotype. Tissue 
fibrosis involves excessive deposition of extracellular matrix material, which might be 
partly due to increased PDGF activity, but is probably more likely to be associated with 
up-regulated TGFβ. Excessive stromal cell proliferation and matrix deposition leads to 
tissue scarring and progressive loss of organ function. An emerging concept common to 
most fibrotic diseases is that inflammatory cells such as activated macrophages release 
PDGFs. The same cells also produce inflammatory cytokines that promote up-
regulation of PDGFRs on mesenchymal cells496. As a result, PDGF-mediated 
proliferation of mesenchymal cells, recruitment of fibroblasts and related cells and 
increased collagen production could all contribute to subsequent fibrosis. A causative 
role in several animal models of lung and cardiac fibrosis and glomerulosclerosis has 
been demonstrated by specific loss- and gain-of-function approaches. Also, very recent 
studies have raised the possibility that PDGFR-activating autoantibodies may 
participate in autoimmune fibroses.  
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5.12.3.3.1 Pulmonary fibrosis (PF) 
PF often results from different types of environmental exposures leading to acute toxic 
or chronic inflammatory responses in the lung. Chronic allergic reactions, transplant 
rejection and auto-immune disorders may also lead to PF, although quite frequently PF 
the cause of the fibrosis is unknown (idiopathic PF). PF involves the proliferation of 
myofibroblasts in alveolar walls, pulmonary blood vessels and small airways. Most of 
the causes of PF have been associated with increased PDGF levels in the lung tissue or 
bronchoalveolar lavage fluid either in humans or animal models of lung injury and 
fibrosis496. Studies in animal models have also shown that pulmonary fibroblasts 
respond to PDGFs by increased proliferation and cell migration. Alveolar macrophages 
appear to be the principal source of PDGF (mainly B) in PF496-499. PDGF-A and PDGF-
C expression has also been detected in injured or fibrotic lungs500. Up-regulated PDGF 
ligand expression is thought to occur via inflammatory cytokines such as IFN-γ, IL-1β 
and IL-1320. Both PDGFR-α- and PDGFR-β-mediated signals appear to play a role in 
PF. PDGFR-α expression is markedly up-regulated in the lung mesenchyme in response 
to inflammatory mediators such as IL-1β and TGF-β. A similar PDGFR-α response has 
also been observed in lungs exposed to a number of environmental factors, including 
asbestos and air pollution particulates501. PDGFR-β expression in the lung appears 
constitutive and unaffected by inflammatory stimuli, but it may mediate fibro-
proliferative responses alone or in heterodimer configuration with PDGFR-α. With 
these findings in mind, attenuation of PDGF-induced signals could potentially be a 
realistic pharmacological target for the prevention and/or treatment of PF. In animal 
models, three distinct TK inhibitors (SU9518, SU11657, and imatinib), which all 
potently inhibit PDGFRs, have all been shown to reduce lung fibrosis and increase life 
span in a model of radiation-induced lung injury502. In this model, several different 
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PDGFs were up-regulated. In another study, mesenchymal cell proliferation and 
collagen accumulation were reduced by the PDGFR TK inhibitor AG1296 in a model of 
metal-induced lung fibrosis503.  
 
5.12.3.3.2 Liver fibrosis 
Liver fibrosis (and cirrhosis) can be caused by a variety of injuries including drugs, 
alcohol, infections, metabolic changes and again idiopathic factors. The key fibrogenic 
cells in the liver are the hepatic stellate cells (of Ito), which are in effect the sinusoidal 
vessel pericytes. Dormant stellate cells do not express PDGFR-β, and, unlike other 
pericytes, they do not depend on PDGF-B or PDGFR-β for their development504. 
PDGFR-β expression is up-regulated in activated stellate cells both in vitro and in vivo 
in animals and humans496. This ability to switch on PDGFR-β renders stellate cells 
highly responsive to PDGF-B and PDGF-D. It appears that TGFβ is a major inducer of 
PDGFR-β in stellate cells and several different cell types produce TGFβ in the reactive 
liver, including stellate cells themselves. Resident hepatic macrophages (Kupffer cells) 
are a major source of PDGF-B, and when activated they can produce large amounts of 
PDGF-B, but infiltrating inflammatory cells can also contribute505. Increased PDGF-D 
expression has been detected in the perisinusoidal and periportal areas in experimental 
liver fibrosis in rats, but the source of the PDGF-D has not yet been established506.  
 
5.12.3.3.3 Dermal fibrosis 
Scleroderma (also known as systemic sclerosis) is an autoimmune disorder 
characterized primarily by progressive dermal and vascular fibrosis. Other organs are 
affected too, including lung, heart, esophagus, intestine, and kidney. Increased 
expression of both PDGFs and PDGFRs has been demonstrated in scleroderma skin496. 
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A role for PDGF signaling in bleomycin-induced experimental scleroderma in mice was 
also suggested by the therapeutic effect of imatinib in this model507.  
As for other fibroses, PDGF-B expression seems to occur in activated macrophages and 
infiltrating inflammatory cells508. In addition, scleroderma myofibroblasts appear to be 
constitutively phenotypically changed in comparison with normal skin fibroblasts, 
perhaps indicating that they have a distinct origin. Possibly, they originate from 
pericytes since the increased PDGFR-β expression was mainly observed around blood 
vessels in the scleroderma skin509. A pericyte origin has also been suggested for 
myofibroblasts in scarring tissue and tumours510,511. One distinct feature of scleroderma 
myofibroblasts is that they constitutively express PDGF-A in an autocrine loop driven 
by Il-1α512. This appears to contrast with normal fibroblasts in which transient PDGF-A 
expression occurs after exposure to mitogens513. Another feature that distinguishes 
scleroderma fibroblasts from their normal counterparts is that TGFβ increases the 
expression of PDGFR-α and enhances the mitogenic effect of PDGF-A in the former 
but seems to have opposite effects on the latter514. Down-regulation of Smad7 and up-
regulation of Smad3 in scleroderma fibroblasts may account for this difference. Also 
thrombin and Il-1α have been implicated in the enhanced responsiveness to PDGF 
stimulation in scleroderma fibroblasts515.  
It was recently reported that autoantibodies directed toward the PDGF receptors are 
present in the serum from patients with scleroderma515. Autoantibodies are commonly 
found in autoimmune disorders and sometimes play direct pathogenic roles. A well-
known example is Grave’s disease, where agonistic autoantibodies for the thyroid-
stimulating hormone receptor activate the thyroid gland, leading to hyperthyroidism. 
PDGFR autoantibodies were detected in serum from 46 out of 46 scleroderma patients 
but in no controls. The antibodies activated both PDGFR-α and PDGFR-β 
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phosphorylation and downstream signaling through the Ras-MAPK pathway. Moreover, 
the antibodies were shown to convert normal human fibroblasts into collagen type-1-
expressing myofibroblasts in vitro. This is an interesting finding with potential openings 
for new diagnostics. If these antibodies play a direct role in scleroderma pathogenesis, 
their elimination may also be considered as a putative therapy. Preliminary data suggest 
that PDGF autoantibodies are present also in patients with chronic graft-versus-host 
disease516. The possibility of PDGFR activation through autoantibodies is a novel and 
provocative concept in autoimmune fibrotic diseases, which will most certainly be 
extensively explored over coming years.  
Furthermore, PDGF has a crucial role in cutaneous wound healing. In fact, recombinant 
human PDGF-BB (becaplermin) has been trialled as a topical treatment for chronic 
neuropathic lower-extremity diabetic ulcers517. In addition, it has been used to prevent 
and treat pressure sores and ulcers and also to speed up healing after various surgical 
procedures. The tissue repair mechanisms induced by PDGF-BB involve the processes 
outlined previously, particularly fibroblast proliferation, collagen production and new 
vessel formation. Successful treatment may involve direct effects on PDGFR-β-
expressing mesenchymal cells and also up-regulation of PDGF-A518. Clinical efficacy 
has been demonstrated in several phase III studies519 and the combined results suggest 
that topical application of PDGF-BB is safe and well tolerated520,521. A recent study 
involving more than 900 patients confirmed that topical treatment with PDGF improved 
healing of chronic full-thickness diabetic foot ulcers522. Local delivery of PDGF-BB has 
also been tested in patients with severe periodontal disease and found to increase 
biomarkers for bone metabolism and turnover523 and provide improved periodontal 
regeneration524.  
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5.12.3.3.4 Renal fibrosis 
Renal fibrosis is universally present in association with chronic renal failure caused by 
diabetes, hypertension, renotoxic drugs, autoimmune disorders, immune-complex 
diseases and idiopathic conditions. The kidney has many components and the fibrosis 
can involve one or more of these structures. Glomerular fibrosis is generally associated 
with mesangial cell reaction. In tubulo-interstitial fibrosis a mixture of mesenchymal 
cells (some of which are currently unidentified) proliferate and deposit the extracellular 
matrix material. It has already been outlined that mesangial cell development depends 
on a PDGF-B–PDGFR-β paracrine loop. On the other hand, tubulointerstitial 
mesenchyme development depends on combined PDGF-A and PDGF-C signalling via 
PDGFR-α. Many studies have shown that identical signalling pathways are involved in 
the development of  renal fibrosis. Glomerular disease is frequently accompanied by up-
regulated expression of PDGFR-β525. In experimental animal models of 
mesangioproliferative disease, neutralizing PDGF antibodies, PDGF-B-binding 
aptamers, or imatinib can all prevent mesangial cell proliferation and matrix 
accumulation526-528. Furthermore, systemic administration of PDGF-BB promotes 
resting mesangial cell proliferation, suggesting that these cells are able to respond to 
PDGF-B independent of prior inflammatory activation529 and increased circulating 
plasma PDGF-B levels have also been correlated with increased numbers of mesangial 
cells in mice530. All PDGFs (A–D) have been shown to be up-regulated in situations 
associated with renal fibrosis. Evidence for a role for PDGF-A and PDGF-C remains 
somewhat circumstantial, but PDGF-D has been shown to play a role in experimental 
mesangial proliferative glomerulonephritis in rats by use of a PDGF-D-specific 
neutralizing antibody531. The source(s) of PDGF-B during mesangial proliferative 
pathology is not entirely clear. Endothelial cells may contribute, as they do during 
development, but it is likely that PDGF-B is also provided by invading mononuclear 
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cells. PDGF-D appears to be strongly up-regulated in the mesangial cells themselves 
during their pathological expansion532 and might act in an autocrine loop.  
 
5.12.3.3.5 Cardiac fibrosis 
Cardiac fibrosis occurs after a range of injuries caused by ischaemia/infarction, 
hypertension, chronic transplant rejection or a variety of endocrine disorders. Cardiac 
fibrosis is thought to involve the proliferation and excessive collagen deposition by 
interstitial cardiac fibroblasts. Most of the information suggesting a role for PDGF 
signalling in cardiac fibrosis originates from gain- and loss-of-function studies in 
experimental animals. Mice treated with neutralizing PDGFR antibodies following 
myocardial infarction show attenuated healing responses depending on antibody 
specificity. PDGFR-β blockade impairs maturation of the new vessels formed in the 
heart, consistent with the known role of PDGFR-β signalling in smooth muscle 
cell/pericyte recruitment and vascular development described earlier. PDGFR-α 
blockade, on the other hand, did not affect the vasculature but decreased collagen 
deposition, suggesting that this receptor may be more important in fibroblast 
activation533. In addition, over-expression of PDGF-C in the heart of transgenic mice 
has been shown to induce diffuse cardiac fibrosis with extensive hyperplasia of 
fibroblast-like cells and large collagen deposits453. This was also coupled with dilated 
cardiomyopathy in females and a hypertrophic response in males. PDGF-D over-
expression in the heart also produced diffuse cardiac fibrosis but it was also associated 
with increased thickness of the medial smooth muscle coat in the coronary vessels534.  
PDGF-A, PDGF-C, or PDGF-D genes were introduced into heterotypic rat heart 
transplant models via adeno-associated virus (AAV)-mediated transfer which led to 
accelerated cardiac fibrosis and chronic rejection535. PDGF-AA causes potent 
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proliferation of cardiac fibroblasts in vitro536 but AAV-derived PDGF-B does not seem 
to. PDGFs have been implicated in the cardiac fibrotic response to angiotensin II537. 
Angiotensin-II-induced cardiac fibrosis is reduced in mice lacking one copy of the 
transcription factor KLF5, correlating with reduced cardiac expression of PDGF-A. 
Evidence for direct binding of KLF5 to the PDGF-A promoter has been described and 
regulation of expression of PDGF-A by KLF5 occurs in other tissues also538. Overall, 
these results implicate PDGFR-α stimulation as a major fibrogenic participant in the 
heart, whereas PDGFR-β stimulation in the heart affects mainly vascular mural cells 
leading to vessel wall pathology.  
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Figure 34. PDGF and tissue fibrosis. In lung fibrosis (A), PDGFs released from 
alveolar macrophages promote proliferation of alveolar (myo)fibroblasts and 
fibrogenesis. In liver fibrosis (B), hepatic stellate cells up-regulate PDGFR-β in 
response to TGF-β. In scleroderma (C), PDGFs released by macrophages promote 
proliferation of dermal (myo)fibroblasts. In a variety of renal diseases and disease 
models (D), PDGF-B released from invading macrophages and PDGF-D released from 
mesangial cells may drive mesangial cell proliferation and matrix deposition, leading to 
glomerulosclerosis. In transgenic models, the expression of PDGFs in myocardial cells 
drives proliferative expansion of PDGFR-α-positive cardiac fibroblasts and collagen 
deposition, leading to severe cardiac fibrosis (E)302(with permission). 
 
5.13 The relationship between platelet derived growth factor and irradiation 
 
There is potential for a complex bidirectional association between PDGF and radiation. 
Firstly, PDGF may play a significant role in the formation of some tumours that are 
subsequently treated by radiotherapy. Secondly, the presence of PDGF may influence 
the response of tissues to irradiation. Thirdly, PDGF may be a key player in cell and 
tissue responses to radiation injury especially through its effects on angiogenesis and 
fibrosis. Finally, PDGF could initiate sequences that lead to the post-radiation tumour 
development occasionally seen many years after irradiation.  
As has been discussed earlier, PDGF can be synthesized by a number of different cell 
types such as macrophages, epithelial and endothelial cells302. PDGF is also implicated 
in a range of physiological and developmental systems together with pathological 
processes, including fibrosis, atherosclerosis, glomerulonephritis and aggressive 
fibromatosis539,540. Aberrant production of PDGF, with autocrine stimulation, may be an 
important mechanism in the neoplastic conversion of PDGF receptor-positive 
cells540,541. Activated RTK phosphorylates numerous signalling molecules that initiate 
intracellular signalling cascades. The latter includes cellular responses involved in the 
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activation of the ras/MAPK pathway, which can promote cellular proliferation, 
migration and differentiation363, and the PI3K/Akt pathway, which influences cell 
survival543. Both of these are crucially important for tumour resistance to radiotherapy 
and chemotherapy. Furthermore, platelet-derived growth factor (PDGF) exerts its potent 
mitogen and chemotactic effects in a variety of mesenchymal cells such as fibroblasts 
and vascular smooth muscle cells. PDGF is therefore a potential key molecule for tissue 
rebuilding in response to radiation injury. 
 
5.13.1 PDGF and tumour formation 
 
This has been discussed previously in some detail. In summary, many studies have 
suggested that autocrine activation of PDGF is an important pathogenetic mechanism 
involved in a variety of brain tumours541-543. Growth stimulation of meningioma and 
neuroblastoma cells in vitro, can be abolished completely by introducing a neutralising 
antibody against PDGF. DNA synthesis in meningioma cell lines can also be inhibited 
using a PDGF antagonist397. Adult fibromatoses (desmoid tumours) have been 
associated with overexpression of PDGF. Inhibition of PDGF signaling by imatinib 
induced overall 1 year tumour control rate of 36.8% in a phase II clinical study441. 
Another important example PDGF’s role in oncogenesis is in gastrointestinal stromal 
tumours (GISTs). Many GISTs have gain-of-function mutations of c-kit receptor 
tyrosine kinase (KIT) gene. In addition, overexpression of PDGF and c-kit has been 
observed in Leydig cell tumours. The clinical success of imatinib/gleevec, a triple 
tyrosine kinase inhibitor of c-kit, PDGF and c-Abl signaling, in chronic myeloid 
leukemia443 and GISTs444 has accelerated the development of molecular targeted cancer 
therapy.  
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5.13.2 PDGF and its role in angiogenesis 
 
Angiogenesis is critical for tumour survival and growth. PDGF has at least two distinct 
functions in pro-angiogenic signalling. Firstly, PDGF increases survival and 
proliferation of endothelial cells and secondly, it regulates vessel growth via pericyte 
recruitment and organisation in newly formed vessels. The dual role for PDGF signaling 
in oncogenesis and angiogenesis suggests the presence of autocrine and paracrine loops 
in tumour formation. Treatment with imatinib/gleevec may disrupt the PDGF/PDGFR 
autocrine loop and may act synergistically with ionising radiation in its antitumoral 
effect (i.e it acts as a radiosensitiser457) and it may also inhibit hypoxia-induced 
angiogenesis and reinforce the anti-angiogenic effect of radiation455. 
 
5.14 PDGF and radiation induced fibrosis 
 
Radiation causes acute inflammation and chronic fibrosis in local tissues, as has been 
described in a previous chapters. This frequently leads to side effects which become a 
dose-limiting factor for treatment efficacy18. Fibrosis in particular frequently leads to 
symptomatic problems. 
In the case of lung tumours, the dose tolerance limitation of normal neighbouring tissue 
often precludes successful radiotherapeutic treatment544. The pulmonary fibrosis 
produced is a progressive condition, characterized by mesenchymal cell proliferation, 
the subsequent deposition of extracellular matrix proteins and extensive remodeling of 
the pulmonary parenchyma545. In both human and animal model systems, acute 
pneumonitis and late fibrosis are directly dependent upon total irradiation dose, fraction 
size, and lung volume irradiated546-548. New precise radiotherapy techniques can spare 
more normal tissue around the tumour and thus reduce the gravity of the side effects. 
However a recent study has shown that 14.6 % patients with lung cancer still developed 
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intermediate grade radiogenic pneumonitis after primary radiotherapy with dose 
escalation using 3D conformal techniques and 13.8 % patients developed fibrosis549. 
Prevention and treatment of fibrosis in general and in particular would be a significant 
break-though in the therapeutic intervention of numerous pathological conditions 
including radiation induced fibrosis. Such treatment remains elusive, partly because the 
exact mediators and mechanisms involved in fibrogenesis are not completely 
understood545. A number of investigations have provided clear evidence for increased 
expression of various cytokines including PDGF, transforming growth factor-β, tumor 
necrosis factor-α and interleukin-1 in response to ionising radiation550-552. In this regard, 
some pro-inflammatory cytokines seem to be important for the acute impairment in the 
pneumonitis phase, for example TNF-α and CD95-ligand553,554, whereas others are 
involved in the regulation of the fibrotic response. For the development of fibrosis, 
transforming growth factor-β is a widely accepted key molecule 555. 
Moreover, recent evidence supports an important role of PDGF for the development of 
lung fibrosis in response to ionising radiation. Firstly, PDGF and PDGFR are expressed 
at low levels in normal adults, while elevated levels are detected in lungs of patients 
with radiation-induced pulmonary fibrosis556. Augmented expression of PDGF is further 
observed in asbestos-associated, bleomycin-induced and idiopathic pulmonary 
fibrosis545,557,558. Increased expression of PDGF in rat lungs by adenoviral delivery or 
lung-specific over-expression in mice is associated with pronounced lung fibrosis559,560. 
Moreover, inhibiting the PDGF pathway with neutralising antibodies to PDGF or 
administration of soluble extracellular region of PDGFR-β can attenuate the 
development of fibrosis561.562. We suggest that PDGF may also be important in radiation 
injury to the lower urinary tract (see later in this Chapter) and that similar therapeutic 
tactics may be helpful at this site too. 
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The radiation-induced overexpression of PDGF led to phosphorylation and activation of 
PDGFR in lungs of irradiated mice, while the phosphorylation of PDGFR was strongly 
inhibited in both irradiated groups treated with RTKIs in vivo502. Treatment with RTKIs 
attenuated the development of pulmonary fibrosis with excellent correlation with 
clinical, histological and computed tomography results, although the acute 
inflammatory response induced by radiation injury was not completely abrogated. 
Moreover, all three tyrosine kinase inhibitors reduced lung fibrosis after radiation injury 
and prolonged animal survival. Thus, there is good evidence to support an important 
role for PDGFs and their receptors in mesenchymal cell recruitment and stimulation in 
fibro-proliferative diseases. 
There are other potential reasons why PDGF may be important in radiation fibrosis. 
Fibroblasts are the putative effector cells of this fibrosis, whether they are resident, 
recruited from local cells or recruited for bone marrow stem cells. Recruitment and 
stimulation of fibroblasts is clearly an important event in the development of fibrosis. 
PDGF exerts a profibrotic effect through its mitogenic and chemotactic stimulus to 
mesenchymal cells, such as fibroblasts, myofibroblasts and smooth muscle cells298. 
Moreover, PDGF has also been shown to stimulate production of extracellular matrix 
proteins, such as collagen, hyaluronic acid, fibronectin and proteoglycan563-566, which 
may be responsible for the irreversibility of fibrotic lesion. The radiation-induced 
secretion of PDGF is unlikely to be derived solely from inflammatory cells. Stromal 
cells, such as fibroblasts and endothelial cells, induce paracrine PDGF in co-culture 
systems which substantially stimulated the proliferation of non-irradiated fibroblasts302. 
Endothelial cells are thought to be a potential source of PDGF after radiation in vitro567 
and increased expression of c-sis mRNA (PDGFRβ) in epithelial cells has also been 
observed in several conditions associated with pulmonary fibrosis503. 
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To support the idea that PDGF is produced by cells other than inflammatory cells, 
treatment with dexamethasone did not decrease the level of PDGF-BB or the mitogenic 
activity of bronchial alveolar lavage fluid for fibroblasts in patients with chronic lung 
disease of prematurity568. Cyclosporin A treatment does not appear to inhibit the 
expression of PDGF ligands and receptors either569. Thus, stromal cells, such as 
endothelial, fibroblasts cells, are likely to be responsible (at least partially) for the 
release of cytokines, including PDGF, in pulmonary fibrosis. 
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Figure 35. Schematic diagram of the potential role of PDGF signalling in radiation 
induced fibrosis300 
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5.15 Platelet-derived growth factor in radiation injury to the bladder 
PDGF has been shown to play a role in several human neoplasms and inflammation 
based, healing and fibrosing conditions including atheroma and fibromatosis. It is 
thought to play a role in radiation fibrosis in the lung and the gastrointestinal tract but its 
potential role in lower urinary tract radiation injury is currently unknown.  As has been 
mentioned in the previous sections, radiation is commonly used to treat urothelial and 
other pelvic malignancies and radiation-induced side effects limit its efficacy.  There are 
different ways to try to minimise the side effects, or treat them, but the possibility of 
influencing the development of or reversing these effects through PDGF does not 
appear to have been considered to date. Medical intervention is now available for PDGF 
and its receptors and it is possible that the use of these compounds may influence effects 
of radiation. With this in mind, an investigation of PDGF expression was undertaken to 
establish whether PDGF plays a significant role in radiation injury to the bladder, 
thereby opening a door for therapeutic amelioration of this dose limiting effect. 
 
5.15.1 Materials and methods 
 
The files of the Pathology Department were searched for all cystectomy specimens 
following radiation. The search was similar to that described previously for the cases 
investigated in Chapters 3 and 4. A total of 110 cases were identified which were 
suitable for inclusion. As before, the patients had received a standard course of 
radiotherapy and the time between radiation and surgery was known. The expression of 
PDGF and its receptors was investigated using standard immunohistochemical 
techniques. For all apart from the PDGF-AB antibody a standard streptavidin-biotin 
method was used, but vectastain enhancement was required for PDGF-AB. The 
techniques are provided in the Appendix. The antibodies were all sourced from 
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commercial companies to ensure that they were well established and likely to work 
satisfactorily. Western blot  and reference data was provided in the datasheets to 
confirm specificity. The antibodies, sources, dilutions and pre-treatment regimens are 
detailed in Table 6.  For all antibodies, suitable positive and negative controls were used 
either as recommended by the Company providing the antibody or from previous 
experience in the laboratory. In fact for the PDGF receptors, normal pituitary gland was 
used as we had found in an earlier study that there was an interesting pattern of 
distribution of the receptors in the normal and neoplastic pituitary gland (Fig 36). 
Furthermore, different antibodies for some antigens were sourced from different 
companies and the best antibody assessed after optimisation and used for this study. For 
confirmation of staining the appropriate positive control tissue was run alongside each 
test according to the manufacturer’s recommendations. Negative controls were also 
performed routinely by omitting the primary antibody. 
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Table 6. PDGF antibodies and their sources and dilutions  
 
 
Antigen Source Antibody 
reference 
Monoclonal 
or polyclonal 
(M/P) 
Dilution Pretreatment 
PDGF-AA Genzyme ZP-214 P (rabbit) 1:100 Microwave 
PDGF-AB TCS 06-127 P (goat) 1:1000 Microwave 
PDGF-BB Genzyme ZP215 P (rabbit) 1:100 Microwave 
PDGFR 
alpha 
Genzyme 1264-00 M (mouse) 1:25 Microwave 
PDGFR 
beta 
Genzyme 1263-00 M (mouse) 1:50 Microwave 
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The distribution was determined by microscopic examination of the 
imunohistochemical slides, specifically looking at all areas of the bladder wall and 
surrounding tissues away from direct tumour involvement. The epithelium, mucosa, 
muscularis propria, superficial and deep vessels and connective tissue structures were 
all looked at. The results of the observations were recorded by two examiners, who had 
scored the first ten cases on a double headed microscope for consistency and in all cases 
where there was disagreement, a negotiated final result was determined by looking at 
the slides together. 
PDGF and PDGFR expression was scored in a semi-quantitative manner with scores 0, 
+, ++ and +++ for no staining, weak staining, moderate staining and strong staining 
respectively. The results from the irradiated group were compared to non-irradiated 
control groups which consisted of cytectomies for transitional cell carcinomas in 
patients who had not received radiotherapy, bladders removed for intractable interstitial 
cystitis and autopsy bladder wall tissue. As the time between radiotherapy and 
cystectomy was known in all study cases, it was also possible to see if there were any 
differences in expression of PDGF/R over time since irradiation. 
The statistics was analysed using the Statistical Package for the Social Sciences, version 
16.0, 2008 (SPSS).  The data was fed into the package and tabulated using the cross-
tabualtion facility. This allowed graphs to be created following which statistical 
analysis, using the Pearson Chi-squared test was performed. A cut-off level of 0.05 was 
used for significance as per routine protocol. 
 
5.15.2 Results  
 
PDGF isoforms and PDGF receptors were identified in all post-irradiation cases (Figs. 
37-39).  An overview of the results is provided here, with an example (Fig.40), but all of 
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the results are contained in Appendix 3. In summary, there was increased expression of 
PDGF and its receptors in many components of the bladder wall, including epithelium, 
superficial and deep endothelial cells, fibroblasts and smooth muscle cells. The results 
for the irradiated group as a whole were compared with the control groups. The most 
significant findings were expression of all proteins in the superficial endothelial cells 
and fibroblasts (mostly p<0.001). PDGFR alpha was also significantly increased in the 
epithelium.   
As a general rule expression appeared to increase in the early phase after radiation, peak 
within a year to 2 years and then decrease. There was persistent expression for many 
years in several of the cases. 
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Figure 36. PDGFR alpha control tissue highlights the acidophil wings of the 
pituitary gland. 
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Figure 37. Light generalised epithelial positivity was seen after radiation. Note the 
positive internal control for platelets. 
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Figure 38. Mast cells cells expressed PDGF AB consistently (again note the internal 
positive control). 
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Figure 39. There was limited or no positivity for the smooth muscle with PDGF-
AB. Mast cells here also positive. 
  210 
 
Figure 40. Intensity of staining for PDGF-AB in the test and control bladders (one 
example- see appendix for the remainder). 
 
5.15.3 Discussion 
 
Radiotherapy causes injury to local normal tissues as well as the tumour at which it is 
directed. One of the most troublesome side effects is fibrosis, which leads to several of 
the complications encountered after radiation therapy including pain and functional loss. 
This is especially prominent in the area of the lower urinary tract, although many organs 
caught in the radiation field show similar changes570. The main pathological feature of 
such radiation toxicity is transmural fibrosis consisting of marked deposition of 
extracellular matrix component within the all layers of the bladder wall. Around the 
microvessels, accumulation of inflammatory cells suggesting an increased vascular 
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permeability likely caused by endothelial cell damage. The muscle is thickened with 
zones of complete disruption. In the subepithelial zone, and deeper within the bladder 
wall, there are dense cords of collagen fibres with few fibroblasts whereas others are 
edematous or contained fibrosis-related fibroblasts and inflammatory cells located 
around hyalinized vessels with interlaced fibres. The nerves can also be involved with 
inflammatory and fibrotic changes571. The serosa is often abnormal with variable 
fibrosis containing newly formed microvessels, myofibroblasts, inflammatory cells, and 
paucicellular zones composed of stromal accumulation. 
The pathophysiological mechanisms of acute radiation injury have been well 
investigated together with the mechanisms underlying delayed radiation-induced 
complications although the precise sequence of cellular and molecular events that 
initiates fibrogenesis are not fully known. Classical radiobiological views present 
radiation-induced tissue injury as the direct consequence of DNA damages and cell 
death induction in target cells, meaning that the severity of tissue damages would be 
directly related to cell depletion during the acute phase. However, it is clear that other 
mechanisms are important since early injury is required for the development of delayed 
complications in the intestine572,573. These observations led to the idea that increasing 
the pool of epithelial cells before irradiation might improve acute damage and inhibit 
the development of late injury574. The functional consequences of radiation-induced 
epithelial depletion are probably far beyond their barrier function. An indirect 
consequence of the epithelial disruption is the initiation of inflammation, particularly 
lymphocyte T helper (TH) involvement. Subsequent production of specific cytokines, 
most notably the secretion of IFN y, is associated with resolution of the wound healing 
process. On the other hand secretion of IL-4, IL-13 and TGF-b1, triggers a tissue 
response towards fibrosis, probably mediated predominantly by TGF-b1575-577. Exposure 
of intestinal stroma to bacteria can also induce a TH1 response576 but in the lung 
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persistent exposure to bacterial antigens seems to prefer a TH2 profile suggesting that 
chronic epithelial depletion is fibrosis-prone577.  
However, delayed tissue response to radiation injury depends upon continuous and 
integrated pathogenic processes, involving cell differentiation and crosstalk between the 
various cellular components of the tissue and the extracellular matrix578. The role of the 
mesenchymal compartment (smooth muscle cells, submucosal fibroblasts, subepithelial 
myofibroblasts and the extracellular matrix) is crucial for the development and the 
maintenance of fibrosis as these cells are responsible of the pathological extracellular 
matrix accumulation observed in fibrosis. 
Radiation-induced urinary tract fibrosis is characterized by the accumulation of 
extracellular matrix due to a global deregulation of the synthesis/degradation 
balance579,580. Whether this dynamic remodelling process is a cause or a consequence of 
the phenotypic alteration of the resident mesenchymal cells is not known581. After 
injury, tissue regeneration relies on the differentiation capacity of its resident cells. In 
the bladder, the mesenchymal compartment is composed of 3 cell types: the sub-
epithelial myofibroblasts, the submucosal fibroblasts and the smooth muscle cells of the 
muscularis propria. The respective contribution of these three cell types to fibrosis is not 
clearly defined, but pathological collagen deposition seems mainly to be derived from 
smooth muscle cells582.  
In many ways, radiation fibrosis can be viewed as an exaggerated wound healing 
process. In general, after injury, loss of homeostasis induces mechanical tension in the 
local wound. This contractile stress added to the secretion of cytokines, such as PDGF, 
triggers fibroblast recruitment and their phenotypic change583 into proto-
myofibroblasts584. Then, the mechanical tension associated with fibronectin and TGF-b1 
deposition induces the differentiation of proto-myofibroblasts into myofibroblasts 
(characterised by altered cytoskeletal filaments; α-smooth muscle actin, myosin, 
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tropomyosin, α-actinin and filamin). Myofibroblastic differentiation is an intermediate 
state between fibroblast and smooth muscle cell that ensures the contraction of 
granulation tissue and the neo-synthesis of the extracellular matrix. After injury, the 
differentiation of smooth muscle cells is characterized by a phenotypic switch from a 
contractile role to a secretory function585. The plasticity of smooth muscle cells allows 
significant alterations in their phenotype in response to changes in local 
environment585,586 and in return these differentiated smooth muscle cells controlled 
tissue response.  
It is generally considered that mesenchymal cell differentiation in radiation-induced 
fibrosis as terminal and thus irreversible587,588. This hypothesis is based on phenotypic 
characterization of fibroblasts irradiated in vitro, which exhibit a premature senescent 
and pro-secretory phenotype (extracellular matrix secretion). Thus, necrosis or 
apoptosis of these fibrosis-activated mesenchymal cells could conceivably avoid or 
reverse fibrosis589,590.  On the other hand, it appears that the cells promoting fibrosis 
after radiation are phenotypically immature and this immaturity has important clinical 
implications as it suggests that fibrotic tissue has high regenerative potential and that 
fibrosis might be reversible.  
There are many cytokines and other factors that are known or thought to play a role in 
fibrosis in general and also radiation induced change. These have already been 
discussed in some detail in Chapter 1. These include TGF-β1 and CCN2 (also called 
CTGF). Although most studies focus on these cytokines, it is certainly logical to turn 
our attention to PDGF and its possible role in radiation injury. PDGF has been 
implicated in many inflammatory and fibrosing conditions and it is a promoter of TGF. 
PDGF has also been found to protect against radiation injury in vivo. We have shown 
that PDGF is found more frequently in the bladder after irradiation. It was identified in 
several cell types including endothelial cells, stromal cells, epithelial cells and incoming 
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cells including inflammatory cells and platelets. It appears to be expressed at increasing 
levels over the first year or so, to decrease over the next year or two but continues to be 
present at relatively low levels after that. 
The recognition of PDGF and its receptors using immunohistochemistry does not 
necessarily mean that there is a functional role for PDGF in radiation injury but the 
previous chapters have provided extensive background information regarding PDGF 
and the pathological processes involved in radiation injury and it seems extremely 
logical that PDGF is implicated in the sequence of events within tissues after irradiation. 
The presence of PDGF in mast cells is particularly interesting. Mast cells are often 
found in conditions characterised by fibrosis such as scleroderma and mast cell 
proliferations are commonly associated with a degree of local fibrosis257,582. It is 
attractive to speculate therefore that PDGF production by mast cells is an important 
feature of such diseases and a similar process might occur in radiation fibrosis. Whether 
mast cells express PDGF in the resting state, or whether PDGF is only produced after 
some type of induction process, is unclear. In any event, the mast cell is another 
potential therapeutic target for the prevention or treatment of radiation fibrosis.  
As the PDGF/R family is a mixed group of similar proteins, it is very difficult to tease 
out which individual isoforms might be more or less involved in radiation injury. It is 
certainly likely that the PDGFs or the receptors might vary in their relevance to the 
radiation response. On the other hand, the various PDGF and receptors might be 
important at different points in the post-radiation cascade, each influencing a number of 
pathways stimulated after radiation. The first is inflammation and cell recruitment. The 
second is angiogenesis and wound healing response. The third is fibrosis. The fourth is 
subsequent malignant transformation. How these impact the various systems is very 
difficult to figure out. Furthermore, although they may be important, their role might be 
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indirect (such as via production of another factor such as TGF) or they may have an 
impact only in combination with any of the other factors involved in the radiation 
response. Nevertheless, the relevance of PDGF could be determined by using agents 
that act against PDGFs either by antagonism or inhibition, or receptor blockade. If this 
is found to be correct, it would also hint that manipulation of the PDGF/R family might 
provide another means of dampening or reversing the complications of irradiation in the 
bladder (and more generally). Of course this could apply equally to other conditions 
involving PDGF/R including post-surgical scarring, wound healing and atherosclerosis.  
 
5.15.4 Conclusion 
 
Radiation injury to the bladder is characterised by an early inflammatory response 
followed by reactive or atrophic epithelial changes and mural fibrosis. PDGF and 
receptors are present in many cells involved in the pathogenesis of the radiation 
response and these appear to be upregulated after radiation exposure. These processes 
include inflammation, healing, fibrosis, vasculopathic alterations and neoplasia. 
PDGF/R may therefore play a significant role either directly, indirectly or in 
combination with other factors in radiation injury to the bladder. Strategies aimed at 
PDGF family might be useful targets to interfere with the development of post-
radiotherapy complications and enable manipulation of treatment regimens, or as a 
therapeutic agent for complications. If this is the case, it clearly has wider implications 
for the prevention and treatment of many other general fibrosing conditions which could 
be exploited clinically. 
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Future work 
 
The overall conclusion of this study is that PDGF has a role in the effect of irradiation 
on the urinary tract. It is also likely that it is important in the response of tissues to 
radiation in general and post-radiation fibrosis in particular. The latter is a potentially 
severe complication of radiotherapy, which can limit its usefulness and lead to 
subsequent distressing symptoms. Our findings predict that targeted therapy against 
PDGFs or their receptors may potentially be beneficial to these patients. However, 
clearly it is essential to support the findings of this thesis with more sophisticated 
techniques, before making the above claims. Furture work will be aimed at validating 
these results in order to justify the statements made and confirm the potential of 
studying PDGF as a target for preventing radiation injury for the future. The work 
envisioned will centre on studies such as western blotting, in situ hybridization and 
polymerase chain reaction, together with cell culture work, examining in vitro 
alterations in endothelial cells, epithelial cells and fibroblasts specifically and how they 
can be manipulated therapeutically for the potential benefit of the many thousands of 
patients whose lives may be devastated by a treatment aimed at ridding them of their 
cancer.  
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Appendix 1. Immunohistochemical methods for PDGF and receptor 
studies and risk asessement 
 
Procedure 
 
1. The following controls were used for each run performed. 
 
 Positive control section for each primary antibody used. 
 Negative control section [omitting primary antibody]. 
 
2. The sections were placed into a black plastic staining rack. 
 
3. They were dewaxed in xylene for 2 changes of 2 minutes each. 
 
4. The xylene was removed in alcohol for 2 changes of 2 minutes each. 
 
5. The sections were placed into the sink and washed in tap water for 5 minutes. 
 
For antigen retrieval: 
a. Take a microwave container and fill it with 1000ml of the appropriate antigen 
unmasking solution. (See Section 4 for the available solutions) 
 
b. Place the rack of slides into this and put on the perforated lid on. 
 
c. Place the container into the microwave oven and close the door. 
 
d. The default of the microwave is maximum power, so this need not be altered. 
 
e. Set the length of time required. Each press of the “Hour” button will 
increment by 10 minutes. Each press of the “Min” button will increment by 1 
minute. 
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f. When the time has been set, press the “Start” button to begin microwaving. 
 
g. When the time has elapsed, the microwave oven will emit a ping to indicate 
that it has finished. 
 
h. Using heat resistant gloves carefully remove the trough from the oven and 
place into the staining tray of running water in the sink beside the microwave 
oven. 
 
i. Allow cool for 5 minutes. 
 
j. Remove the rack and place into the sink and wash in tap water for 5 minutes. 
 
k. Return to the staining procedure and continue with step 6. 
 
6. At this stage avidin/biotin blocking was performed (if required) 
 
7. The the endogenous peroxidase blocking solution was prepared by adding 6ml. of 
hydrogen peroxide to 194ml. of distilled water in a black staining trough. 
 
8. The rack of sections was placed into the endogenous peroxidise blocking solution 
for 15 minutes. 
 
9. The rack was removed and placed into the sink and washed in tap water for 5 
minutes. 
 
10. The black plastic staining trough previously used for the endogenous block was 
washed out with distilled water and filled with wash buffer obtained from the 
aspirator. 
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11. The rack of slides was placed into the wash buffer and left to soak for 5 minutes. 
 
12. The immuno staining tray was prepared by adding a few drops of wash buffer to 
create a moist chamber. 
 
13. Taking each slide in turn, the sections were wiped around to remove excess wash 
buffer and with a PAP pen a line was drawn across the slide above and below the 
section. 
 
14. The sections were then placed onto the rack in the immuno staining tray and 
covered with wash buffer, being careful not to allow the sections to dry out. 
 
15. When all of the sections were on the rack the wash buffer was tipped off. 
 
16. Sufficient drops of normal blocking serum was applied to cover each section. 
 
17. The lid was placed on the immuno staining tray and left for 20 minutes. 
 
18. The primary antibody was prepared at the appropriate dilution using antibody 
diluent. 
 
19. The normal blocking serum was tipped off. 
 
20. The primary antibody was applied to each test section and the positive control 
section. 
 
21. Only the antibody diluent was applied to the negative control section.  
 
22. The immuno staining tray lid was replaced and left for 40 minutes. 
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23. The primary antibody was rinsed off with wash buffer. 
 
24. Each section was covered with wash buffer and the immuno staining tray lid was 
replaced and left for 2 minutes. The sections were rinse with wash buffer and 
covered again and left for a further 2 minutes. 
 
25. The wash buffer was then tipped off. 
 
26. The sections were all covered by drops of the universal biotinylated secondary 
antibody. 
 
27. The immuno staining tray lid was replaced and left for 30 minutes. 
 
28. The secondary antibody was rinsed off with wash buffer. 
 
29. Each section was covered with wash buffer and the immuno staining tray lid was 
replaced and left for 2 minutes. The sections were rinsed again with wash buffer, 
covered and left for a further 2 minutes. 
 
30. The wash buffer was tipped off. 
 
31. Sufficient drops of the Vectastain elite ABC reagent were added to cover each 
section. 
 
32. The immuno staining tray lid was replaced and left for 30 minutes. 
 
33. The ABC reagent was rinsed off with wash buffer. 
 
34. Each section was covered with wash buffer and the immuno staining tray lid was 
replaced and left for 2 minutes. The sections were rinsed with wash buffer and 
covered again and left for a further 2 minutes. 
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35. 1ml of substrate buffer from the Biogenex two component DAB kit was placed 
into a yellow topped tube. 
 
36. One drop of the DAB chromogen was added from the kit and mixed well. 
 
37 The wash buffer was tipped from the slides and the DAB solution was applied to 
each of the slides for 5 minutes. 
 
38. The slides were washed in tap water for 5 minutes. 
 
39. The slides were loaded into a machine staining rack (ensuring that all of the 
sections were facing in the direction of the arrow on the rack). 
 
40.  The remainder of the technique was automated, staining the sections with the 
haematoxylin, dehydrating in alcohol to remove water and washing in xylene 
before coverslipping.  
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Flow Chart 
 
 
 
Antigen Retrieval No Antigen Retrieval 
Tap Water 5 minutes 
Endogenous Peroxidase Block 
3% Hydrogen Peroxide 15 minutes 
 
 
Tap Water 5 minutes 
 
 
Wash Buffer 5 minutes 
 
 
Xylene 2 x 2minutes 
Alcohol 2 x 2minutes 
    
 
 
Steps 1 - 5 
Steps 6 - 8 
Step 9 
Steps 10 - 11 
Prepare the immuno staining tray 
Pap pen the slides 
    
 
 
 
Steps 12 - 14 
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Steps 19 - 22 
Tip off Wash Buffer and apply Normal Horse Serum 
(Yellow Bottle) 20 minutes 
 
Tip off Horse Serum and apply 
Primary Antibody 40 minutes 
 
 
Wash Buffer 2 x 2 minutes 
 
 
Step 15 - 18 
Steps 23 - 24 
Biotinylated Anti Rabbit and Mouse (Blue Bottle) 30 
minutes 
 
 
 
Steps 25 - 27 
Positive Sections Negative Control 
Tip off Horse Serum and apply 
Antibody Diluent Antibody 40 
minutes 
 
 
Wash Buffer 2 x 2 minutes 
 
 
Steps 28 - 30 
ABC Reagent (Grey Bottle) 30 minutes 
 
 
 
Steps 31 - 32 
Wash Buffer 2 x 2 minutes 
 
 
Steps 33 - 34 
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DAB (1ml substrate buffer + 1 drop of DAB chromogen) 
for 5 minutes 
 
 
Steps 35 - 37 
Wash in Tap water for 5 minutes 
 
 
Step 38 
Staining Machine Immuno Program 
 
 
Steps 39 - 40 
Coverslipping Machine 
 
 
Step 41 
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Safety Measures 
1. Wear personal protective clothing especially safety glasses at all times. 
 
2. Do not undertake of activities likely to cause any reagents to come into contact with skin, eyes 
and  mucosal surfaces. 
 
3. Avoid skin contact with any chemical where possible by the use of forceps to carry out 
manipulations. 
 
4. Ensure that there is adequate ventilation of the work area.All waste reagents must disposed of 
in accordance with the manufacturers instruction or local by laws. 
 
5. All flammable reagents must be stored in the laboratory in fire cabinets where the volumes are 
kept as low as possible consistent with their frequency of use. 
 
6. Bulk staining troughs must be used on a spillage containment tray and where possible within a 
fume hood. 
 
7. Spillage containment kits are available to limit the extent of any spillage. 
 
8. All reagent bottles must be marked with risk phrase labels and a departmental COSHH 
number, which indicates the page in the COSHH files where safety information can be found. 
 
9. All hand mounting must be carried out in the mounting hood with extraction through a filter 
system. 
 
10. Hydrogen peroxide must be stored in loosely capped black containers at 4°C. 
 
11. Open hydrogen peroxide containers with caution if pressure has built up in the container it can 
spray out. 
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12. Wear gloves and discharge static electricity if weighing out diaminobenzidene 
tetrahydrochloride (DAB). 
 
13. All weighing of solid chemicals must be carried out within balance extraction hoods. 
 
14. All immunochemicals are measured using automatic pipettes with disposable tips. 
 
15. Large bottles of chemicalsmust be transported in bottle carriers, unless a trolley is used.  
 
16. Pipette tips amd other plasticware must be discarded into the yellow plastic bins on each bench 
before placing in an orange clinical waste sack for disposal. 
 
17. Sharps must be discarded into the sharps bin and not into the plasticware bins on the benches. 
 
18. Dispose of each category of waste in the approved manner. 
19. Under no circumstances should any attempt be made to operate the microwave oven with the 
door open or to tamper with the safety interlocks (door latches) or to insert anything into the 
safety interlock holes. 
 
20. Do not place any object between the oven door and front face, or allow residues to accumulate 
on sealing surfaces. 
 
21. Ensure that the door and door sealing surfaces are kept clean by wiping after use with first a 
damp cloth and then a final wipe with a soft dry cloth. 
 
22. The microwave oven should not be operated if it has sustained damage to the door or door 
sealing area. 
 
23. Do not use any metal containers or instruments in the microwave oven. 
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24. Only use microwave compatible containers. 
 
25. Do not place any sealed containers in the microwave oven. 
 
26. Use heat resistant gloves when removing items from the microwave oven. 
 
27. Do not operate the microwave oven if it is empty. 
 
28. Liquids should be left in the microwave oven for at least 20 seconds after it has stopped to 
allow the temperature to equalize.  
 
29. Only use cling film suitable for use in a microwave. 
 
30. Stand away from the oven when opening the microwave oven door. The hot air or steam which 
escapes can cause burns. 
 
31. Keep the microwave oven vent ducts unobstructed. 
 
32. Never use flammable materials in the microwave oven. 
 
33. If materials inside the microwave oven should ignite, keep the oven door closed, turn oven off, 
and disconnect the power cord. 
 
34. Do not touch or allow any object to cover the openings on the top of the outer case of the 
microwave oven during operation. 
 
35. Cracked and damaged glassware should not be used. 
 
36. Use heat resistant gloves when removing solutions from the microwave oven. 
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37. A visor, heat protective gloves and heavy-duty apron are available for wearing when using the 
pressure cooker. 
 
38. The pressure cooker must be visually checked for damage before use. 
 
39. Do not leave the pressure cooker unattended during use. 
 
40. Do not lean over the cooker whilst in operation in case an explosive release of steam occurs
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Appendix 2. Fibronectin data and statistics (N/A = negative/absent) 
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Mucosal Stroma Crosstabulation 
 
 
 
 
Group 
Mucosal Stroma 
mild staining moderate staining strong staining N/A Total 
 CYSTITIS 0 0 0 6 6 
IRRAD 25 12 5 23 65 
NONIRRAD 2 9 1 6 18 
PM 4 1 0 10 15 
 31 22 6 45 104 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 24.977a 9 .003 
Likelihood Ratio 26.929 9 .001 
N of Valid Cases 104   
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Mucosal Basement Membrane Crosstabulation 
 
 
 
 
Group 
Mucosal Basement Membrane 
mild staining moderate staining N/A Total 
 CYSTITIS 0 0 6 6 
IRRAD 15 0 50 65 
NONIRRAD 1 2 15 18 
PM 0 0 15 15 
 16 2 86 104 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 17.440a 6 .008 
Likelihood Ratio 18.124 6 .006 
N of Valid Cases 104   
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Mucosal Fibroblasts Crosstabulation 
 
 
 
 
Group 
Mucosal Fibroblasts 
mild staining moderate staining N/A Total 
 CYSTITIS 0 0 6 6 
IRRAD 20 3 42 65 
NONIRRAD 0 3 15 18 
PM 2 1 12 15 
 22 7 75 104 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 13.425a 6 .037 
Likelihood Ratio 17.825 6 .007 
N of Valid Cases 104   
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Mucosal Endothelium Crosstabulation 
 
 
 
 
Group 
Mucosal Endothelium 
mild staining moderate staining strong staining N/A Total 
 CYSTITIS 0 0 0 6 6 
IRRAD 44 10 4 7 65 
NONIRRAD 5 9 0 4 18 
PM 6 3 1 5 15 
 55 22 5 22 104 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 41.381a 9 .000 
Likelihood Ratio 37.471 9 .000 
N of Valid Cases 104   
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Intermuscular Stroma Crosstabulation 
 
 
 
 
Group 
Intermuscular Stroma 
mild staining moderate staining strong staining N/A Total 
 CYSTITIS 0 0 0 6 6 
IRRAD 21 10 2 32 65 
NONIRRAD 4 0 0 14 18 
PM 0 1 0 14 15 
 25 11 2 66 104 
 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 18.324a 9 .032 
Likelihood Ratio 25.942 9 .002 
N of Valid Cases 104   
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Intermuscular Fibroblasts Crosstabulation 
 
 
 
Group 
Intermuscular Fibroblasts 
mild staining N/A Total 
 CYSTITIS 0 6 6 
IRRAD 14 51 65 
NONIRRAD 0 18 18 
PM 2 13 15 
 16 88 104 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 6.303a 3 .098 
Likelihood Ratio 9.788 3 .020 
N of Valid Cases 104   
  297 
 
  298 
 
Intermuscular Endothelium Crosstabulation 
 
 
 
 
Group 
Intermuscular Endothelium 
mild staining moderate staining strong staining N/A Total 
 CYSTITIS 0 0 0 6 6 
IRRAD 47 10 5 3 65 
NONIRRAD 8 2 0 8 18 
PM 8 3 1 3 15 
 63 15 6 20 104 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 42.733a 9 .000 
Likelihood Ratio 39.882 9 .000 
N of Valid Cases 104   
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Appendix 3. Statistics for PDGF and receptor analysis (N/A = unreadable) 
 
PDGFAA 
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Epithelium crosstabulation 
 Epithelium 
 
Group mild staining moderate staining strong staining no staining N/A Total 
 CYSTITIS 2 2 0 1 1 6 
IRRAD 20 27 6 2 15 70 
NONIRRAD 6 9 0 1 2 18 
PM 7 6 0 0 6 19 
Total 35 44 6 4 24 113 
 
 
Chi-Square tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 10.729a 12 .552 
Likelihood Ratio 12.070 12 .440 
N of Valid Cases 113   
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Superficial endothelial cells crosstabulation 
 Superficial Endothelial Cells 
 
             Group mild staining moderate staining no staining N/A Total 
 CYSTITIS 4 1 1 0 6 
IRRAD 33 24 1 12 70 
NONIRRAD 7 4 6 1 18 
PM 8 4 1 6 19 
 52 33 9 19 113 
 
Chi-Square tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 26.389a 9 .002 
Likelihood Ratio 22.761 9 .007 
N of Valid Cases 113   
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Deep endothelial cells crosstabulation 
 
 
 
 
Group 
Deep Endothelial Cells 
mild staining moderate staining no staining N/A Total 
 CYSTITIS 2 3 1 0 6 
IRRAD 36 22 0 12 70 
NONIRRAD 8 7 2 1 18 
PM 3 9 1 6 19 
 49 41 4 19 113 
 
 
Chi-Square tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 19.275a 9 .023 
Likelihood Ratio 21.217 9 .012 
N of Valid Cases 113   
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Large vessels crosstabulation 
 
 
 
 
Group 
Large Vessels 
mild staining moderate staining no staining N/A Total 
 CYSTITIS 4 2 0 0 6 
IRRAD 36 22 0 12 70 
NONIRRAD 7 7 3 1 18 
PM 5 7 1 6 19 
 52 38 4 19 113 
 
 
Chi-Square tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 19.556a 9 .021 
Likelihood Ratio 19.228 9 .023 
N of Valid Cases 113   
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PDGFAB 
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Epithelium Crosstabulation 
 
 
 
 
 Group 
Epithelium 
mild staining moderate staining strong staining no staining N/A Total 
 CYSTITIS 2 2 0 1 1 6 
IRRAD 21 29 3 1 16 70 
NONIRRAD 3 13 0 0 2 18 
PM 4 9 0 0 6 19 
 30 53 3 2 25 113 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 16.359a 12 .175 
Likelihood Ratio 13.154 12 .358 
N of Valid Cases 113   
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Superficial Endothelial Cells Crosstabulation 
 
 
 
 
Group 
Superficial Endothelial Cells 
mild staining moderate staining no staining Not applicable Total 
 CYSTITIS 2 2 2 0 6 
IRRAD 41 17 0 12 70 
NONIRRAD 8 8 1 1 18 
PM 6 7 0 6 19 
 57 34 3 19 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 34.097a 9 .000 
Likelihood Ratio 22.561 9 .007 
N of Valid Cases 113   
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Deep Endothelial Cells Crosstabulation 
 
 
 
 
Group 
Deep Endothelial Cells 
mild staining moderate staining Not applicable Total 
 CYSTITIS 4 2 0 6 
IRRAD 39 19 12 70 
NONIRRAD 8 9 1 18 
PM 2 11 6 19 
 53 41 19 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 16.881a 6 .010 
Likelihood Ratio 19.900 6 .003 
N of Valid Cases 113   
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Large Vessels Crosstabulation 
 
 
 
 
Group 
Large Vessels 
mild staining moderate staining no staining Not applicable Total 
 CYSTITIS 6 0 0 0 6 
IRRAD 42 16 0 12 70 
NONIRRAD 6 10 1 1 18 
PM 4 9 0 6 19 
 58 35 1 19 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 26.943a 9 .001 
Likelihood Ratio 27.903 9 .001 
N of Valid Cases 113   
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Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 50.549a 15 .000 
Likelihood Ratio 42.274 15 .000 
N of Valid Cases 118   
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Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 84.777a 20 .000 
Likelihood Ratio 57.815 20 .000 
N of Valid Cases 118   
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Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 45.515a 20 .001 
Likelihood Ratio 43.618 20 .002 
N of Valid Cases 118   
 
  334 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 53.856a 20 .000 
Likelihood Ratio 56.761 20 .000 
N of Valid Cases 118   
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PDGFR-alpha 
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Epithelium Crosstabulation 
 
 
 
 
Group 
Epithelium 
mild staining moderate staining strong staining no staining N/A Total 
 CYSTITIS 4 1 0 0 1 6 
IRRAD 43 11 0 1 15 70 
NONIRRAD 4 12 0 0 2 18 
PM 3 9 1 0 6 19 
 54 33 1 1 24 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 32.635a 12 .001 
Likelihood Ratio 31.723 12 .002 
N of Valid Cases 113   
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Superficial Endothelial Cells Crosstabulation 
 
 
 
 
Group 
Superficial Endothelial Cells 
mild staining moderate staining no staining N/A Total 
 CYSTITIS 3 1 2 0 6 
IRRAD 45 3 10 12 70 
NONIRRAD 8 8 1 1 18 
PM 9 4 0 6 19 
 65 16 13 19 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 29.164a 9 .001 
Likelihood Ratio 29.115 9 .001 
N of Valid Cases 113   
  346 
 
 
  347 
 
Deep Endothelial Cells Crosstabulation 
 
 
 
 
Group 
Deep Endothelial Cells 
mild staining moderate staining no staining Not applicable Total 
 CYSTITIS 4 2 0 0 6 
IRRAD 45 4 9 12 70 
NONIRRAD 10 7 0 1 18 
PM 7 6 0 6 19 
 66 19 9 19 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 26.167a 9 .002 
Likelihood Ratio 30.075 9 .000 
N of Valid Cases 113   
  348 
 
 
  349 
 
 
 
 
 
 
Large Vessels Crosstabulation 
 
 
 
 
    Group 
Large Vessels 
mild staining moderate staining no staining Not applicable Total 
 CYSTITIS 5 1 0 0 6 
IRRAD 46 2 9 13 70 
NONIRRAD 10 7 0 1 18 
PM 6 7 0 6 19 
 67 17 9 20 113 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 34.277a 12 .001 
Likelihood Ratio 38.790 12 .000 
N of Valid Cases 113   
  350 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 43.671a 20 .002 
Likelihood Ratio 44.459 20 .001 
N of Valid Cases 118   
 
 
 
 
  351 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 50.495a 20 .000 
Likelihood Ratio 48.636 20 .000 
N of Valid Cases 118   
 
  352 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 41.400a 20 .003 
Likelihood Ratio 36.201 20 .015 
N of Valid Cases 118   
 
 
  353 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 73.418a 20 .000 
Likelihood Ratio 53.660 20 .000 
N of Valid Cases 118   
 
  354 
 
 
 
 
 
 
 
 
 
  355 
 
 
 
  356 
 
 
 
  357 
 
 
 
  358 
 
 
 
 
  359 
 
 
 
  360 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  361 
PDGFBB 
 
 
  362 
 
Epithelium crosstabulation 
 
 
 
 
   Group 
Epithelium 
mild staining moderate staining strong staining no staining N/A Total 
 CYSTITIS 3 1 0 1 1 6 
IRRAD 22 25 6 2 15 70 
NONIRRAD 15 0 0 1 2 18 
PM 9 4 0 0 6 19 
 49 30 6 4 24 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 25.957a 12 .011 
Likelihood Ratio 30.761 12 .002 
N of Valid Cases 113   
  363 
 
  364 
 
Superficial Endothelial Cells Crosstabulation 
 
 
 
 
Group 
Superficial Endothelial Cells 
mild staining moderate staining no staining N/A Total 
 CYSTITIS 4 0 2 0 6 
IRRAD 39 18 1 12 70 
NONIRRAD 2 0 15 1 18 
PM 9 0 4 6 19 
 54 18 22 19 113 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 72.354a 9 .000 
Likelihood Ratio 72.866 9 .000 
N of Valid Cases 113   
 
 
  365 
 
  366 
 
Deep Endothelial Cells Crosstabulation 
 
 
 
 
Group 
Deep Endothelial Cells 
mild staining moderate staining no staining N/A Total 
 CYSTITIS 3 1 2 0 6 
IRRAD 35 22 1 12 70 
NONIRRAD 7 0 10 1 18 
PM 10 2 1 6 19 
 55 25 14 19 113 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 49.996a 9 .000 
Likelihood Ratio 46.127 9 .000 
N of Valid Cases 113   
  367 
 
  368 
 
 
 
 
Large Vessels Crosstabulation 
 
 
 
 
Group 
Large Vessels 
mild staining moderate staining no staining N/A Total 
 CYSTITIS 2 3 1 0 6 
IRRAD 39 18 1 12 70 
NONIRRAD 7 1 9 1 18 
PM 10 2 1 6 19 
 58 24 12 19 113 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 44.706a 9 .000 
Likelihood Ratio 37.004 9 .000 
N of Valid Cases 113   
  369 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 55.481a 15 .000 
Likelihood Ratio 54.028 15 .000 
N of Valid Cases 118   
 
  370 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 68.514a 20 .000 
Likelihood Ratio 77.089 20 .000 
N of Valid Cases 118   
 
  371 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 30.386a 20 .064 
Likelihood Ratio 37.198 20 .011 
N of Valid Cases 118   
 
  372 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 47.936a 20 .000 
Likelihood Ratio 57.480 20 .000 
N of Valid Cases 118   
 
  373 
 
 
 
 
 
 
 
 
 
  374 
 
 
 
  375 
 
 
 
  376 
 
 
 
  377 
 
 
 
  378 
 
 
 
  379 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  380 
 
 
PDGFR-beta 
 
  381 
 
Epithelium Crosstabulation 
 
 
 
 
Group 
Epithelium 
mild staining moderate staining strong staining no staining N/A Total 
 CYSTITIS 6 0 0 0 0 6 
IRRAD 19 33 1 0 17 70 
NONIRRAD 8 7 0 1 2 18 
PM 6 7 0 0 6 19 
 39 47 1 1 25 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 21.390a 12 .045 
Likelihood Ratio 21.562 12 .043 
N of Valid Cases 113   
  382 
 
  383 
 
Superficial Endothelial Cells Crosstabulation 
 
 
 
 
Group 
Superficial Endothelial Cells 
mild staining moderate staining no staining N/A Total 
 CYSTITIS 2 1 3 0 6 
IRRAD 37 21 0 12 70 
NONIRRAD 7 2 8 1 18 
PM 11 2 0 6 19 
 57 26 11 19 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 50.869a 9 .000 
Likelihood Ratio 45.580 9 .000 
N of Valid Cases 113   
  384 
 
  385 
 
Deep Endothelial Cells Crosstabulation 
 
 
 
 
Group 
Deep Endothelial Cells 
mild staining moderate staining no staining N/A Total 
 CYSTITIS 3 2 1 0 6 
IRRAD 32 24 0 14 70 
NONIRRAD 9 2 6 1 18 
PM 5 6 2 6 19 
 49 34 9 21 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 29.614a 9 .001 
Likelihood Ratio 30.851 9 .000 
N of Valid Cases 113   
  386 
 
  387 
 
Large Vessels Crosstabulation 
 
 
 
 
Group 
Large Vessels 
mild staining moderate staining no staining N/A Total 
 CYSTITIS 3 2 1 0 6 
IRRAD 32 25 0 13 70 
NONIRRAD 7 3 7 1 18 
PM 8 5 0 6 19 
 50 35 8 20 113 
 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 39.522a 9 .000 
Likelihood Ratio 33.728 9 .000 
N of Valid Cases 113   
  388 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 74.926a 15 .000 
Likelihood Ratio 62.680 15 .000 
N of Valid Cases 118   
 
  389 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 74.333a 15 .000 
Likelihood Ratio 74.176 15 .000 
N of Valid Cases 118   
 
  390 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 57.403a 20 .000 
Likelihood Ratio 52.839 20 .000 
N of Valid Cases 118   
 
  391 
 
 
Chi-Square Tests 
 
Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 47.909a 20 .000 
Likelihood Ratio 48.697 20 .000 
N of Valid Cases 118   
 
  392 
 
 
 
 
 
 
 
 
 
  393 
 
 
 
  394 
 
 
 
  395 
 
 
 
  396 
 
 
 
  397 
 
 
 
  398 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
